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1.1 Antibody production by mammalian cells 
Therapeutic proteins are an important class of medicines for treating diseases such as 
different types of cancer1. Among these proteins, monoclonal antibodies (mAbs) are 
an important and rapidly growing class with total sales of $85 billion in 20152,3. A 
monoclonal antibody can specifically bind to antigens expressed by tumor cells and 
therefore, can be used to effectively target pathways important for treatment of 
malignancies4,5. Monoclonal antibodies are large and complex molecules (Figure 1). 
Their biosynthesis requires specific post-translational modifications which are very 
important for the protein efficacy, safety, and stability. In this regard, mammalian 
cells are used instead of other expression systems, such as bacteria and yeast, due to 
the ability to produce proteins with proper folding and post-translational 
modifications (e.g. glycosylation). However, mammalian cells have lower growth and 
production rates compared to bacterial and yeast cells. Furthermore, mammalian 
cells have complex nutrient requirements6–8 and are sensitive to culture conditions9–12. 
Such characteristics challenge the development of mammalian cell culture processes. 
Of all the types of mammalian cells used for pharmaceutical protein production (e.g. 
HEK, PER.C6, and hybridoma cells), Chinese Hamster Ovary (CHO) cells are the 
most well studied. CHO cells are used for nearly 70% of all recombinant protein 
therapeutics produced1. A lot of progress has been made during the past decades 
regarding cell line, culture medium, and culture process development. This has 
resulted in an improvement of product titers with more than a factor 100 to the 
current level of grams/L, compared to 50 mg/L in the 1980s 13. Currently, the market 
demand for mAb-based products is still increasing at a fast pace. In order to meet the 
market demand, efforts are being made to further increase the product yield of a 
culture process as well as to shorten the timeline for process development. 
  
Figure 1. The representative structure of a monoclonal antibody. Fc, fragment crystallizable region; 
Fab, fragment antigen-binding region; CDR, complementarity-determining region; CH, heavy chain 
constant domain; CL, light chain constant domain; VH, heavy chain variable domain; VL, light chain 
variable domain. Figure adopted from Beck, A. et al. (2010)14 with permission from the author 
published in this thesis. 
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1.2  Production processes 
Several culture processes are currently being used in industry for CHO cell culture. 
These processes are (i) batch process: cells are cultured in a basal medium with no 
addition of nutrients during the culture time. The product is harvested after the cell 
viability starts dropping. This type of process is generally used during the pre-
culture phase where cells are generated for inoculation of the production bioreactor.  
(ii) Fed-batch process: the culture starts in batch process mode, but the consumed 
nutrients are fed to the cells either continuously or as a bolus. In this way, the cells 
can grow to a higher concentration and can be maintained viable for a longer period 
of time, which together result in a higher product titer at the end of the process. (iii) 
Perfusion process: cells are retained in the reactor while being perfused constantly 
with fresh medium. In this way, the spent medium which contains inhibitory 
compounds produced by the cells are removed. This process typically results in a 
very high biomass concentration in the bioreactor and thus a high volumetric 
productivity. 
Amongst these culture processes, fed-batch (as exemplified in Figure 2) is currently 
the most common process for the production of monoclonal antibodies in industry, 
thanks to the fact that it is easy to operate, robust, and flexible. Hence, this thesis 
focuses on the fed-batch process. Considerable progress has been made during the 
past decades on the fed-batch process for CHO cell cultures. They include designing 
and tailoring of medium and feed composition as well as the feeding strategy8,15–17 for 
specific CHO cell types, optimizing culture parameters18–20, and designing 
bioreactors21–24. Many metabolic studies have been carried out in order to gain 
mechanistic insights into cell physiology during the fed-batch processes. These 
studies measured the change of extracellular nutrients as well as the change of 
biomass composition during the process and combined them with the existing 
metabolic networks to calculate the intracellular metabolic fluxes. Furthermore, by 
incorporating isotopic labeling in metabolic flux analysis, more detailed information 
on the flux distribution was obtained25. More recently, with the advances of system 
biology tools and the publication of the CHO genome26, omics’ studies (e.g. 
transcriptomics, proteomics, and metabolomics) have been increasingly applied in 
cell culture process development to identify genes related to recombinant protein 
productivity27–29, and to study different culture conditions that affect the culture 
performance19,30–32. These studies have contributed to the fundamental understanding 
of CHO cell metabolism and resulted in improved process performances.  
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Figure 2. (A) Fed-batch culture process in a stirred tank bioreactor. (B) An example of typical cell 
growth and mAb production profiles in a fed-batch process. 
1.3  Process development and scale-up 
A cell culture production process is developed in laboratory scale (≤10 L) bioreactors 
and is scaled up to large scale (e.g. kL-scale) for commercial production. The main 
steps comprise of cell line generation and selection, media and feed screening, 
process parameter determination, robustness evaluation, and scale-up to generate 
material for clinical trials and subsequent commercial production at the production 
scale (Figure 1.3). The work described in this thesis which is related to the tasks 
during the upstream process development is indicated in Figure 3. Different types of 
culture systems which are used in different steps during process development are 
shown in Figure 4. 
A 
B 
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Figure 3. Main steps in upstream process development of mammalian cell cultures. 
Upstream process development starts with clone generation and selection. This is 
typically done in microtiter plates and spin tubes with culture volumes ranging from 
µL to a few mL33,34. Up to thousands of clones and sub-clones, which harbor 
recombinant genes encoding the protein of interest, are generated in this step. After 
several rounds of screening, a few top productive clone candidates are selected for 
the subsequent step being medium and feed screening. In this step, various 
medium/feed systems are tested on the selected clones and this is typically done in 
shake flasks with a culture volume up to 100 mL. The medium for mammalian cell 
culture has a complex formulation which is composed of more than 80 compounds 
that are needed for cell growth and production35. Various media systems are 
available for CHO cell culture and the formulations of these media differ8. As a result, 
a cell line can have a distinct performance in different media systems, which makes 
media selection an important step. Normally, media systems that support high 
product titers will be selected. Up to this step, the cells are cultured in an 
“uncontrolled” condition with regard to dissolved oxygen (DO) and pH. Next, the 
selected culture platforms (e.g. several clones and medium/feed candidates) will 
enter bench-scale bioreactors (1 to 10 L) to examine the performance of the culture 
process under pH and DO controlled conditions. In this step, the number of clone 
and medium candidates will be further narrowed down. One or two selected 
processes will be further developed and optimized in the bench-scale bioreactors 
using the Design of Experiment (DoE) approach in order to find the optimal culture 
conditions for maximal mAb production. Typical culture conditions to be tested in 
this step include DO, pH, agitation rate, feeding rate, seeding density, and 
temperature. Once the process is more or less defined, the generated product can be 
used for product quality studies and pre-clinical trials. In the meantime, a process 
characterization study is carried out to better understand the process and to further 
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define the process. In such a study, a range of culture parameters around the set 
point will be tested in order to define the acceptable ranges of these parameters. 
Operating the process within these ranges ensures a good product quality and 
productivity. Finally, the process design space is defined for the filing of the product, 
before further scale-up to a production scale (~kL) is carried out. The time frame 
from clone generation to a manufacturing run varies for different projects, but 
typically takes one to two years. 
 
Figure 4. Typical cell culture systems used during process development. 
Scale-up is an important step during the upstream development of mammalian cell 
culture processes. Unacceptable changes in process performance during the process 
scale-up means a lot of additional research into the causes, which is labor intensive 
and costly36. It is therefore very important that the culture system at the laboratory 
scale (scale-down system) is representative for the large scale. In this way, the design 
space can be translated one to one to the large scale. This is, however, not a 
straightforward task. The mass transfer (e.g. gas-liquid transfer and bulk mixing) and 
shear (from agitation and sparging) phenomena in a reactor are strongly dependent 
on the volume (scale) of the reactor. This makes it impossible to reproduce the same 
culture condition in a different scale, which may result in a different culture 
performance. In order to develop a representative scale-down process, the critical 
parameters which influence the process performance should be kept as much as 
possible the same between scales while allowing differences for the non-critical 
parameters. A lot of experience has been gained on how to keep critical parameters 
within acceptable ranges during the past decades37–40. Nevertheless, differences in 
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process performance such as the maximum cell density and volumetric productivity 
are still sometimes observed between large scale and laboratory scale41–43. It is not 
always clear how scale differences lead to differences in process performance. 
Therefore, to improve scale-up/down, a better understanding on how the different 
conditions present at the different scales influence process performance is needed. 
For this, a good understanding of the relation between cell physiology and the 
specific process conditions is required. 
1.4  Aim and thesis outline 
The aim of this thesis is to obtain a better understanding of cell physiology in fed-
batch cultures and on the scale-down of these processes. In the end, this knowledge 
should increase the efficiency of process development and thus shorten the time-to-
market for the biopharmaceutical products. The different scales used in this thesis 
and the associated culture systems are exemplified in Figure 5. 
       
 
 
Figure 5. Culture systems used in this study. (A) Shake flask, used in Chapter 2. (B) BIOSTAT STR® 10 
L stir tank bioreactor (STR) from Sartorius, used in Chapter 3, 4, and 5. (C) ambr® 15 miniature 
bioreactor system from Sartorius, used in Chapter 5. Figure B and C are adopted from Sartorius with 
their permission to be published in this thesis. 
This study is part of the project consortium Animal Cell Cultivation and Screening 
System (ACCESS) with an aim to develop smart cultivation and screening 
technologies for accelerating early process development. The consortium comprises 
of Wageningen University, Synthon Biopharmaceuticals BV, Bioceros Holding BV, 
Biostream International BV, and IBIS Technologies BV with close collaboration 
among partners.  
In Chapter 2, a study on CHO cell fed-batch culture platform selection is presented. 
The study aims to select a suitable CHO cell clone and a media system for the next 
process development and scale-up/down studies. Two CHOBC®  clone candidates 
derived from the same parent and producing the same mAb are used. Four basal 
media and three feed media are tested in fed-batch cultures in all possible 
combinations (=12 conditions) for each clone, using shake flasks. Metabolic and 
physiological phenotypes associated with the individual CHO cell clone in the 
A B C 
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different media are studied. Moreover, the balancing properties of each basal 
medium and feed medium combination are investigated for both clones. Finally, 
based on the maximum biomass concentration and product titer, the BC-P clone in 
combination with ActiCHO-P and ActiCHO feed A&B is selected for further process 
development and scale up/down in this study.  
In Chapter 3 and 4, the designed fed-batch process is run in a 10 L bioreactor system 
to characterize and to better understand the dynamics of cell metabolism and 
physiology. These studies focus on the observed substantial cell size increase (SI) 
phase which occurs right after the exponential cell number increase (NI) phase. In 
Chapter 3, Biomass composition and metabolic flux balance analysis are performed 
for both phases, in order to characterize the metabolic changes during the fed-batch 
culture and to better understand its relation to cell size. In Chapter 4, changes in gene 
expression are studied upon the switch to increasing cell size to better understand 
regulatory mechanisms behind the cell size increase and the relation to the process 
conditions. Chapter 3 and 4 together result in a thorough characterization of the 
physiology of the CHO cells during the fed-batch process at the 10 L scale and form a 
sound basis for comparison to a scaled-down process in Chapter 5. 
In Chapter 5, a scale-down process for the 10 L scale is carried out in the ambr®  15 
system which contains 48 miniature bioreactors with a maximum working volume of 
15 mL. In this chapter, two different scale-down criteria are compared in the ambr®  
15 system. One is based on matching both O2 transfer rate and agitation tip-speed 
(vtip) with the 10 L process, the other is based on matching O2 transfer rate and 
agitation power input per volume of liquid (P/V). Finally, the scale-down process 
performance is evaluated and verified by comparing the ambr®  15 results to the 10 L 
process in terms of cell growth, metabolism, transcriptome, mAb production, and 
mAb glycosylation. 
This thesis investigates the CHO cell physiology underlying the fed-batch process 
dynamics. Such information is used to verify the scale-down process and can be used 
further to develop more representative scale-up/down systems. Finally, Chapter 6 
discusses the major findings in this thesis and the current status and challenges in 
bioprocess scale-up/down. Additional opportunities as well as challenges can be seen 
by further scale-down to mL or even µL scales. The future perspectives are presented 
to better implement such systems in process development.  
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CHO cell fed-batch culture processes 
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Abstract: 
Two CHO cell clones derived from the same parental CHOBC®  cell line and producing 
the same monoclonal antibody (BC-G, a low producing clone; BC-P, a high 
producing clone) were tested in four basal media in all possible combinations with 
three feeds (=12 conditions) in fed-batch cultures. Higher amino acid feeding did not 
always lead to higher mAb production. The two clones showed differences in cell 
physiology, metabolism and optimal medium-feed combinations. During the phase 
transitions of all cultures, cell metabolism showed a shift represented by lower 
specific consumption and production rates, except for the specific glucose 
consumption rate in cultures fed by Actifeed A/B. The BC-P clone fed by Actifeed 
A/B showed a 3-fold cell volume increase and an increase of the specific consumption 
rate of glucose in the stationary phase. Since feeding was based on glucose this 
resulted in accumulation of amino acids for this feed, while this did not occur for the 
poorer feed (EFA/B). The same feed also led to an increase of cell size for the BC-G 
clone, but to a lesser extent. 
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2.1  Introduction: 
Chinese Hamster Ovary (CHO) cells are the main production host for recombinant 
therapeutic proteins13. Fed-batch culture is currently the most common industrial 
process for CHO cell culture. For a fed-batch process, volumetric productivity and 
product titer are important outputs. These outputs are a function of viable cell 
density (VCD), specific productivity (qp), and culture longevity, which in turn are 
influenced by the medium and feed composition. Selecting a suitable culture 
medium and feed platform is therefore pivotal for developing a fed-batch 
manufacturing process. Chemically defined basal media and feeds are currently the 
standard for CHO cell fed-batch cultures. In a fed-batch culture, CHO cells are 
inoculated and start to grow in a basal medium. A feed is added to the culture when 
a certain culture state is reached, such as when a certain cell density is reached, a 
certain culture time point is reached, or a certain nutrient concentration is reached. 
The basal medium and especially the feed should contain a balanced set of essential 
nutrients in a ratio that meets the demand of the cells for proliferation and 
production of the pharmaceutical protein. A feed is generally more concentrated 
than a basal medium to maximize culture volumetric productivity and product titer. 
Studies have shown that the composition of culture media and feeds can influence 
cell growth, protein productivity44, gene expression45, product quality10,46,47, and 
metabolism of lactate and ammonia6,45,48,49.  
To design a chemically defined medium in-house is time and labor consuming. 
Currently, process development of CHO cell culture usually starts with commercially 
available culture media systems as a basis44. Several well performing chemically 
defined media have become commercially available for CHO cells. These media are 
designed based on different strategies to reach high volumetric productivities and 
product titers. For instance, some media are designed to boost cell growth to a high 
cell density, others are designed to extend the longevity of cells or to enhance cell 
specific productivity. For different medium-feed combinations the richness and 
composition of the basal media and feeds differ widely. The optimal composition of a 
basal medium or a feed is highly dependent upon the basic type of CHO cell used, 
specific characteristics of the generated sub-clones, and type of product44,47. Thus, 
there is no single basal medium or feed suitable for all CHO cultures. 
A problem with media selection is that different CHO cell types and clones have 
different nutrient requirements and therefore for each clone candidate the medium 
and feed formulation and feeding strategies would have to be screened, designed 
and optimized. Generally this information is not disclosed by manufacturers, which 
makes the early process development difficult for start-ups. Some studies were 
conducted and reported to select or compare commercial media for CHO cell 
cultures. Rodrigues et al.44 have compared viable cell concentration and antibody 
production in seven commercially available media in batch cultures of a CHO-K1 cell 
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line and stressed the importance of selecting the correct medium for the outcome of a 
process. Reinhart et al.47 compared cell growth, antibody production, antibody 
quality on eight chemically defined media for a CHO DG44 cell line in batch, and 
with a subset of conditions in fed-batch.  
To investigate how differences between clones derived from the same parental cell 
line may affect the choice of basal media and feeds in fed batch processes. This study 
investigates the effects of different basal media and feeds on cell growth, metabolism, 
physiology, and mAb production for two differentially behaving clones derived from 
the same parental cell line. The two clones were compared in 12 basal medium-feed 
combinations, resulting in total 24 fed-batch culture conditions. Each clone was best 
supported by a different basal medium-feed combination, even though they are 
derived from the same parental cell line. Clear metabolic shifts are observed for all 
the cultures when going from the growth phase to the stationary phase. Also the type 
and extent of these metabolic shifts are different for the 2 clones for the different 
basal medium-feed combinations used. Cultures fed by Actifeed A/B showed a 
marked increase in cell volume, which also was different for both clones being 
respectively 3-fold for BC-P and 2-fold for BC-G. Further improvements of cell 
growth and volumetric productivity by tailoring feed composition and/or feeding 
strategy based on specific cellular requirement are discussed. 
 
2.2  Materials and methods 
2.2.1 Cell line and culture medium 
Two Chinese Hamster Ovary (CHO) BC®  (Provided by Bioceros Holding BV, The 
Netherlands) suspension cell clones with different growth and production patterns 
being BC-G (high maximum cell density, low productivity) and BC-P (low maximum 
cell density, high productivity) were used. Both clones were derived from the same 
parental cell line by the same transfection and cell line generation program, and 
produce the same recombinant human monoclonal antibody (mAb), 
immunoglobulin G1 (IgG1). Each clone contained two constructs: one with a heavy 
chain and one with a light chain, where each construct had a different resistance 
marker allowing for a double selection.  
Four chemically defined basal media were compared being: 1. CD FortiCHO™ (Forti, 
or FortiCHO) Medium, 2. CD OptiCHO™ (Opti, or OptiCHO) Medium, 3. CD-CHO 
Medium, and 4. ActiCHO-P (Acti, or ActiCHO) medium. With 1, 2 and 3 purchased 
from Life Technologies and 4 purchased from GE Healthcare. In combination with 
these basal media, three chemically defined feed systems were compared being: 1. 
Efficient Feed™ A and B (EFA/B) from Life Technologies added in a ratio of 1:1 (v/v), 
based on supplier’s information; 2. Efficient Feed™ C (EFC) from Life Technologies; 
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and 3. ActiCHO Feed™-A and -B (Acti A/B, or Actifeed A/B) from GE Healthcare 
added in a ratio 10:1 (v/v), based on supplier’s information. All basal media were 
supplemented with 4 mM L-glutamine (Gibco® , Life Technologies) and 0.5% (v/v) 
Anti-clumping agent (Gibco® , Life Technologies). All possible combinations of these 
media and feeds (3×4) were compared for the two CHOBC®  clones in fed-batch 
cultures. 
2.2.2 Pre-culture and fed-batch culture 
One ampoule of cells from a working cell bank was thawed in FortiCHO medium in 
a 125 mL un-baffled shake flask (VWR, USA) with a 12 mL working volume. Next, 
the thawed culture was washed with fresh FortiCHO medium and sub-cultured in 
the four different basal media supplemented with selection reagents (200 µg/mL 
ZeocinTM and 5 µg/mL blasticidin, both from Life technologies). Cells were sub-
cultured every 3 days (1 passage) in the exponential growth phase to an initial 
density of 2×105 cells/mL for at least five passages and considered adapted when they 
had a stable specific growth rate (µ) for two consecutive passages. Just before 
inoculation of the fed-batch cultures, cells were spun down at 300×g. Spent medium 
was discarded and cells were re-suspended in fresh medium without selection 
reagents. The actual fed-batch culture experiments were done in 250 mL shake flasks 
(VWR, USA) with a 25 mL initial working volume in duplicate at a seeding density of 
2×105 cells/mL. Cultures were incubated with 100 rpm shaking speed and 50 mm 
orbital shaking diameter in an incubator (Multitron CO2 incubator; Infors HT) 
operated with 8 % CO2 at 37 °C and 90 % humidity. Feed addition started from 
culture day 3 on for all the tested conditions with a daily bolus addition. The 
determination of feed supply rate is explained in section 2.2.6. Cultures were 
harvested on day 14, or when viability dropped below 60%. 
2.2.3 Cell density and viability determination  
Samples were taken daily starting from culture day 2. A 1 mL sample was taken from 
each culture flask for measurements of total cell density, viable cell density and cell 
diameter using an Automated Cell Counter (TC20™; BIO-RAD) by trypan blue dye 
(Sigma-Aldrich) exclusion method. Next, the sample was filtered through a 0.2 µm 
filter (Minisart, Sartorius™). The cell free flow-through was stored at -20 °C for later 
analysis. 
2.2.4 Culture spent medium, osmolality and product titer analysis 
Glucose and lactate concentrations were daily measured using an YSI analyzer (YSI 
2700, YSI Life Sciences). Ammonium concentrations were analyzed by a BioProfile®  
FLEX analyzer (Nova biomedical) after the experiment was finished. Spent medium 
composition including all the extracellular amino acids was quantified using NMR 
    
23 
 
2 
(Spinnovation biologics BV) based on the sample scheme (Table I) after the 
experiment was finished. IgG concentration was determined by Bioceros 
Netherlands BV, using the Octet system with protein G biosensors (ForteBio). 
Osmolality was measured using an Osmomat 030-D cryoscopic osmometer (Gonotec). 
Table I. Sample points for spent media analysis. Samples for spent media analysis were carried out on 
every other day for each culture. Grey cells: culture was terminated. 
 
Day 0 2 4 6 8 10 12 13 14 
BC-P 
Opti + EFA/B √ √ √ √ √ √    
Opti + Acti A/B √ √ √ √ √ √ √ 
 
√ 
Acti + EFA/B √ √ √ √ √ √ √ √ 
 
Acti + Acti A/B √ √ √ √ √ √ √ 
 
√ 
BC-G 
Opti + EFA/B √ √ √ √ √ √ √ 
 
√ 
Opti + Acti A/B √ √ √ √ √ √ √ 
 
 
Acti + EFA/B √ √ √ √ √ √ √ 
 
√ 
Acti + Acti A/B √ √ √ √ √ √ √ 
 
√ 
2.2.5 Productivity 
Based on cell growth patterns of fed-batch cultures, four culture phases were 
distinguished:  
1. Start-up phase (L-Phase), from the inoculation day until day 2;  
2. Exponential growth phase (G-phase), from day 2 until the day that the 
cultures reached the maximum cell density;   
3. Stationary phase (S-Phase), from the end of G-Phase until the culture viability 
was lower than 80 %; and  
4. Death phase (D-Phase), is from the end of S-Phase until the end of the culture. 
This study mainly focuses on the G- and the S-phase during the cultures. The 
calculation of average specific consumption/production rates was done separately for 
the growth and stationary phase (Figure 8).  
Change in the total amount of compound x in the shaker flask is given by: 
𝑑𝑀𝑥
𝑑𝑡
= 𝑞𝑥 ∙ 𝑀𝑉𝐶(𝑡)    Equation 1 
Where Mx (mg; mmol) is the total amount of compound x in a culture, MVC (cells) is 
the number of viable cells in a culture and qx (mmol·cell-1·day-1) is the specific 
production rate of compound x. With constant qx, integration of Equation 1 gives: 
𝑀𝑥(𝑡) − 𝑀𝑥(0) = 𝑞𝑥 ∙ ∫ 𝑀𝑉𝐶
𝑡
0
    Equation 2 
The average specific production rates of glucose, essential amino acids and antibody 
were obtained from a plot of the total amount of a compound against the integral of 
    
24  
   
viable cell numbers using linear regression. Positive values indicate production while 
negative values indicate consumption.  
2.2.6 Feed supply  
Glucose serves as one of the main carbon and energy sources for CHO cells50. The 
consumption rate of glucose is often used as an indicator of cell culture activity to 
guide feeding strategies. Since the specific consumption rate of glucose at per cell 
level does not vary much if cell activity is unchanged and glucose concentrations are 
well above the Monod saturation constant. In this study, it was not possible to 
conduct daily measurement for nutrients other than glucose and lactate. The daily 
amount of feed addition, therefore, was based on the glucose concentration at the 
moment of feeding and the anticipated glucose consumption rate for the next 24 
hours according to glucose specific consumption rate of the cells. The feeding 
strategy used in this study is different from the supplier’s protocol. However, since 
the protocols differ among suppliers, the feeding strategy of this study gives fairer 
comparison between different feed systems. The feeding strategy presumes that the 
glucose concentration in the feed is well balanced with the rest of the nutrients. To 
calculate the daily feed amount, the following method was used. First, the specific 
growth rate µ g (day-1) is calculated by  
µ𝒈 =
𝒍𝒏
𝑽𝑪𝑫𝒀
𝑽𝑪𝑫𝒀−𝟏
𝒕𝒀−𝒕𝒀−𝟏
    Equation 3 
Where VCDY-1 and VCDY (cells·mL-1) are the viable cell densities of the last and the 
current feeding points, respectively. tY-1 and tY (day) are the time points for the last 
and the current feeding points, respectively. Then, the VCD of the next day can be 
predicted based on Equation 4. 
𝑽𝑪𝑫𝒀+𝟏 = 𝑽𝑪𝑫𝒀 × 𝒆
𝝁𝒈∙(𝒕𝒀+𝟏−𝒕𝒀)    Equation 4 
Next the integral viable cell density (IVCD) of the previous and the next culture day 
was calculated by Equation 5 and Equation 6 respectively.  
𝜟𝑰𝑽𝑪𝑫𝒀 = 𝑽𝑪𝑫𝒀−𝟏 × (𝒕𝒀 − 𝒕𝒀−𝟏) +
(𝑽𝑪𝑫𝒀−𝑽𝑪𝑫𝒀−𝟏)×(𝒕𝒀−𝒕𝒀−𝟏)
𝟐
    Equation 5 
𝜟𝑰𝑽𝑪𝑫𝒀+𝟏 = 𝑽𝑪𝑫𝒀 × (𝒕𝒀+𝟏 − 𝒕𝒀) +
(𝑽𝑪𝑫𝒀+𝟏−𝑽𝑪𝑫𝒀)×(𝒕𝒀+𝟏−𝒕𝒀)
𝟐
    Equation 6 
IVCD was defined as the area under the viable cell growth curve using the trapezium 
rule. ΔIVCDY and ΔIVCDY+1 (cells·day·mL-1) are the IVCD of the past day and the 
predicted next day respectively.  
The specific glucose consumption rate ( 𝑞GlucY , mmol·cell
-1·day-1) can then be 
calculated by: 
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𝜟𝑮𝑳𝑪𝒀
𝜟𝑰𝑽𝑪𝑫𝒀
= 𝒒𝑮𝒍𝒄𝒀   Equation 7 
Assuming the specific glucose consumption rate stays constant, the glucose 
consumption during the next day (ΔGLCY+1, mM) can then be predicted by: 
𝜟𝑮𝑳𝑪𝒀+𝟏 = 𝒒𝑮𝒍𝒄𝒀 × 𝜟𝑰𝑽𝑪𝑫𝒀+𝟏    Equation 8 
Finally, the feed volume to be added was determined by using Equation 9. Glucose 
concentration was kept at 10 mM (as a safe threshold) by the next day sample point. 
𝑽𝑭 =
(𝜟𝑮𝑳𝑪𝒀+𝟏+(𝟏𝟎−𝑮𝑳𝑪𝒀))×𝑽𝒀
𝑪𝑭
    Equation 9 
Where GLCY is the current glucose concentration (mM), VF is the feed volume to be 
added (mL), VY is the current culture volume (mL) and CF is the glucose 
concentration in the feed (mM). 
For each duplicate culture the feeding volume was calculated. Next, the two obtained 
values were averaged and the average feeding volume was added to both cultures. 
By using this feeding method, we managed to keep the range of glucose between 10 
to 30 mM throughout the fed-batch cultures by daily bolus feeding.  
2.2.7 Balance of essential amino acids in feeds 
To check whether the essential amino acid and glucose concentrations in the feed are 
balanced with respect to the needs of the cells, a relative balancing level is defined  
Relative balancing level =  (
𝑪𝑬𝑨𝑨𝒙
𝑪𝒈𝒍𝒄
𝒒𝑬𝑨𝑨𝒙
𝒒𝒈𝒍𝒄
)   Equation 10 
Where CEAAx and Cglc (all in mM) are concentrations of essential amino acid x and 
glucose in the feed, qEAAx and qglc (all in mmol·cell-1·day-1) are the specific consumption 
rates of essential amino acid x and glucose during the growth phase or the stationary 
phase of the culture. In this way, the ratio of essential amino acid x to glucose is 
compared between the formulation of feed and the cell specific consumption rates. 
Since the feed supply rate was based on glucose concentration in this experiment, the 
feed balance of essential amino acids was evaluated based on glucose. A relative 
balancing level equal to 1 means that the rate with which the essential amino acid is 
supplied by the feed equals its consumption rate when feed addition is based on 
glucose. A value other than 1 means that the supply rate of the essential amino acid 
is either lower (<1) than or higher (>1) than the specific consumption rate, resulting in 
either depletion or accumulation. 
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2.3  Results 
2.3.1 Media and feed compositions 
The composition of the used basal media and feeds was measured with respect to 
amino acids and glucose (Figure 1). All basal media and feeds contain glucose, non-
essential amino acids and essential amino acids. In general, the feeds are 5 to 10 times 
more concentrated than the basal media in both glucose and amino acids. For the 
basal media, OptiCHO is relatively poorer whereas FortiCHO and ActiCHO-P are 
richer in amino acids content. For the feeds, Actifeed a/b is richer than EFA/B (3-fold) 
and EFC (2-fold) in amino acids and glucose content.  
 
 
 
Figure 1. Sum of concentrations of non-essential amino acids, of essential amino acids, and 
concentration of glucose in different basal media (A) and feeds (B). EFA and EFB are used in a ratio of 
1:1 (v/v) and Actifeed a/b in a ratio of 10:1 (v/v). 
2.3.2 Performance of BC-P and BC-G clones in different medium-feed 
combinations 
Volumetric productivity and product titer of the mAb are the most often used 
parameters during media and clone selection in the early culture process 
development phase. Therefore the volumetric productivity and IgG product titer of 
all the studied conditions were compared (Figure 2). For the BC-G clone, FortiCHO + 
EFA/B resulted in the highest titer (190 mg∙L-1) and volumetric productivity (14 mg∙L-
1∙day-1). For the BC-P clone, ActiCHO + Actifeed A/B resulted in the highest titer 
(1250 mg∙L-1) and volumetric productivity (90 mg∙L-1∙day-1). Overall, the BC-P clone 
showed clearly broader ranges (up to 6-fold higher) of IgG titer and volumetric 
productivity compared to the BC-G clone. Compared to the other basal media, the 
use of CD-CHO resulted in the lowest volumetric productivities and product titers 
for both clones irrespective of the feed used. Other output parameters including 
maximum viable cell density, integral viable cell density, specific growth rate, 
number of days where the viability is above 80% and specific productivity can be 
found in Table II. 
A B 
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Cell physiology responded differently to medium-feed combinations. Remarkably, 
for both clones when fed by Actifeed A/B, an increase of cell diameter during the 
stationary phase was observed. The increase was not observed when the other feeds 
(EFA/B and EFC) were used (data in Figure 3 only shows EFA/B). For the BC-P clone 
the size increase was most prominent with an increase of the average cell diameter 
from 16 to 24 µm (Figure 3), which is equivalent to a cell volume increase of nearly 3-
fold. The cell size increase was also observed for the BC-G clone fed by Actifeed A/B, 
but to a lesser extent being from 14 to 18 µm. For the culture using Opti+Actieed A/B 
with the BC-G clone in Figure 3, the cell size increase could not be observed because 
it was terminated on day 9 due to a low viability. The observation implies a common 
response between the two clones towards the feed addition. The sudden decrease of 
cell diameter in the end of the cultures was due to cell death. 
 
 
 
Figure 2. Product titer (mg∙L-1) and volumetric productivity (mg∙L-1∙day-1) of clone BC-G and BC-P for 
all tested basal medium-feed combinations. Error bars indicate the deviation of the duplicate data 
points from the average value. Conditions marked with arrows were selected for further comparisons. 
Conditions marked with (*) indicate cell aggregation during the cultures. 
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Table II. Fed-batch culture results of clone BC-G and BC-P for all possible combinations of 4 types of 
media and 3 feed systems. “±” indicates the deviation of the duplicate data points from the average 
value. Asterisks at the max viable cell density values indicate cell aggregate during the cultures. 
Conditions marked in blue are selected for further comparison. 
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Figure 3. Average cell diameters (µm) of the BC-G (A) and BC-P (B) clones in the selected fed-batch 
culture conditions.  
2.3.3 Metabolite profiles in fed-batch cultures 
To study the effect of different medium-feed combinations on cell metabolism, 4 
combinations (marked with arrows in Figure 2) were selected for further comparison 
being: a relatively poor medium (OptiCHO) with a poor feed (EFA/B) and a rich feed 
(Actifeed A/B) and a rich basal medium (ActiCHO) with the same feeds. In this way, 
the impact of the richness of media and feeds was compared in more detail. Amongst 
these conditions the cultures in which the highest volumetric productivities were 
obtained (BC-G in OptiCHO + Actifeed A/B and BC-P in ActiCHO + Actifeed A/B) 
are included. For these conditions spent media analysis was conducted on different 
time points according to Table I.  
Figure 4 shows the viable cell density and viability of the selected culture conditions. 
For the BC-G clone, the growth patterns are similar when using the same basal 
medium, while for the BC-P clone, the growth patterns are similar when using the 
same feed. In all medium-feed combinations, cell division stopped after culture day 6, 
except for the BC-G clone in ActiCHO medium, where cell division lasted until day 8 
but at a lower maximum specific rate of ~0.55 /day compared to ~0.70 /day for the 
BC-G clone in OptiCHO medium  (Table II). The decline of viable cell density during 
the stationary phase was caused by dilution due to sampling and feeding, and/or due 
to cell death. 
A B 
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Figure 4. Viable cell density and viability of the BC-G (A) and BC-P (B) clones in the selected 
conditions. Error bars show the deviation of the duplicate data points from the average value. 
 
2.3.3.1 Glucose, lactate, ammonium and osmolality profiles  
Glucose shows similar zigzag profiles for the tested conditions due to consumption 
and daily feed addition starting from day 3 on (Figure 5 A&E). For the BC-P clone 
fed by Actifeed A/B during the stationary phase, a considerably higher daily glucose 
consumption is observed (Figure 5 E). For both clones the lactate concentration 
shows a similar trend with an initial increase followed by a decrease after 3 to 4 days 
except again for the BC-P clone fed by Actifeed A/B, where the lactate concentration 
kept increasing until the end of the culture. The observed simultaneous consumption 
of lactate and glucose agrees with literature on various other CHO cell lines15,45,51. 
Ammonium levels keep increasing during all fed-batch cultures. For the BC-P clone 
fed with Actifeed A/B, clearly higher ammonium concentrations are observed 
(Figure 5 C&G). The osmolality is constant except for the cultures fed by Actifeed 
A/B, where an increase up to 400 and 620 mOsm/kg is observed for respectively the 
BC-G and the BC-P clone (Figure 5 D&H). Both clones seem to cope well with the 
osmolality since the viability maintained higher than 80 % until day 12. 
A 
B 
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Figure 5. Extracellular concentration of glucose, lactate, ammonium (Graph A, B, C, E, F and G: unit 
in mM) and culture osmolality (Graph D and H: unit in mOsm/kg) for the two clones during fed-batch 
cultures. Error bars show the deviation of the duplicate data points from the average value. 
 
2.3.3.2 Essential amino acid profiles 
In each culture condition, the essential amino acid profiles show similar trends. As an 
example, threonine concentrations of the selected culture conditions are shown 
(Figure 6). None of the essential amino acids was depleted during fed-batch cultures, 
indicating that they were not the limiting nutrients for cell growth or production in 
all studied cases. Cultures fed by EFA/B resulted in stable essential amino acid 
concentrations, whereas cultures fed by Actifeed A/B resulted in accumulation of 
essential amino acids starting from the stationary phase (day 6). The accumulation 
was larger for the BC-P clone than for the BC-G clone.  
A 
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Figure 6. Extracellular threonine concentrations (mM) during fed-batch cultures of the both clones. 
Error bars show the deviation of the duplicate data points from the average value. 
 
2.3.3.3 Non-essential amino acid profiles 
Figure 7 shows the profiles of asparagine, aspartic acid, glutamine, glutamic acid and 
alanine, which are the non-essential amino acids directly related to the primary 
carbon metabolism. In most of the conditions, asparagine and glutamine were 
depleted between day 4 and day 6 (Figure 7 A, C, F and H). When using Actifeed 
A/B feed, glutamine, which is not present in the feed, was produced in the later 
culture stage as indicated by the increased glutamine concentration. The sudden 
increase of asparagine concentration at day 14 in Figure 7 F was most likely a 
measurement error, since it was not observed throughout other cultures. Aspartic 
acid and glutamic acid stayed at low concentrations during EFA/B fed cultures, but 
increased during Actifeed A/B fed cultures (Figure 7 B, D, G and I), because of the 
high content of these two compounds (~50 mM and ~70 mM respectively) in Actifeed 
A/B. Alanine is not present in the basal media, but is present in EFA/B feed (~1 mM) 
and Actifeed A/B (~16 mM). As seen in Figure 7 E&J, all selected culture conditions 
showed an increase of alanine concentration except for the poor medium and poor 
feed (OptiCHO + EFA/B) where alanine was consumed after day 6. In the cultures 
with the rich medium and poor feed (ActiCHO + EFA/B), the alanine increase was 
mostly due to production by cells, whereas when fed by the rich feed (Actifeed A/B) 
the increase was due to both feeding and production. When fed by feed EFA/B, 
depletions of tyrosine and cystine were observed at around day 6 for both the clones 
(see Appendix 4 of the online published data).  
A B 
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Figure 7. Non-essential amino acid profiles of selected culture conditions in fed-batch cultures. 
Concentrations are shown in mM. Graph A,B,C,D,E show the profiles of asparagine, aspartic acid, 
glutamine, glutamic acid and alanine of the BC-G clone; Graph F,G,H,I,J show their profiles of the 
BC-P clone. Error bars show the deviation of the duplicate data points from the average value. 
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2.3.4 Specific consumption rates 
In a fed-batch culture, the essential amino acid feeding rate should match the 
consumption rates of the cells. The average specific consumption rates of essential 
amino acids and glucose are presented during the growth and the stationary phase 
for both clones (Figure 8). Note that on average, the ratios among essential amino 
acids for two clones are similar during the growth phase, indicating similar 
requirements for both clones to make biomass during this phase. In general, average 
specific consumption rates of most of the essential amino acids during the growth 
phase are significantly (T tests, data not shown) higher than during the stationary 
phase. This is also true for the average specific consumption rate of glucose, except 
for the BC-P clone fed by Actifeed A/B, where the average specific glucose 
consumption rate is higher in the stationary phase than in growth phase (Figure 8 
C&D). Overall, the BC-P clone shows higher average specific glucose and essential 
amino acids consumption rates compared to the BC-G clone, which may be related to 
the larger cell size of the BC-P clone (~16 µm) compared to the BC-G clone (~13 µm) 
(Figure 3). In order to show the variation of specific glucose consumption rate during, 
a boxplot of the specific glucose consumption rate for all the tested conditions during 
different culture phases is shown in Figure 9. The specific glucose consumption rate 
varies in a wide range in different media/feed conditions for the BC-P clone, whereas 
in a much smaller range for the BC-G clone. 
  
    
35 
 
2 
   
  
F
ig
u
re
 8
. 
A
ve
ra
g
e 
sp
ec
if
ic
 c
o
n
su
m
p
ti
o
n
 r
a
te
s 
(f
 f
m
o
l∙
ce
ll
-1
∙d
a
y-
1
) 
o
f 
th
e 
9
 e
ss
en
ti
a
l 
a
m
in
o
 a
ci
d
s 
a
n
d
 g
lu
co
se
 o
f 
th
e 
B
C
-G
 (
A
&
B
) 
a
n
d
 
th
e 
B
C
-P
 (
C
&
D
) 
cl
o
n
es
 i
n
 t
h
e 
se
le
c
te
d
 f
ed
-b
a
tc
h
 c
u
lt
u
re
 c
o
n
d
it
io
n
s.
 G
-P
h
a
se
: 
g
ro
w
th
 p
h
a
se
; 
S
-P
h
a
se
: 
st
a
ti
o
n
a
ry
 p
h
a
se
. 
A
ve
ra
g
e 
sp
ec
if
ic
 c
o
n
su
m
p
ti
o
n
 r
a
te
s 
o
f 
th
e 
c
o
n
d
it
io
n
s 
in
d
ic
a
te
d
 w
it
h
 (
×
) 
a
n
d
 (
*
) 
ca
n
n
o
t 
b
e 
ca
lc
u
la
te
d
 d
u
e 
to
 e
a
rl
y 
ce
ll
 d
ea
th
 a
n
d
 i
n
a
c
cu
ra
te
 
(R
2
<
0
.8
) 
sp
ec
if
ic
 c
o
n
su
m
p
ti
o
n
 r
a
te
 c
a
lc
u
la
ti
o
n
s,
 r
es
p
ec
ti
ve
ly
. 
“
  
  
”
sh
o
w
s 
a
 s
ig
n
if
ic
a
n
t 
(P
<
0
.0
5
) 
d
if
fe
re
n
ce
 b
et
w
ee
n
 t
h
e 
li
n
k
ed
 t
w
o
 
va
lu
es
. 
    
36  
   
 
Figure 9. Overall cell specific glucose consumption rates (f mol/cell/day) for the BC-P and BC-G clone 
ranges observed in all the tested conditions. The maximum (Max), minimum (Min), median, quartile 1 
(Q1), and quartile 2 (Q2) values are shown by arrows for the BC-P clones; same follows for the BC-G 
clone. 
 
2.4  Discussion 
2.4.1 Effects of media and feed on culture performances and cell physiology 
In total, 12 combinations of four basal media and three feeds were tested for two 
CHO daughter clones. As expected, the BC-P clone reached higher volumetric 
productivities and product titers. Overall, no clear correlation between richness level 
of the media or feed and the performance of the clones was observed. For example, 
the BC-G clone reached the highest titer (191 mg∙L-1) in FortiCHO + EFA/B, which is a 
rich medium with a poor feed, while for this clone ActiCHO with Actifeed A/B, 
which is a rich medium with a rich feed performed clearly poorer (Figure 2). For 
both clones, CD-CHO medium did not support mAb production. Notably, even 
though the 2 clones are generated from the same parent and produce the same mAb, 
they do not share a common medium-feed for their optimal mAb production. 
It was observed that the addition of Actifeed A/B resulted in a cell volume increase 
for both the clones with a 3-fold increase for the BC-P clone and a 2-fold increase for 
the BC-G clone. The increase of cell size did not occur when fed by EFA/B and EFC, 
which indicates that the cell size increase is not an intrinsic property of the cell line, 
but rather a physiological response to the feed system. Several possibilities might 
cause the size increase: 1. Cell cycle arrest. It was reported that overexpression of a 
cell cycle inhibitor (p21CIP1) in a CHO cell line resulted in a 4-fold increase of cell 
volume52  for overexpression of another inhibitor (p27) in a CHO cell line a 2-fold 
increase of cell protein content was measured53. When cells are arrested at the G1 
phase, they continue to grow in size instead of passing the dividing checkpoint. It 
might be that in this study the depletion of certain nutrients has led to a cell cycle 
arrest. Note that there are still many nutrients (eg. vitamins and trace elements) in the 
basal media and feeds that were not measured in this study. 2. Another possibility 
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could be that the overfed nutrients resulted in higher rate of cellular transportation of 
amino acids, the accumulation of these precursors triggers the higher formation rate 
of biopolymers. Oh et al.54 demonstrated an increase of amino acid uptake via Na+-
dependent transport systems caused by elevation of osmolality. 3. It might also be 
that the cells get larger by taking up water. However, this is typically seen when cells 
are exposed to hypotonic pressure55. Furthermore, it was observed that a higher 
average mAb specific productivity is correlated with conditions that result in a larger 
cell size (the BC-P clone fed by Actifeed A/B; Table II). Cell specific mAb 
productivity has been reported to correlate with cell volume52,56,57. Kim et al.58 
suggested a linear correlation between the increase in specific thrombopoietin 
productivity and the increase of cell size for the 9 CHO sub-clones they studied. 
Results from this study seem to agree with their observation. However, this 
experiment is unable to present the precise comparison of the specific mAb 
productivity before and after the cell size increase, since the cultures were performed 
in uncontrolled shake flasks with culture volumes constantly changing by sampling 
and feeding.  
The BC-P clone tended to form aggregates in more medium-feed combinations 
compared to the BC-G clone (indicated by the asterisks in Figure 2). Formation of 
aggregates indicates suboptimal growth conditions as aggregates were reported to be 
formed around decaying and dead cells through the released DNA59. In this study, 
addition of 0.5% anti-clumping agent in the basal media helped to alleviate the 
aggregating problem, especially to the BC-P clone. The longevity of cultures, 
therefore, was prolonged up to 4 more days (data not shown). 
2.4.2 Cell metabolism and feed composition 
Around day 4-6 all cultures showed a transition from the growth phase to the 
stationary phase, which is commonly observed for CHO cells in batch and fed-batch 
cultures51,60–62. Nevertheless, the relation between overall metabolite profiles and this 
transition is still poorly understood, which is due to the highly complex and dynamic 
nature of CHO cell metabolism and the complexity of the media used. In this section, 
metabolite profiles are described with a focus on the changes that occurred during 
the culture phase transition. It is clear from section 2.3.3.1 that the transition from 
growth to stationary phase was not caused by depletion of glucose or essential amino 
acids. It is also not likely that the transition was caused by lactate and ammonium 
inhibition, since the concentrations of lactate and ammonium at the transition points 
were below the reported growth inhibition levels of 5-8 mM for ammonia63,64 and 30 
mM for lactate65. In most of the tested conditions, however, glutamine and 
asparagine were depleted between day 4 and day 6 (Figure 7), which coincided with 
the phase transition, and a shift of lactate metabolism from net production to net 
consumption. For the BC-G clone cultured in ActiCHO medium, depletion of 
asparagine and glutamine (Figure 7) occurred later probably as a consequence of a 
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lower growth rate (Table II). For this culture the transition to stationary phase and 
the shift in lactate metabolism were also delayed (Figure 5B). It was reported that the 
depletion of asparagine and glutamine coincides with CHO cell growth suppression66. 
On the other hand, as can be seen in this study, glutamate and glutamine were 
accumulated at the later stage of the cultures. Since glutamine is not present in the 
feed, this shows that the CHO cells used in this study can produce glutamine from 
glutamate and therefore glutamine is not likely limiting the cultures. Asparagine is 
present in the feed. Although asparagine was depleted during the later stage of the 
cultures, it might be converted to aspartate by cells resulting in the accumulation of 
aspartate (Figure 7 B&G). In the combination of OptiCHO + EFA/B, apart from 
asparagine and glutamine, also tyrosine and cystine were depleted around the 
culture transition point for both clones, which might be related to the lower mAb 
productivities (Table II). Similar observations of tyrosine and cystine depletion 
affecting protein production were shown for CHO cells67 and hybridoma cells68. The 
non-essential amino acids can be produced by cells, therefore the effects of their 
depletion at extracellular level to the culture performance could not be confirmed in 
this study. The essential amino acids however, cannot be made by cells. It is 
important to avoid their depletion. 
Specific consumption rates of glucose and amino acids are expected to decrease 
when a culture shifts from the growth to the stationary phase60 due to decrease of the 
specific  growth rate. However, in contrast to all the other tested conditions, for the 
BC-P clone fed by Actifeed A/B, the average specific glucose consumption rate 
increased in the stationary phase with a factor 1.5: from 2000 to 3200 fmol∙cell-1∙day-1 
grown in OptiCHO basal medium and from 2700 to 3900 fmol∙cell-1∙day-1 grown in 
ActiCHO basal medium (Figure 8). The higher specific glucose consumption rate 
correlates with fact that cells become bigger (only for BC-G in Opti + Actifeed A/B 
this is not observed, because this culture had to be stopped before the increase 
became apparent). It is likely that bigger cells need more energy for growth and 
maintenance which is supplied by higher glucose consumption rates. It is also worth 
noting that when the average glucose consumption rate is calculated per cell volume 
(data not shown), a drop is observed upon the transition from growth to stationary 
phase just as with the other conditions. For the BC-P clone also more lactate is 
formed during the stationary phase (Figure 5 F), which means even more glucose 
needs to be consumed, since lactate formation is less efficient for ATP generation. In 
addition, production of alanine for both clones was observed (Figure 7 E&J). The 
production was not observed when both clones were cultured in poor medium-feed 
combinations (OptiCHO + EFA/B). Extra carbons generated from glycolysis can also 
be diverted to alanine production through transaminase. This step at the same time 
transports amine groups out of the cells. Richer media and feeds (eg. ActiCHO + 
Actifeed A/B) supply sufficient amino acid nitrogen to make all the needed alanine 
and thus alanine was even produced in these cases, while for the poor media and 
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feeds (eg. OptiCHO + EFA/B) this is not the case and additional alanine is taken up 
by the cells.  
 
 
Figure 10. Relative feed balancing level of essential amino acids in different culture conditions during 
growth phase (G-Phase) and stationary phase (S-Phase). A value other than 1 means that the supply 
of the essential amino acid is either lower (<1) than or higher (>1) than the specific consumption rate, 
resulting in either depletion or accumulation. Relative balancing levels indicated with (×) and (*) 
cannot be calculated due to early cell death and inaccurate (R2<0.8) specific consumption rate 
calculations, respectively.  
Correlated with the drastic increase of cell size for the BC-P clone fed by Actifeed 
A/B, glucose metabolic activity showed large variation for this clone (Figure 9). Since 
the feeding strategy in this experiment was based on glucose consumption, the 
addition of other nutrients may be out of balance. In order to evaluate the balance of 
the feeds, we studied the relative balancing levels of the feeds for each condition 
(Figure 10). The definition of the relative balancing level can be found in the material 
and methods section (2.7). For the growth phase of both clones, both feeds are 
reasonably well balanced. Only for the combination of the BC-G clone with the rich 
medium and feed (ActiCHO with Actifeed A/B) balancing of the feed Actifeed A/B is 
poorer with concentrations of essential amino acids being too high relative to the 
glucose concentration. Upon the transition of growth to stationary phase the specific 
consumption rates of amino acids changes in a different way than the specific 
glucose consumption rate (Figure 8), which results in an increase of balancing level 
values for most of the amino acids, and explains the overfeeding for these amino 
acids (Figure 6). Especially for the BC-P clone fed by Actifeed A/B feed, accumulation 
of essential amino acids occurred when the feed addition is based on glucose 
consumption, due to the fact that the specific consumption rate of glucose increased 
while the specific consumption rates of amino acids decreased during the stationary 
phase. Increased amino acid levels could result in increased catabolic breakdown, 
which explains the increase in ammonium levels. High ammonia and glutamic acid 
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levels would also favor formation of alanine through the transaminase reaction63,69 
and formation of glutamine through glutamine synthase, which explains the 
formation of these compounds in these cultures (Figure 11). 
 
 
Figure 11. Schematic diagram of pathways related to the fates of lactate and ammonia. 
2.4.3 Optimization of fed-batch cultures 
Optimization of medium and feed formulations, and feeding strategy is an important 
step in process development. To keep stable nutrient levels, a feed formulation that is 
balanced with respect to the needs of a cell line over the whole culture period is 
required. In this study, a glucose based feeding strategy is applied instead of 
following the prescribed feeding strategy by suppliers in order to obtain a fairer cross 
comparison between basal media and feeds. This feeding strategy resulted in 
overfeeding of amino acids by Actifeed A/B on both clones (Figure 6) due to an 
imbalance in the feed. Notably, overfeeding of amino acids also occurred when 
following the protocols prescribed by the suppliers47. This study demonstrates that 
CHO cells may display a high variation in specific glucose consumption in different 
basal medium-feed combinations and during different phases. The increase of the 
specific glucose consumption is related to the increase of cell size. Moreover, the 
variation of the specific glucose consumption rate does not always correlate with the 
specific amino acid consumption rate, in other words, they do not shift up or down 
at the same time and to the same extent. Thus, as was done in other studies15,49, it is 
better to add glucose through a separate feed from the amino acids. Part of the 
variation in glucose consumption rate may be caused by uncontrolled glucose levels. 
The high glucose levels were shown to induce inefficient use of glucose, thus result 
in higher glucose consumption rate and higher lactate production rate47. Hence, 
control of glucose concentration at low values may reduce the variation and keep 
feeds more balanced throughout the process. 
For all tested culture conditions the ratios of specific amino acids consumption rates 
changed upon transition from the growth phase to the stationary phase, implying 
that the composition of amino acids in the feed should also be changed accordingly. 
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However, within the growth and the stationary phases, the behavior of the cells is 
fairly constant. Therefore, it would be possible to have two different feeds for the 
growth and the stationary phases. To our knowledge, a feed system design to meet 
different nutrient requirements for different culture phases has not been reported. 
Another feeding strategy would be to separate feed streams with nutrients that have 
the same ratio of specific uptake rates (eg. essential amino acids, which ratios of 
requirement do not change much) in the same stream. Changes in specific 
consumption rates during, for example a phase transition, can then be addressed by 
adjusting the feed rates for the separate feeds. An extra challenge for feed design is 
the solubility of different nutrients. Using more feed streams may circumvent this 
problem and make the feeds more concentrated and balanced. To solve this the 
amino acids could also be added as di- or tripeptides. It was shown that amino acids 
supplemented in the form of a dipeptide or tripeptide improved their solubility, yet 
resulted in similar culture effects70. 
The outcome of clone generation at this moment remains unpredictable. Intensive 
screening of clones and media is therefore still the most common industrial practice. 
It is shown in this study that although 2 clones were generated in the same way from 
the same parental cell line, they can still have distinct metabolic behavior for the 
different medium-feed systems. Only for the essential amino acids in the growth 
phase, ratios of the specific consumption rates were similar for the two clones (Figure 
8 A&C). Thus, for essential amino acids a single feed can be used for both clones in 
the growth phase. 
 
2.5  Conclusion 
The aim of this work is to investigate the effects of different basal media and feeds on 
cell growth, metabolism, physiology, and mAb production for two differentially 
behaving clones derived from the same parental cell line. The two clones show 
different metabolic and physiological responses for the different medium-feed 
combinations that were applied. The best mAb product titer (1.2 g/L) is obtained 
with ActiCHO basal medium and feeds. For all the tested conditions, the specific 
consumption rates for amino acids and glucose are different for the growth and 
stationary phase. Also the ratio of specific uptake rates are different in the different 
phases. However, the ratios of the consumption rates for amino acids within a phase 
are fairly constant for each of the two clones. Cells grown in cultures fed by Actifeed 
A/B show an increase in cell size during the stationary phase. The size increase 
correlates with an increase in specific glucose consumption rate in the stationary 
phase, whereas for all other conditions the specific glucose consumption rate 
decreases in the stationary phase. The increase of specific glucose consumption rate 
in the stationary phase of the cultures fed by Actifeed A/B leads to overfeeding of the 
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other nutrients, since the feeding is based on glucose. The result of this study can 
help to design better feed formulation and feeding strategy. 
 
  
         
 
 
         
 
Chapter 3 
 
Metabolic characterization of a CHO cell 
size increase phase in fed-batch cultures 
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Abstract: 
Normally, the growth profile of a CHO cell fed-batch process can be divided into two 
main phases based on changes in cell concentration, being an exponential growth 
phase and a stationary (non-growth) phase. In this study, an additional phase is 
observed during which the cell division comes to a halt but the cell growth continues 
in the form of an increase in cell size. The cell size increase (SI) phase occurs between 
the exponential proliferation phase (also called the number increase or NI phase) and 
the stationary phase. During the SI phase, the average volume and dry weight per 
cell increase threefold linearly with time. The average mAb-specific productivity per 
cell increases linearly with the cell volume and therefore is on average two times 
higher in the SI phase than in the NI phase. The specific essential amino acids 
consumption rates per cell remain fairly constant between the NI and the SI phase, 
which agrees with the similar biomass production rate per cell between these two 
phases. Accumulation of fatty acids and formation of lipid droplets in the cells are 
observed during the SI phase, indicating that the fatty acids synthesis rate exceeds 
the demand for the synthesis of membrane lipids. A metabolic comparison between 
NI and SI phase shows that the cells with a larger size produce more mAb per unit of 
O2 and nutrient consumed, which can be used for further process optimization. 
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3.1 Introduction 
Chinese Hamster Ovary (CHO) cells are the predominant host for the production of 
therapeutic monoclonal antibodies (mAbs). At the moment, fed-batch is the most 
common industrial process for CHO cell cultures, due to its ease of operation and 
flexibility. Three different culture phases can normally be discerned in a fed-batch 
culture: an exponential growth phase, a stationary phase, and a death phase60,71,72. The 
transitions between these phases are caused by the changes in culture conditions (e.g. 
nutrient depletion and/or waste accumulation). The transition from the growth to the 
stationary phase determines the maximum viable cell density (VCD), whereas the 
transition from stationary to death phase determines the culture longevity. These 
collectively determine the integral viable cell density (IVCD) which is positively 
correlated with the final mAb product titer. A better understanding of the underlying 
mechanisms causing these transitions can be used to develop cultivation processes in 
which cells grow to higher densities or to remain viable for a longer period of time, 
which both will result in an increased mAb volumetric productivity. Many studies 
have compared the metabolic and physiological states of different CHO cell culture 
phases. The growth phase is characterized by higher specific rates of glycolysis and 
glutaminolysis and, as a result, also by a higher lactate production rate. During the 
stationary phase, the metabolism shifts towards a more efficient use of substrates, 
represented by a lower metabolic flux through glycolysis, a higher flux through the 
TCA cycle, and often the consumption of lactate. Martínez et al.61 showed that a CHO 
cell line grown in a batch culture had a six times higher energy efficiency when 
consuming lactate as compared to the situation where lactate was produced. Using 
isotopic labeling in combination with metabolic flux analysis, Sengupta et al.72 and 
Templeton et al.73 both reported higher metabolic fluxes through the pentose 
phosphate pathway (PPP) and TCA cycle during the stationary phase as compared to 
the growth phase of CHO cell cultures. Furthermore, Templeton et al.73 showed that 
the high PPP and TCA activities are associated with peak mAb production. Results 
from Wahrheit et al.74 suggested that the metabolic shift in different culture phases of 
CHO cells is controlled by glycolytic regulation which affects the intracellular 
pyruvate availability. Ahn and Antoniewicz75 reported a higher fatty acids 
biosynthesis rate than needed by the cells during the stationary phase of CHO cell 
cultures. Despite that these studies have contributed to the fundamental 
understanding of CHO cell metabolism and resulted in improved process 
performances, the mechanisms underlying the phase are not yet fully understood, 
due to the complexity of media and feeds used and the highly dynamic nature of the 
current fed-batch processes. 
In a previous study on the selection of basal media and feeds for CHO cell fed-batch 
cultures8, it was observed that a cell size increase occurred after the exponential 
growth phase when ActiCHO feed A/B (GE Healthcare) was used but not when 
Efficient feed A, B, and C (Gibco™) were used. The cell size increase correlated with 
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higher final product titers. The physiological state of the larger cells and the cause of 
the size increase were not clear. The aim of this paper is to characterize the metabolic 
changes that occur upon the cell size increase in order to obtain more insight in the 
underlying mechanisms that cause the cell size increase and identify possible 
implications for process design. The metabolic changes are characterized in terms of 
biomass composition, specific consumption and production rates, and overall 
metabolic flux distributions using flux balance analysis (FBA). 
3.2 Materials and Methods 
3.2.1 Cell line and pre-culture 
A suspension CHOBC®  cell clone (BC-P, provided by Bioceros Holding BV, Utrecht, 
NL) producing a recombinant immunoglobulin G1 (IgG1) was used in this study. 
Cells were thawed from a working cell bank and maintained in ActiCHO-P medium 
(GE Healthcare, France) supplemented with 4 mM glutamine (Gibco™, Paisley, 
Scotland, UK) and 0.5% Anti-clumping agent (Gibco™ Paisley, Scotland, UK). 200 
µg/mL ZeocinTM and 5 µg/mL Blasticidin (both from Gibco™, Grand Island, NY, USA) 
as selection reagents were added during the pre-cultures. Cells were maintained in a 
125 mL un-baffled shake flask (Corning, NY, USA) with a 25 mL working volume in 
a CO2 (8%) and temperature (37oC) controlled incubator. The maintained cultures 
were sub-cultured every 3 days to 2×105 viable cells/mL. The seed train was scaled up 
through 2 L and 20 L rocking bag systems. During the seed train scale-up, the 
medium described above was used but without the two selection reagents. 
3.2.2 Fed-batch process 
Triplicate fed-batch cultures were conducted in 10 L bioreactors (Sartorius Stedim 
Biotech, France) controlled by BIOSTAT®  B-DCU II. Each bioreactor was inoculated 
with a starting density of 3×105 viable cells/mL at a starting volume of 5 L. Culture 
temperature was controlled at 37°C, dissolved oxygen (DO) was controlled at 40% by 
enriched O2 flow, pH was controlled at 7.2 by using base and CO2. From day 3 
onward, feeds were added to each bioreactor daily. First, the glucose concentration 
was measured. If the concentration was lower than 18 mM, a 45% (w/w) glucose 
solution was added as one bolus to reach a glucose concentration of 28 mM in the 
reactor. Next, 4.5% (v/v) ActiCHO feed A, also containing about 500 mM glucose 
amongst other nutrients, and 0.45% (v/v) ActiCHO feed B (both from GE Healthcare, 
USA) per culture volume per day were fed to each reactor. Simethicone antifoam 
solution was added to each bioreactor prior to inoculation and during the culture 
when needed. 
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3.2.3 Sampling and analysis 
For each bioreactor, a-15 mL sample was taken daily before and after the feed 
addition. Total cell density, viable cell density, and cell diameter were measured 
using a CedexHiRes®  analyzer (Roche, Switzerland). Off-line pH, pCO2, glucose 
concentration, lactate concentration, ammonium concentration and osmolality were 
measured by a Nova FLEX analyzer (Nova Biomedical, USA). The remaining sample 
was spun down at 3345×g for 15 min and stored at -20°C for later analysis. On culture 
day 4, 7, and 10, biomass samples were taken from each bioreactor containing 300 
million cells per sample. The samples were spun down at 500×g for 10 min and re-
suspended in PBS solution (Lonza, Switzerland). Next, the viable cell density was 
measured again, and each sample was aliquoted into six 15 mL centrifuge tubes with 
each tube containing 50 million viable cells. The tubes were spun down at 500×g for 
10 min again after which the PBS supernatant was discarded and the wet cell pellets 
were stored at -20°C for later biomass analysis. 
Total soluble cellular protein was determined using Lowry Bio-Rad DC Protein assay 
kit (Bio-Rad, NL). Bovine serum albumin (BSA, Sigma-Aldrich) was used as a 
reference standard. The extraction, separation, and quantification of triacylglyceride 
(TAG) and polar lipids were performed as described by Breuer et al.76 using the 
sample preparation method 2. Lipid droplets in CHO cells were stained with 
BODIPY 505/515 (Invitrogen Molecular Probes, Carlsbad, CA) and visualized using a 
confocal laser scanning microscope (LSM510; Carl Zeiss, Jena, Germany), as 
described by Cooper et al.77. Total cellular carbohydrate content was measured 
according to the DuBois’ method78. A glucose solution (Sigma-Aldrich) was used as a 
reference standard. Cell dry weight (DW) was calculated based on the difference in 
weight of the tube with the 50 million freeze-dried cells and the pre-weighed 
centrifuge tube itself. 
Compositions of the spent medium including extracellular amino acids, sugars, and 
organic acids were quantified using NMR (Spinnovation Biologics BV, Oss, NL). 
IgG1 titer was quantified by Protein-A Chromatography (Agilent, 5069-3639). The N-
glycans were quantified by Hydrophilic Interaction Chromatography (HILIC UPLC). 
A dextran calibration ladder standard (Waters) solution was used to identify the 
glucose unit of the measured N-glycans. Both mAb quantification and N-glycan 
analysis were developed by Bioprocess engineering group of Wageningen University. 
3.2.4 Average specific metabolic rates 
The average specific metabolic rates were calculated for the NI and the SI phase, 
respectively. Day 0 and 1 were not considered in calculating the average specific 
rates for the NI phase, due to a metabolic adaptation period just after inoculation. 
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The average specific production rate of antibody was calculated by averaging the 
daily specific rates during both the NI and the SI phases. The following equation is 
used to calculate the specific production rate of a compound x, as described in 
Chapter 28: 
𝑀𝑥(𝑡) − 𝑀𝑥(0) − 𝑉𝑓 × 𝐶𝑓 = 𝑞𝑥 ∙ ∫ 𝑋𝑉𝐶
𝑡
0
𝑑𝑡     (Equation 1) 
where Mx (mg; mmol) is the total amount of compound x in a culture, XVC is the 
number of viable cells in the reactor, Vf (mm3) is the total volume of feed added, Cf 
(mM) is the concentration of compound x in the feed, and qx (mg·cell-1·day-1; 
mmol·cell-1·day-1) is the cell-specific production rate of the compound x. When the 
rates are calculated based on cell volume, XVC (mm3) presents the volume of viable 
cells in a culture and qx (mg·mm-3·day-1 or mmol·mm-3·day-1) is the cell volume-
specific production rate of compound x. The average specific production rates (q) of 
glucose, amino acids, and organic acids were obtained from a plot of the total 
amount of production/consumption against the total integral viable cell number (or 
total integral viable cell volume) using linear regression. Positive values indicate 
production while negative values indicate consumption. The specific cell growth rate 
(µ NI; day-1) during the NI (exponential growth) phase is given by: 
µ𝑁𝐼 =
ln
𝑋𝑉𝐶(𝑡)
𝑋𝑉𝐶(0)
𝑡
⁄       (Equation 2) 
where XVC is the total number of viable cells in the reactor. During the SI phase in 
which the cell concentration is constant and the cell volume increases linearly with 
time, the cell-specific production rate of biomass (qSI; day-1) is calculated by: 
q𝑆𝐼 =
𝑀(𝑡𝑒)−𝑀(𝑡𝑠)
𝑡𝑒−𝑡𝑠
𝑋𝑉𝐶
⁄      (Equation 3) 
where M(te) and M(ts) are the amounts of biomass in a reactor at the end (te) and the 
start (ts) of the SI phase. In principle, the unit of M is gram dry weight. However, to 
compare the growth in the SI phase to the exponential growth in the NI phase, the 
amount of biomass is still expressed in cell number by dividing the dry weight by the 
dry weight of a cell in the NI phase. In this way, the specific biomass production rate 
in the SI phase can still be compared to the specific growth rate in the NI phase. The 
specific growth rate in the NI phase and the specific biomass production rate in the SI 
phase are used as input values for the subsequent flux balance analysis. 
3.2.5 Flux balance analysis (FBA) and flux variability analysis (FVA) 
A basic model of CHO cell primary metabolism was developed starting from an 
earlier published basic model for mammalian cells79. The reactions in the model were 
cross-checked with the iCHOv1 model80. Several modifications were made based on 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, the iCHOv1 
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model, and the measurements done in this study. A Chi-square test was used to 
check whether the nitrogen balances closed for both phases. The FBA was conducted 
using the constraint-based reconstruction and analysis (COBRA 2.0) Toolbox81, using 
MATLAB software (The MathWorks, Inc.). Geometric FBA82 was performed to find a 
unique solution for the underdetermined parts of the metabolic model. The growth 
rate was used as an objective function for the model. The measured cell-specific 
production rates were used as inputs for FBA. To study the possible range of flux 
values that results in the same optimal growth rate while still meeting all constraints, 
flux variability analysis (FVA) was performed using the COBRA Toolbox.  
3.3 Results 
3.3.1 Cell growth 
Based on cell concentration, the growth curve of CHO cells normally consists of an 
exponential cell proliferation phase, a stationary phase, and a death phase. In this 
study, an additional cell size increase phase is reported (Figure 1), resulting in four 
phases for this CHO cell fed-batch process being: (i) A phase in which the cell 
concentration increases exponentially (day 0 to 4) and the volume per cell remains 
constant (the number increase or NI phase). (ii) A phase in which the cell size 
increases nearly linear (R2=0.99) in time (day 4 to 8) and the cell concentration stays 
approximately constant (the size increase or SI phase). (iii) A short stationary phase 
(day 8 to 10) in which the biomass concentration remains approximately constant 
and the culture viability is always higher than 80%. (iv) A death phase (day 10 to 12) 
in which the viability declines and is always lower than 80%. Since the observed 
change from growth in cell concentration to growth in cell size has not been reported 
in regular fed-batch processes and can have consequences for process development, 
this study mainly focuses on the NI phase and the SI phase.  
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Figure 1. (a) Total number of viable cells (×109, solid lines) and total volume of viable cells (mm3, dotted 
lines), and (b) average cell diameter (µm, solid lines) and viability (%, dotted lines) of reactor 1 (closed 
circles), 2 (closed diamonds), and 3 (closed squares). Cultures were divided into a number increase (NI) phase, 
a size increase (SI) phase, a stationary phase, and a death phase. (c) Cell diameter (µm) distribution during a 
representative fed-batch culture on day 4 (closed squares), 7 (closed diamonds), and 10 (closed triangles) 
3.3.2 Metabolites profiles 
To identify possible limiting or inhibitory compounds and to characterize 
metabolism in the different phases, extracellular concentrations of substrates and 
products were measured. Concentrations of extracellular glucose, lactate, and 
ammonium are shown in Figure 2a. The 45% glucose solution is added on culture 
day 3, 7, 8, and 10 when the glucose concentration is lower than 18 mM, as described 
in materials and methods. Next to this, the ActiCHO feed A&B are added daily. On 
the days other than 3, 7, 8, and 10, the increases in culture glucose concentrations 
were caused by the addition of ActiCHO feed A only. Using this feeding strategy, the 
glucose concentration in each bioreactor stayed above 5 mM throughout the fed-
batch cultures. Furthermore, since the ActiCHO feed A also contains glucose, the 
culture glucose concentration after feeding can be higher than 28 mM. Lactate is 
produced during the NI phase (day 0-4) until nearly 30 mM and is consumed at a 
A 
B 
C 
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lower rate during the SI phase and stationary phase (day 4-10), followed by 
production again during the death phase (day 10-12). Ammonium concentrations 
stay constant at values lower than 5 mM until culture day 7 and start to increase 
gradually thereafter up to 15 mM on day 12. Production of formic acid (up to 7 mM 
at day 10) and acetic acid (up to 15 mM at day 10) are observed in the cultures 
(Figure 2b). Succinic acid is present in the basal medium and is consumed during the 
culture (Figure 2b). None of the essential amino acids is depleted during the fed-
batch cultures (Figure 2c). The gradual increase in their concentrations after day 3 is 
caused by the feed addition, since these essential amino acids cannot be made by 
CHO cells from the other compounds. Note that for some of the non-essential amino 
acids the cell may not be able to synthesize them fast enough to support growth 
making them essential for a robust process, consequently, they also need to be 
present in the medium and feed. For some of the non-essential amino acids, 
asparagine, glutamine, and cyst(e)ine (cysteine is measured in the form of cystine in 
this study) are consumed during the NI phase and are depleted around day 4 (Figure 
2d). Glutamine, which is not present in the feed, is produced after day 7. Cyst(e)ine 
concentration increases after day 5.  
 
 
 
Figure 2. (a) Extracellular glucose (solid lines), lactate (dotted lines with closed marks), and ammonium 
(dotted lines with open marks) concentrations (mM) of reactor 1 (circles), 2 (diamonds), and 3 (squares). (b) 
Extracellular concentrations of measured organic acids. (c) Extracellular concentrations of essential amino 
A B 
C D 
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acids. (d) Extracellular concentrations of non-essential amino acids. Feeding started on day 3. For glucose, 
lactate, and ammonium, samples were taken daily before and after feed addition. For the other organic acids 
and amino acids, samples were taken daily before feed addition. Error bars for all graphs indicate the 
standard deviation for the triplicate bioreactors 
3.3.3 Cell-specific rates vs. volume-specific rates 
In order to obtain insight into the relationship between cell volume and the specific 
consumption and production rates of nutrients and products, including mAb, their 
metabolic rates were calculated and compared in this section. The rates are calculated 
on a per cell and per cellular volume basis for the NI and the SI phase, respectively.  
The average specific mAb productivities calculated based on cell-volume and cell-
number are shown in Figure 3a. Average specific productivity expressed per cell is 
twofold higher (15 compared to 7.5 pg×cell-1×day-1) in the SI phase compared to the 
NI phase. When calculated per cell volume, the specific productivities in the two 
phases are not significantly different, indicating that the mAb productivity of a cell is 
related to its volume. This becomes clearer when the productivity per cell is plotted 
against the cellular volume, which results in a linear correlation between average cell 
volume and specific mAb productivity as shown in Figure 3c. The specific glucose 
consumption based on cell number shows only a slight decrease (4.5 to 4.1 µmol×10-6 
cells×day-1) from the NI to the SI phase. The decrease is larger (1.9 to 0.8 µmol×mm-
3×day-1) when the rate is calculated based on cell volume. Thus, the specific glucose 
consumption rate is related more to the cell number and less to the cell volume. 
Lactate is produced during the NI phase at a high rate (3 µmol×10-6 cells×day-1; 1.3 
µmol×mm-3×day-1) and is consumed during the SI phase at a much lower rate (0.25 
µmol×10-6 cells×day-1; 0.05 µmol×mm-3×day-1) (Figure 4). The cell number-specific and 
cell volume-specific consumption rates of ten essential amino acids during the NI 
and the SI phase are shown in Figure 5. When the consumption rates are expressed 
based on cell number, six out of ten essential amino acids do not show a significant 
difference between the two phases. However, as the cell volume increases in the SI 
phase, the cell volume-specific consumption rates of all the essential amino acids 
show significant drops. This implies that the consumption of the essential amino 
acids is more related to the cell number than to the cell volume. 
 
 
    
54  
   
 
Figure 3. (a) Average cell number-specific (pg×cell-1×day-1) and average cell volume-specific (g×L-1×day-1) 
mAb productivity compared between the number increase (NI) and size increase (SI) phase of the cultures. *: 
significantly different (P<0.05). (b) Total mAb produced (g) in reactor 1 (closed circles), 2 (closed diamonds), 
and 3 (closed squares). (c) Plot of specific mAb productivity (pg×cell-1×day-1) against cell volume (µm3). 
Calculation was done per day from day 2 through day 12. Error bars of graph (a) and (c) show the standard 
deviation of triplicate fed-batch cultures. Error bars of graph (b) show the standard deviation of triplicate 
measurements for each fed-batch culture 
3.3.4 Biomass composition 
The composition of biomass with respect to protein, fatty acids, carbohydrate, RNA, 
and DNA is shown in Table I as a percentage of the cell dry weight (DW). The amino 
acid composition of the cellular protein and the fatty acids composition of the lipids 
stayed constant during the fed-batch culture (the average values are given in ESM_3 
Table S1 & S2 of the online published data). The cell DW increased linearly with the 
cell volume over the culture time, from 770 pg/cell on day 4 to 2440 pg/cell on day 10 
(Table I). Furthermore, the relative composition of the biomass shifted during the 
cultures. The protein content in the biomass decreased from 74.5% to 67% whereas 
the fatty acid content increased from 7.2% to 10.3% from culture day 4 until culture 
day 10. A microscopic image (Figure 6) shows a clear accumulation of lipid droplets 
during the SI phase. These droplets are not composed of triacylglyceride (TAG) (data 
not shown). The sum of all biomass components adds up to around 90% of the cell 
DW. 
 
B C 
A 
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Table I. CHO cell biomass composition during the fed-batch cultures 
Biomass composition Day 4 Day 7 Day 10 Hybridoma83 Hybridoma84 
Protein (%) 
74.5 
±1.0 
70.0 
±1.2 
67.0 
±1.0 
72.9 70.6 
Fatty acids (%) 
7.2 
±0.2 
8.4 
±0.3 
10.3 
±0.1 
13.5 b 9.7 b 
Carbohydrate (%) 
4.0 
±0.1 
3.8 
±0.2 
4.1 
±0.1 
3.5 7.1 
RNA a (%) 6.0 5.6 5.4 3.8 5.8 
DNA a (%) 1.6 0.8 0.6 1.4 1.4 
Total (%) 
93.1 
±1.4 
88.6 
±1.7 
87.4 
±1.2 
95.1 94.6 
Cell dry weight 
(pg/cell) 
770 
±47 
1530 
±77 
2440 
±86 
250 470 
Cell volume 
(mm3/106 cells) 
2.7 
±0.02 
5.5 
±0.16 
6.9 
±0.14 
N/R 1.8 
 
All percentage values are in w/w % 
a Not measured in this study, data were calculated by assuming a constant DNA content per cell and a constant 
ratio of RNA to protein 
b Values for lipid including glycerol 
± Standard deviation for biological triplicates 
N/R not reported 
 
 
 
Figure 4. (a) Cell number-based specific rates (µmol×10-6 cells×day-1) and (b) cell volume-based specific rates 
(µmol×mm-3×day-1) of glucose consumption and lactate production/consumption during the number increase 
(NI) and size increase (SI) phase of the fed-batch cultures. Positive values indicate production and negative 
values indicate consumption. Error bars show the standard deviation of triplicate fed-batch cultures. *: 
significantly different (P<0.05) 
A B 
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Figure 5. (a) Cell number-specific consumption rates (µmol×10-6 cells×day-1) and (b) Cell volume-specific 
consumption rates (µmol×mm-3×day-1) of essential amino acids during the number increase (NI) and size 
increase (SI) phase of the fed-batch cultures. Error bars show the standard deviation of triplicate fed-batch 
cultures. *: significantly different (P<0.05) 
 
                  
Figure 6. Lipid droplets stained with BODIPY 505/515 (green) during the CHO cell fed-batch on culture day 
3 (a) and culture day 6 (b) 
 
B 
A 
A B 
       
57 
 
3 
3.3.5 Flux balance analysis 
Geometric flux balance analysis (FBA) is carried out to further investigate the shift of 
the overall metabolic flux distribution from the NI phase to the SI phase. The FBA 
results for both phases are summarized in Figure 7. The metabolic fluxes are 
expressed per cell because the uptake rates of essential amino acids and glucose, and 
the biomass formation rate are constant on a per cell basis in the NI and SI phase. On 
a per volume basis rates are continuously decreasing during the SI phase due to the 
increase in cell volume. During the SI phase, the change in biomass content per cell 
and in biomass composition is considered in the biomass equation in the FBA model. 
The flux variability analysis (FVA) shows that the flux variability results in 
overlapping flux values with respect to the two different phases for the PPP as well 
as for the TCA cycle, as indicated by the red numbers in Figure 7. This means the 
value of these fluxes cannot be identified as being different between the two phases, 
which is further addressed in the discussion. During the NI phase, high fluxes 
through lactate and alanine production are calculated. During the SI phase, lactate 
metabolic flux shifts to a consumption and the flux from pyruvate to alanine 
decreases. Higher O2 consumption and CO2 production fluxes (~1.5-fold higher) are 
calculated for the SI phase, which agrees with the higher ATP generation flux in the 
mitochondria. The ATP is transported to the cytosol through ATP/ADP translocases 
and used for biomass and product synthesis, and for cell maintenance. The cellular 
protein formation rate decreases by 25% whereas the mAb formation increases by 
250% during the SI phase. In the NI phase, mAb production is about 1.5% of the total 
protein synthesized, whereas in the SI phase this becomes 5%. In the SI phase, the 
fatty acids synthesis flux is slightly higher and the flux from AcCoA to acetic acid is 
also higher than in the NI phase.  
3.3.6 mAb N-glycan composition 
The glycosylation profile of a mAb is routinely analyzed throughout process 
development to ensure process consistency. In order to investigate whether or not 
the mAb glycosylation changes as cell size increases, the N-glycan composition of the 
produced mAb is measured on culture days 5, 8 and 12 (Figure 8). The relative 
composition of N-glycans does not show differences between culture day 5 and 8, 
indicating that the mAb glycosylation does not change as cell size increases. 
Differences on day 12 are observed which is most likely related to cell death and 
release of degradative enzymes, since the culture viability drops to 60% on day 12.  
3.4 Discussion 
In this study using ActiCHO medium as basal medium and Actifeed A and B as 
feeds, a cell size increase phase was observed during which the cell concentration 
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remained approximately constant, while the cell volume increased almost three times. 
A previous study 8 showed that the cell size increase in CHO fed-batch processes is 
clone and medium/feed dependent. Furthermore, an experiment with the same 
process and medium system but with a lower feed addition rate, the same extent of 
cell size increase was observed (data not shown), implying that the cell size increase 
is not merely caused by nutrient oversupply. However, several non-essential amino 
acids were depleted around day 4 (Figure 2d), which might play a role in the 
metabolic transition from the NI to the SI phase.  
 
Figure 7. Major metabolic flux changes between (a) the number increase (NI) and size increase (SI) phase 
during the fed-batch cultures. The line thickness indicates the relative flux changes between the two presented 
phases. The average flux of the TCA cycle is represented by the average fluxes between the flux from citrate 
(CIT) to α-ketoglutarate (AKG) and the flux from succinate (SUC) to fumarate (FUM). The colors of the flux 
values indicate the flux variability result between the two phases. The green values show no overlap of the 
variable flux values between the two phases whereas the red values show there is overlap. The unit for flux 
values is mmol×10-9 cells×day-1 
The cell diameter distribution during the fed-batch cultures (Figure 1c) showed that 
the increase in cell diameter occurred for the whole cell population instead of only a 
sub-population. It was also established in this study that the cell size increase is due 
to a proportional increase in biomass content (Table I), rather than due to a cell 
swelling effect through the uptake of water and salts. The cell DW measurement 
resulted in higher values (770 pg/cell or higher) than commonly reported for CHO 
cells (300-400 pg/cell) 57,85,86. This can be explained by the larger cell size (17 µm 
diameter on day 4) of the CHO cell line used in this study, compared to those 
reported (12-14 µm diameter) 57. We applied the same DW measurement for another 
cell line with an average cell diameter of 14 µm at a viability higher than 90%, which 
A B 
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resulted in ~330 pg/cell (data not shown). Furthermore, the amino acid composition 
of the cellular protein and the fatty acids composition of the lipids analyzed in this 
study (ESM_3 Table S1 & S2 of the online published data) are comparable to those 
reported for other CHO cells 87,88. With respect to the content of protein, lipids, 
carbohydrates DNA, and RNA, such data could not be found in or derived from 
CHO cell studies and therefore, a comparison to the biomass composition of 
hybridoma cells 83,84 is shown (Table I). As can be seen, the compositions are more or 
less comparable.  
 
Figure 8. Relative mAb N-glycan composition (%) of the 10 L cultures. N-glycans with different numbers of 
terminal residuals (G: galactose, F: fucose, S: sialic acid) are shown. Error bars show the standard deviation 
of the triplicate runs. *: significantly different (P<0.05) 
The results for the CHO cell line used in this study show that the mAb specific 
productivity is directly proportional to the cell volume (Figure 3a & 3c), and further 
confirm that the mAb glycosylation profile does not change as the cell size increases 
(Figure 8). This is in agreement with Lloyd et al.56, who argued that the cell size is the 
major cellular determinant of productivity rather than the cell cycle phase. In 
addition to this, Edros et al.89 and Khoo and Al-Rubeai90 showed that the increase in 
specific productivity is directly related to the increase in cell volume due to increase 
in transcription, translation, and secretion machinery. Kim et al.58 reported that the 
enhancement of the specific thrombopoietin productivity is linearly correlated with 
the increase in cell size for nine CHO cell clones generated using the same 
transfection process. In a number of studies the relation between cell size and specific 
productivity was used to enhance mAb productivity, by directly or indirectly 
increasing the cell size, for example, through cell cycle arrest 53,91, hyperosmotic 
pressure 92,93, and mild hypothermia 57,94. 
Acetic acid and formic acid accumulation were observed during the cultures (Figure 
2b). Possibly the acetic acid is formed from acetyl-CoA by one of the thioesterases 
that may be present in CHO cells 95. This is further supported by the formation of 
isovaleric acid during the SI phase (Figure 2b), which is formed from isovaleric acid-
CoA as a breakdown product of leucine 96 and also requires the activity of an esterase. 
The formic acid concentration in this experiment reached 4 mM on day 5 (Figure 2b), 
    
60  
   
which concentration was shown to inhibit CHO cell growth 97. Formic acid is 
considered a breakdown product of serine 71,98. In the present study, formic acid is 
mainly produced by the breakdown of serine through folate metabolism (ESM_1 of 
online published data), which is also reported by Carinhas et al.71 and Duarte et al.98 
and a small fraction is generated in the breakdown of tryptophan and during 
synthesis of cholesterol (ESM_1 of online published data). The high breakdown rates 
for some amino acids are likely caused by the overfeeding of these nutrients after the 
NI phase as can be seen in Figure 2. In addition, lactate concentration showed a peak 
at 30 mM at around the point where the transition from the NI to SI phase occurred 
(Figure 2). However, the lactate concentration in this study is not expected to be the 
trigger of the phase transition, since the cell clone used in this study was observed to 
be able to grow in cell concentration at a lactate concentration up to 40 mM (data not 
shown).  
During the SI phase, the slightly higher fatty acids synthesis fluxes (Figure 7) 
occurred together with the formation of lipid droplets (Figure 6). Formation of lipid 
droplets has been reported in CHO cells 99. In addition, high fatty acids synthesis rate 
during stationary phase was previously reported in a CHO cell study using 13C 
isotopic tracers 75. However, the fate of the excessive fatty acids was unclear in that 
study. We hypothesize that the accumulation of lipids in the present study is mainly 
caused by a maintained fatty acids synthesis rate in combination with a decreased 
membrane lipid demand during the SI phase. A slight increase in the fatty acid 
synthesis flux from the NI (0.07) to the SI (0.09) phase (Figure 7) is observed. The 
amount of extra NAD(P)H needed for this is negligibly small compared to the total 
NAD(P)H oxidation flux. The slight increase in the fatty acid synthesis flux, therefore, 
is not expected to largely affect the overall redox rearrangement and through this 
play a role in the change in lactate metabolism. 
3.4.1 Metabolic patterns of cell size increase 
Based on FVA, higher O2 consumption and oxidative phosphorylation fluxes were 
calculated in the SI phase as compared to the NI phase. This results in a higher ATP 
synthesis flux during the NI phase, which is reflected in the higher ATP translocation 
flux from mitochondria to cytosol in the SI phase (Figure 7). The higher flux through 
oxidative phosphorylation means that more NADH is generated in the SI phase. The 
NADH can be generated in glycolysis and the TCA cycle or by the combined activity 
of the PPP and transhydrogenase systems. However, the fluxes in these pathways 
cannot be independently calculated (shown by the red flux values in Figure 7) and 
thus it remains unknown whether the increased O2 consumption and oxidative 
phosphorylation activity are due to an increase in TCA flux or an increased flux 
through the PPP or both. Bi et al.52 reported a significant increase in mitochondrial 
activity (1.6-fold) and mitochondrial mass (twofold) for a CHO cell line with a 
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similar cell volume increase (three- to fourfold). Furthermore, Zagari et al.100 showed 
that the lactate metabolism shift from production to consumption was correlated 
with higher mitochondrial activity. The same lactate metabolic shift also occurred in 
the SI phase of our study, which also may point to an increase in TCA cycle activity 
during the SI phase. These studies support that the increased NADH generation flux 
during the SI phase is mainly generated from a higher flux through the TCA cycle. 
However, Sengupta et al.72 and Templeton et al.73 showed by using isotopic labeling 
that the flux through both the oxidative PPP as well as through the TCA cycle 
increased during the non-growth phase. In addition, Ahn and Antoniewicz60 
reported a significant increase in oxidative PPP together with a constant TCA flux 
from the growth phase to the stationary phase. However, in these last three studies, 
the increase in cell size was not reported and thus the metabolic condition of the non-
growth phase in their studies may not be fully illustrative for the SI phase of this 
study. In conclusion, increased O2 consumption and oxidative phosphorylation 
fluxes are calculated and it seems most likely that an increased TCA cycle flux is the 
cause for the faster NADH generation in the SI phase. 
The increased NADH demand and likely higher TCA cycle activity to generate this 
NADH could result in a lower NADH/NAD ratio and a lower pyruvate 
concentration in the cell. This might be related to the metabolic switch from lactate 
production to consumption, since the conversion of lactate to pyruvate generates 
NADH and the pyruvate that is generated can support the higher TCA flux. The 
higher flux through oxidative phosphorylation may have two causes: (i) a higher 
energy demand of cells in the SI phase for maintenance and/or growth. This may be 
directly related to cell size, but may also be related to other factors that change over 
time like for example the ammonium concentration. The energy requirement for 
maintenance can increase when cells are exposed to ammonium due to its 
competitive inward transport over potassium ions via the Na+/K+-ATPase and the 
Na+K+2C1- cotransporter 101. However, the ammonium is not likely to cause an 
increase in energy demand since its concentration remains reasonably constant 
between the NI and SI phase. (ii). A decrease in mitochondrial efficiency by 
uncoupling of the oxidative phosphorylation. An “uncoupler” (i.e. leaky membrane) 
enables protons to flow back without passing through the ATP synthase, therefore, 
less ATP is generated from the same amount of NADH and FADH2 (i.e. a lower P/O 
ratio) 102. If the demand for ATP stays the same, a higher flux through oxidative 
phosphorylation and a higher O2 consumption rate are needed to meet this demand. 
The thioesterases responsible for the production of acetic acid and isovaleric acid as 
mentioned before may also be responsible for the release of free fatty acids that are 
known to uncouple the oxidative phosphorylation 103,104. The slightly higher fatty 
acids synthesis fluxes during the SI phase could be related to this. 
    
62  
   
3.4.2 Implications of cell size increase during a culture process 
The results of this study stress that cell size and the amount of biomass per cell 
should be taken into account during the process characterization. Based on cell 
density measurement alone, the threefold increase in biomass observed in this work 
would not have been captured (Figure 1), and the cell size increase phase would 
have been mistakenly identified as part of the stationary phase. In fact, a two-micron 
increase in cell diameter, for instance, from 14 to 16 µm, may already lead to a 50% 
increase in total cell volume or biomass. Furthermore, it can skew the process 
interpretation such as final biomass concentration reached, mAb productivity, and 
cellular metabolism. Similarly, skewed biological interpretation of a transcriptomic 
study due to cell size changes was reported by Fomina-Yadlin et al.31. The occurrence 
of cell size increase is also important for feed development. Since biomass continues 
to grow after the exponential cell concentration increase phase, the nutrients 
provided to the culture should contain not only nutrients assigned for maintenance 
and mAb production reactions, but also all the precursors and building blocks for 
biomass growth. In this specific culture process, a simple feeding concept would be 
to keep the feeding rate of essential amino acids at a per cell level the same during 
the SI phase and the NI phase, since the cell number-specific consumption rates 
remain fairly constant (Figure 5a).  
The present study further shows that during the SI phase the average mAb 
production per cell increased by a factor 2 (Figure 3), while the average O2 
consumption and CO2 production increased only by a factor 1.5 (Figure 7). In 
addition, compared to the NI phase, during the SI phase a higher proportion of the 
amino acids taken up from the medium is used for mAb synthesis (Figure 7). 
Collectively, the amount of mAb production per mol of oxygen and amino acid 
consumed increases for larger cells, which can be used for further process 
optimization. Especially for high-density perfusion processes where O2 and/or CO2 
transfer may be limiting, it may be favorable to have larger cells. 
This study demonstrates that cell size is an important factor for characterizing and 
optimizing a cell culture process. Correlations between the cell size increase and 
metabolic changes were found. However, further research is needed to understand 
the relationship between changes in cell size and changes in metabolism. In addition, 
studies on the cellular pathways that control cell size, such as the mammalian target 
of rapamycin (mTOR) pathway 105,106, and the extracellular stimuli involved could 
promote mechanistic understandings for the cell size increase, and enable controlled 
cell size manipulation during a culture process. 
 
 
 
         
 
  
         
 
 
Chapter 4 
 
Transcriptome analysis of CHO cell size 
increase during a fed-batch process 
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Abstract: 
Transcriptome analysis is performed to identify the molecular mechanisms 
associated with a cell size increase phase observed in a CHO fed-batch process. Cell 
cycle analysis reveals that upon the stop of division, the cells are arrested in both the 
G0/G1 and G2/M phase. Moreover, in both phases, the cells continue to grow in size. 
Gene expression results show that the cell cycle arrest is associated with significant 
up-regulation of cyclin-dependent kinases inhibitors (CDKNs) and down-regulation 
of various cyclin-dependent kinases (CDKs) and cyclins that are involved in all cell 
cycle phases. During the cell size increase phase, the gene expression of the upstream 
pathways of mTOR, which are linked to the extracellular growth factor, cytokine, 
and amino acid conditions, shows a strongly synchronized pattern to promote the 
mTOR activity. In addition, the downstream genes of mTOR, such as 4ebp1 and 
Srebf1, also show a synchronized pattern to stimulate protein translation and lipid 
synthesis. The results demonstrate that a strong cell cycle inhibition with a 
stimulated mTOR activity at the transcriptome level are important elements for the 
observed CHO cell size increase. Furthermore, the activities of the cell cycle and 
mTOR regulator genes show a close link to the extracellular nutrient conditions 
through a number of cascade pathways. This indicates that by rational design of 
media and feeds, CHO cell size can be manipulated during industrial culture 
processes, which may further improve cell growth and specific productivity. 
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1. Introduction 
Chinese Hamster Ovary (CHO) cells are currently the predominant expression 
system for the production of biopharmaceuticals. In order to increase the volumetric 
productivity of CHO cell cultures, advances have been made with respect to media 
development, process optimization, and cell line engineering. To obtain an increased 
volumetric productivity without increasing cell density, an increase in specific 
productivity (qp) is needed. For this, several strategies have been described, 
including hyperosmotic pressure92, cell cycle arrest53, and mild hypothermia57. In 
these studies, the increase in qp was found to be correlated with an increase in cell 
size. Furthermore, Kim et al.58 showed that the enhancement of the qp was linearly 
correlated with an increase in cell size for nine CHO cell clones generated using the 
same transfection process. Edros et al.89 and Khoo and Al-Rubeai90 showed that the 
increase in qp was directly related to the increase in cell volume due to enhancement 
of the transcription, translation, and secretion machinery.  
The regulation of mammalian cell size is controlled by cell growth and cell division 
through multiple complex mechanisms and pathways107,108. Proliferating cells are 
maintained at a more or less constant cell size by doubling their cell mass before each 
cell division. The mechanistic target of rapamycin (mTOR) signaling pathway has 
shown to be a central controller of cell size by controlling biomass synthesis109–111. 
Dreesen and Fussenegger112 showed that an increase in the mTOR activity led to an 
increase in CHO cell size together with an up to four-fold higher protein content per 
cell, and a four-fold higher specific productivity of recombinant IgG. Furthermore, 
manipulation of the positive or negative upstream pathways of mTOR has been 
shown to influence mammalian cell size. Backman et al.113 showed that deletion of a 
mTOR inhibitor, phosphatase and tensin homolog (PTEN), resulted in mammalian 
cell size increase. McVey et al.114 showed that the knock-out of another mTOR 
inhibitor, tuberous sclerosis complex 2 (TSC2), also resulted in larger CHO cells with 
higher protein synthesis and an over two-fold increased qp. In addition, an increase 
in the PI3K/Akt pathway activity which positively regulates mTOR resulted in cell 
size increase in both mammals and Drosophila108.  
As mentioned before, cell size is also altered during the cycle of each cell division. 
Cell size and biomass content per cell increase during the interphase (G1, S, and G2 
phase) of the cell cycle. A cell reaches the largest cell size at the end of the G2 phase, 
which is two times the size as the cell in the G1 phase, before the mitosis (M phase) 
takes place115. Hence, cell cycle control is also a way to increase cell size. In the study 
of Bi et al.91, overexpression of the p21CIP1 induced G1-phase cell cycle arrest in a CHO 
cell culture, which resulted in nearly fourfold increase in cell volume as well as in qp. 
In the study of Fomina-Yadlin et al.31, the addition of small molecule inhibitors that 
arrest mammalian cells in the G1 phase or G1/S transition resulted in a 1.5-fold 
increase in cell volume and qp. The regulation of cell size is a complex process that 
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involves a large network including both cell growth and division. Until now, the 
molecular mechanism of cell size regulation is not fully understood.  
In Chapter 3116, a cell number increase (NI) phase followed by a cell size increase (SI) 
phase was observed in a CHO cell fed-batch culture process using ActiCHO-P as 
basal medium and Actifeed A/B as feeds (from now on called the ActiCHO process). 
In the cell size increase phase, cell division comes to a halt but cell growth continues 
in the form of an increase in cell size. In this process, a standard feeding approach 
was used. No special strategies, such as lowering of the temperature, were used to 
arrest the cell cycle. The increase in cell volume was due to an increase in cell dry 
weight as a result of increases in protein, lipid, and carbohydrate content per cell. 
Furthermore, an increase in qp was observed, which linearly correlated with the 
increase in cell volume. The metabolic changes associated with the cell size increase 
were studied in detail using flux balance analysis, however, the cause and molecular 
mechanisms for the cell size increase remained unclear. The aim of the present study 
is to obtain more insights into the cause and the molecular mechanisms involved 
using transcriptome analysis.  
Due to the dynamic nature of the fed-batch culture (e.g. continuously changing cell 
density and nutrient and waste metabolite concentrations), many genes will be 
regulated over time of which only a part is related to the cell size increase. In order to 
enrich the genes that are related to cell size regulation, we used a FortiCHO process 
(FortiCHO basal medium fed with Efficient feed A/B) which did not result in cell size 
increase as a “filter”. In this way, the genes that are significantly regulated as a result 
of culture development but are not related to cell size increase can be identified and 
filtered out. 
2. Materials and methods 
2.1 Cell line and fed-batch process set-up 
A suspension CHOBC®  cell clone (BC-P, provided by Bioceros Holding BV) producing 
a recombinant immunoglobulin G1 (IgG1) as described in Chapter 28 was used in 
this study. Two fed-batch processes using the same cell line but different medium-
feed systems are studied. One process resulted in cell size increase whereas for the 
other this was not the case. 
(i) The ActiCHO culture process. Triplicate fed-batch cultures were conducted in 10 L 
Sartorius bioreactors (sartorius stedim) controlled by BIOSTAT®  B-DCU II. Each 
bioreactor was inoculated with a starting density of 3×105 viable cells/mL at a starting 
volume of 5 L. Culture temperature was controlled at 37°C, dissolved oxygen (DO) 
was controlled at 40% by pure O2 flow enrichment, pH was controlled at 7.2 by CO2 
flow enrichment and 0.5 M NaOH. The feeding strategy was the same as described in 
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Chapter 3116. Briefly, from day 3 on, 4.5% ActiCHO feed A and 0.45% ActiCHO feed 
B (both from GE Healthcare) per culture volume per day were fed to each reactor 
daily. A 45% (w/w) glucose solution was added to each bioreactor, to ensure that the 
glucose concentration stayed above 5 mM at the next feeding point. 
(ii) The FortiCHO culture process. Triplicate fed-batch cultures were conducted in 1 
L DASGIP bioreactors (Eppendorf). Each bioreactor was inoculated with a starting 
density of 3×105 viable cells/mL at a starting volume of 500 mL. Culture temperature, 
DO, and pH are controlled at the same set-point as the ActiCHO process with similar 
approaches. From day 3 on, Efficient Feed A/B™ (with a 1:1 combination) was added 
to each bioreactor as one bolus. The feeding strategy was similar as described in 
Chapter 28. Briefly, the daily volume added was calculated based on the specific 
glucose consumption rate, to ensure that the glucose concentration stayed above 5 
mM at the next feeding point. 
2.2 Daily sampling and analysis 
A sample was taken from each bioreactor every day before the feed addition. Viable 
cell density, viability, and cell diameter were measured using a CedexHiRes®  
analyzer (Innovatis; Roche) for the ActiCHO process, and a TC20™ cell counter (Bio-
Rad) for the FortiCHO process. 3 mL of the sample was spun down at 300×g for 5 
min (Heraeus Multifuge X3R, Thermo Scientific). The cell pellet was collected and the 
total RNA was extracted using 3 mL TRIzol reagent (Invitrogen™) and stored at -
80°C for later transcriptome analysis. For cell cycle analysis, 2 mL cell culture sample 
was spun down at 300×g for 5 min. The cell pellet was fixated in 2 mL ice-cold 70% 
ethanol overnight at -20°C. Next, the cells were prepared and stained using 
Cycletest™ Plus DNA Reagent Kit (BD Biosciences) and the cell cycle was analyzed 
on the BD Accuri™ C6 Flow Cytometer (BD Biosciences).  
2.3 Transcriptome analysis 
For each bioreactor of the ActiCHO and FortiCHO process, transcriptome analysis 
was done for the samples taken on culture day 3, 5, and 7. Total RNA was purified 
using the RNeasy Mini kit (Qiagen, Valencia, CA). RNA concentration was measured 
on a Nanodrop 2000 (Thermo Scientific, Wilmington, DE). RNA quality was assessed 
on a 2100 Bioanalyzer using the RNA 6000 Nano Kit (Agilent, Santa Clara, CA), and 
all samples had a greater than 8 in RNA integrity number (RIN). Affymetrix 
GeneChip™ CHO Gene 2.1 ST Arrays (Affymetrix, Santa Clara, USA) were used for 
transcriptome expression profiling. In short, the same amount of RNA was labeled 
by the Whole-transcript Sense Target Assay (Affymetrix, Santa Clara, USA) and 
hybridized according to the manufacturer’s instructions. Quality control and data 
analysis were done as described in Lin, K. et al.117. Normalized expression estimates 
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of probe sets were computed by the robust multi-array analysis (RMA)118, using 
R/Bioconductor package AffyPLM119. The well-annotated reference sequences are 
based on the CriGri_1.0 genome assembly NCBI reference sequence project (RefSeq) 
Release 72, which resulted in 60626 annotated sequences (transcripts profiles) 
(custom CDF v20). After averaging the expression levels of probe sets targeting the 
same gene, expression data for 20858 unique genes were obtained, which was used 
for all subsequent analysis. Linear models (Limma package) were used to identify 
the differential expressed genes taking into account correlation due to the repeated 
sampling from the same bioreactors followed by an intensity-based moderated t-
statistic120,121. P-values were adjusted for multiple testing using the Benjamin and 
Hochberg (FDR.BH) method122. Genes regulation that satisfied the criterion of 
FDR.BH<0.05 and absolute fold-change (FC)>1.4 were defined to be significant and 
were subjected to KEGG pathways over-representation analysis using fisher’s exact 
test and Venn diagram. These cut-off values are commonly applied to reduce the 
number of false-positive genes and the background noises that are picked up by the 
differential gene analysis51,123,124. 
Gene regulations that satisfied the criterion of Benjamin and Hochberg false 
discovery rate (FDR.BH) <5% and absolute fold-change (FC)>1.4 were defined to be 
significant and were subjected to KEGG pathways over-representation analysis using 
fisher’s exact test. These cut-off values are applied to reduce the number of false-
positive genes and the background noises that are picked up by the differential gene 
analysis51,123,125. 
3. Results and Discussion 
3.1 Cell growth, cell size, and cell cycle dynamics 
The cell growth characteristics including viable cell density (VCD), viability, and 
average cell diameter are shown in Figure 1. The VCD profile is similar for both 
processes (Figure 1A). The cell viability in the ActiCHO process (black dashed line) 
started to decrease on day 10, while in the FortiCHO process (red dashed line) the 
decrease started on day 7. Figure 1B shows that for the ActiCHO process, upon the 
stop of cell division on day 5, the cells continued to grow in size, from an average cell 
diameter of 17 µm on day 4, to 24 µm on day 10. The ActiCHO process in Chapter 
3116 showed that the size increase was proportional to the increase in biomass content. 
In contrast, the average cell diameter in the FortiCHO process went down gradually 
from 17 µm on day 1, to 15 µm day 7. The sharp decrease in cell diameter after day 7 
was caused by cell death resulting in the formation of small particles which were 
probably apoptotic bodies.  
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Figure 1. (A) Viable cell density (×106 cells/mL, solid lines) and viability (%, dashed lines), and (B) average 
cell diameter (µm) of the ActiCHO process in Chapter 3116 (round mark, black lines) and the FortiCHO 
process (square mark, red lines). The error bars show the standard deviation for three bioreactors of each 
process. In (A), only the positive error bars are shown in order to avoid overlap. 
To study the cell cycle status during the cell size increase of the ActiCHO process, the 
cell cycle distribution was measured. In Figure 2, the propidium iodide (PI) DNA 
stain intensity area (FL2-A) which is a measure of the DNA content, is plotted against 
the forward scatter area (FSC-A) which is a measure of cell size for day 3, 5, 7, and 9. 
A clear cell cycle distribution can be seen at FL2-A intensities between 10 and 
2.000.000. The populations observed above a FL2-A of 2.000.000 are probably due to 
aggregates. On day 3 they represent about 3% of the total events and they gradually 
disappear with the progression of culture time to about 1.5% on day 9. With culture 
time a population develops at very low FL2-A intensities which probably represents 
cell debris and apoptotic bodies and agrees with the slight decrease in viability 
observed. It can be seen from Figure 2 that: 
(i) The cells in the G2/M phase are larger (higher FSC-A) than the cells in the G0/G1 
phase for all the analyzed culture days. This agrees with the fact that the volume and 
biomass per cell increase from the G1 phase until the G2/M phase126. 
(ii) Going from day 3 to day 9, it can be seen that the S-phase population disappears 
and cells are arrested in both the G0/G1 and the G2/M phase. When the cell debris 
population is gated out from the total population, the G0/G1 population presents 58% 
of the total population on day 3 and increases to 85% on day 9, whereas for the G2/M 
population the number decreases from 31% on day 3 to 11% on day 9 (data not 
shown). The result agrees with the fact that after day 5 cell proliferation has stopped 
in the ActiCHO process (Figure 1). In several CHO cell culture processes, 
hypothermia19,127,128, hyperosmotic stress92,129, and cell cycle inhibitors53,91,130 were 
applied that mediated a G0/G1 arrest without influencing G2/M phase. This was, 
however, not the case in the present study where cell cycle arrest occurred in both 
G0/G1 and the G2/M phase. In theory, cells at twice the FL2-A intensity could be 
aggregates of two cells arrested in the G1phase.  
A B 
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 (iii) Cell size starts to increase after day 5 in both the G0/G1 and G2/M phase, as 
shown by the increase in FSC-A values. The extent of the size increase in both phases 
is comparable. This indicates that the cell size increase is not influenced by the cell 
cycle phase the cell is arrested in. Rather, the cell biomass growth and cell cycle arrest 
seem to be two independent processes.  
In summary, the cell cycle analysis confirms that the cell cycle arrest occurs in both 
the G0/G1 and the G2/M phase of the ActiCHO process. Moreover, the cells arrested in 
both phases are able to grow in cell size. 
 
Figure 2. Cell cycle analysis for the ActiCHO process on day 3 (A), 5 (B), 7 (C), and 9 (D). The propidium 
iodide (PI) DNA stain intensity (FL2-A) is plotted against the forward scatter area (FSC-A). FL2-A indicates 
the amount of DNA in a cell while FSC-A indicates the size of a cell. The sample events at high FL2-A 
intensity (>2.000.000) are likely caused by cell aggregates. 
3.2 Transcriptome analysis  
Transcriptome analysis using Affymetrix CHO Gene microarrays was performed to 
gain insights into the molecular mechanism underlying the cell cycle arrest and the 
cell size increase. The same amount of mRNA was brought on CHO Gene 
microarrays for each sample during the transcriptome analysis. Therefore, a change 
in gene expression is relative against the total transcripts and is not influenced by the 
possible fact that larger cells have a higher overall transcriptome activity.  
The sample points on culture day 3, 5, and 7 of the two processes are selected for 
transcriptome analysis. Day 3 represents the middle of the cell proliferation phase 
where the cell size is still similar in both processes (Figure 1). For the ActiCHO 
process, day 5 represents the start of the cell size increase phase whereas day 7 
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represents the middle of the cell size increase phase. For the FortiCHO process, day 5 
represents the stop of exponential growth phase whereas day 7 represents the end of 
the stationary phase and the start of the death phase.  
3.2.1 Overall transcriptome profiles 
The principal component analysis (PCA) (Figure 3A) shows the overall variation in 
gene expression for all analyzed samples. PC1 and PC2 contribute 26% and 18% to 
the total variation, respectively. The contribution for the rest of the PCs are minor (e.g. 
7% of the PC3) and are not considered. PC1and PC2 both capture a change in gene 
expression in time as well as a difference in gene expression between both systems 
(ActiCHO and FortiCHO). The Venn diagram (Figure 3B) shows the differential gene 
expression between day 3 and 7 which is unique to the ActiCHO and FortiCHO 
process, and which occurs in both processes. Genes are considered differentially 
expressed between the two days if the FDR.BH value is smaller than 5% and the 
absolute fold change is larger than 1.4 (see section 2.3). For the total 20858 probed 
genes on the CHO gene array, 5684 genes (25%) are regulated in either the ActiCHO 
or FortiCHO process. In the ActiCHO process, 4824 genes (total number of genes in 
the blue circle) are differentially expressed, of which 3037 (total number of genes in 
the blue circle excluding the number of genes that overlap with the red circle) are 
unique to the ActiCHO process, and of which 1787 (overlap between the two circles) 
are also differentially expressed in the FortiCHO process in the same direction. 
 
 
Figure 3. (A) Score plot generated from the transcriptome results of the ActiCHO (filled blue markers) and 
the FortiCHO (open red markers) processes. The same sample marker represents the sample taken from the 
same bioreactor. Samples taken from the same day and the same process is marked in a circle. (B) Venn 
diagram of the number of genes that are differentially regulated from day 3 to 7 compared between the two 
processes. Red numbers indicate up-regulation, blue numbers indicate down-regulation. 
From the significantly regulated genes in the ActiCHO process from day 3 to 7, we 
first selected the top 10 fold-changes of the up- and down-regulated individuals 
(Table I). Compared to the top 10 up- and down-regulated genes in the ActiCHO 
A B 
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process, many of these genes also showed significant (fold-change>1.4, FDR.BH<5%) 
regulations in the FortiCHO process, however, the fold-changes are much smaller 
(data to be published in Supplementary 1). In the top 10 up-regulated genes in the 
ActiCHO process, the Fam213a and Ranbp3l genes have extremely high fold-changes 
(188 and 145, respectively) compared to the others. The expression of Fam213a was 
shown to protect cells from oxidative stress131. Oxidative stress in cells can be caused 
by increased reactive oxygen species (ROS) which are reduced forms of oxygen, such 
as superoxide radical (O2−), hydrogen peroxide (H2O2), and hydroxyl radical (HO−). 
The dissolved oxygen tension (DO) during all the cultures in this study was 
maintained at 40%. It is unlikely that a high extracellular DO was the cause of the 
ROS formation. However, increased oxidative metabolism was reported in CHO cells 
with increased mAb production as well as with increased cell size52,73. In Chapter 3116, 
a 1.5-fold increase in cellular oxygen consumption flux was observed during the size 
increase phase of the ActiCHO process. This might be related to the formation of 
ROS in cells and subsequently the overexpression of Fam213a. If this was the case, the 
extreme overexpression of Fam213a would likely be a response of the cell size 
increase, rather than the cause of it. Another extremely up-regulated gene, Ranbp3l, 
was reported to be involved in Bone Morphogenetic Protein (BMP) signaling and 
regulating mesenchymal stem cell differentiation132. The exact function of this gene in 
the context of cell size increase in CHO cells is however unknown. In addition, two 
genes involved in osmotic regulation (Slc6a12 and Scn7a) are significantly up-
regulated. This could be related to the increase in culture osmolality due to the feed 
addition which was described in Chapter 3 for the ActiCHO process116. Next to the 
top 10 up-regulated genes, also the top 10 down-regulated genes are listed in Table I, 
together with the functions of these genes in biological processes. As can be seen, all 
the top 10 down-regulated genes are involved in cell cycle regulation and mitosis. 
This agrees with the inhibition of cell cycle progression as described in the previous 
section. Some of these genes are further discussed in the next section.  
Table I. Top 10 fold-changes of up- and down-regulation genes in the ActiCHO process from day 3 to 7. The 
gene functions are searched against the Gene Ontology (GO) and UniProt database. 
Top 10 up-regulation 
 Gene symbol Fold-change Gene function in biological process 
 Fam213a 188.20 Redox regulation 
 Ranbp3l 145.63 Protein transport 
 Sema4d 24.12 Differentiation 
 Spp1 20.56 Cytokine activity, extracellular matrix binding 
 Slc6a12 19.64 Osmotic regulation/transport 
 Myl9 14.68 Myosin regulation 
 Pcp4l1 14.02 Protein coding 
 Scn7a 13.78 Sodium channeling 
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 S100a4 11.42 Protein binding 
 LOC100768899 11.40 Protein coding 
Top 10 down-regulation 
 Gene symbol Fold-change Gene function in biological process 
 Kif15 -17.19 Mitosis, spindle assembly 
 Ect2 -16.84 DNA synthesis, cell cycle 
 Nuf2 -16.73 Mitosis, chromosome segregation 
 Rrm2 -16.55 DNA synthesis, cell cycle 
 LOC100752904 -15.90 nucleosome assembly 
 Ccna2 -14.97 Cell cycle 
 Bub1b -14.87 Mitosis, chromosome segregation 
 Cenpw -14.77 Mitosis, chromosome segregation 
 Ccnb2 -14.63 Cell cycle 
 Aurkb -14.08 Mitosis, chromosome segregation 
 
In order to get a better understanding of the relationship between gene regulation 
and the cell size increase, a targeted approach is used in the next sections. From the 
genes that are differentially expressed in the ActiCHO process (the blue circle in 
Figure 3B), a subset of genes (~500 genes in total) are examined in more detail. This 
subset of genes are selected based on the fact that they are known to play critical 
roles in cell cycle progression and biomass growth as well as in the signaling 
pathways involved in these processes. The regulation of these genes is compared to 
that in the FortiCHO process, to enrich genes that are uniquely related to the cell size 
increase. An overview of the selected pathways is shown in Figure 4. Note that some 
pathways in Figure 4 are known to be post-transcriptional regulated (e.g. by 
phosphorylation), and it is not completely clear whether they are regulated 
transcriptionally as well. Thus, genes that are not differentially expressed could still 
be important due to post-transcriptional regulation. However, if the transcription of 
these pathways shows a synchronized regulation, it may still mean that at least part 
of the regulation is done transcriptionally, and it may still give an indication of these 
gene functions in cell size increase. 
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Figure 4. Signaling pathways channel the information of extracellular conditions to the cell cycle and cell 
growth regulations eventually result in cell size increase. Mammalian cell cycle progression is controlled by 
cyclin dependent kinases (Cdks) and their binding partner cyclins (Cycs). Cell cycle arrest can be achieved by 
intracellular signals initiated by DNA damage (Box A), and extracellular signals mediated by regulating 
factors such as transforming growth factor betas (TGFβs) (Box B). In the case of DNA damage, activities of 
various Cdk/Cyc complexes are inhibited through p53 and checkpoint kinases (CHK) pathways. In the case of 
extracellular stresses, p21CIP1 and p27KIP1 as inhibitors of Cdks can be transcriptionally induced by TGFβs. 
The activities of Cdk/Cyc complexes are negatively regulated by a family of cyclin-dependent kinase inhibitors 
including p16INK4a, p21CIP1, and p27KIP1. The Cdk4,6 and CycD complex also works as a sensor for 
extracellular mitogenic factors, which controls the progression of cell cycle. mTOR promotes the cell growth 
by activating translation and transcription through the regulation of its downstream factors such as P70-S6 
Kinase 1 (S6K) and eukaryotic translation initiation factor 4E (EIF4E) and its binding protein (4EBP) (Box 
E). mTOR also promotes the lipid synthesis by regulating sterol responsive element binding protein (SREBP) 
activity (Box F). Protein kinase B (PKB/Akt) pathway can activate mTOR through tuberous sclerosis complex 
(TSC) 1/2 dependent and independent pathways110 (Box C). The activation of Akt inactivates TSC1/2, 
promoting the GTP-bound form of Ras homolog enriched in brain (Rheb) protein. The latter one acts as an 
activated switch for the mTOR pathway. Akt can also promote the phosphorylation and dissociation of 
PRAS40 from mTOR complex 1 (mTORC1) thus release the mTOR activity through a TSC1/2 independent 
pathway133. Akt induces lipid synthesis by up-regulating the ATP citrate lyase (Acly) activity which is a key 
enzyme that catalyzes the reaction from citrate to cytosolic acetyl-CoA134 (Box C-F). Akt can be up-regulated 
upon sensing the extracellular growth factors (e.g. insulin, IGF, and TNFα) through the phosphatidylinositol 
3'-kinase (PI3K)-Akt dependent pathway, as well as the TNFα-IKKα/β mediated pathway135 (Box C). Upon 
sensing the extracellular amino acids, vacuolar H+-ATPase (V-ATPase) is stimulated which activates the 
mTOR regulator (Lamtor) (Box D). The regulator acts as a guanine exchange factor (GEF) that promotes the 
conversion of RagA/B-GDP to RagA/B-GTP which activates the mTORC1. A high ATP/AMP ratio can 
activate mTORC1 by preventing the activation of AMP-activated protein kinase (AMPK). The inactivation of 
AMPK activity also favors the SREBP activity136 (Box F).The expression of growth arrest specific (GAS) 
genes are closely involved in growth suppression. They negatively regulate cell growth and cell cycle 
progression (Box E). 
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3.2.2 Cell cycle regulation 
Figure 4 Box A and B show the pathways related to the cell cycle regulation. The 
genes of these pathways that are significantly regulated from culture day 3 to 7 in the 
ActiCHO process are presented and their changes in expression are compared to 
those in the FortiCHO process (Table II). Mammalian cell cycle regulation involves 
the participation of two classes of proteins: the cyclin-dependent kinases (Cdks), and 
their binding partners, cyclins (Cycs)137. Binding of a Cdk to a Cyc forms an active 
complex that enables the cell cycle to progress through a specific phase. For both 
processes in Table II, down-regulations of various cyclin-dependent kinase genes 
(Cdks) and their binding partner cyclin genes (Cycs) are observed, which agrees with 
the stop of cell division in both processes. However, the extent of down-regulation 
(fold change) and significance (FDR.BH) for these genes are much higher in the 
ActiCHO process than in the FortiCHO process, indicating that the cell cycle arrest is 
stronger in the ActiCHO process.  
For the ActiCHO process, especially one CycA gene (Ccna2, FC=-14.97, 
FDR.BH<0.5%), two CycB genes (Ccnb1, FC=-11.20, FDR.BH<0.5%, and Ccnb2, FC=-
14.63, FDR.BH<0.5%), and to a lesser extent a Cdk gene (Cdk1, FC=-3.89, 
FDR.BH<0.5%), have much stronger down-regulations as compared to the other Cdk 
and Cyc genes (Table II). Binding of CycA with Cdk1 is required for the G2/M 
transition115, binding of CycA with Cdk2 plays an important role in S phase 
progression and DNA replication138, and binding of CycB with Cdk1 is required for 
mitosis115. The strong down-regulation of CycA, CycB and Cdk1 genes in the 
ActiCHO process agrees with the observed arrest of the cell cycle in G2/M phase and 
indicates a delay in S phase and mitosis. In addition, binding CycE with Cdk2 is 
required for progression through the G1/S phase139. The down-regulation of Cdk2 
(FC=-2.29, FDR.BH<0.5%) may be related to the cell cycle arrest in the G1 phase. 
In order to find the cause of the cell cycle arrest, next, signaling pathways that 
coordinate the cell cycle are studied. The cell cycle activities are regulated by a 
number of Cdk inhibitors (Cdkns) such as p16INK4a (Cdkn2a), p21CIP1 (Cdkn1a), and 
p27KIP1 (Cdkn1b)115 (Figure 4 Box A). Binding of these Cdkns to the Cdks inhibits 
formation of the active Cdk/Cyc complexes, which suppresses the cell cycle 
progression137. The high up-regulations of Cdkns (Cdkn2a, FC=1.62, FDR.BH<0.5%, 
and Cdkn1a, FC=1.73, FDR.BH<0.5%) in the ActiCHO process indicate a strong cell 
cycle inhibition (Table II). In contrast, the Cdkns in the FortiCHO process showed 
much less regulation (Cdkn2a, FC=1.11, FDR.BH=24%, and Cdkn1a, FC=1.28, 
FDR.BH<0.5%).  
Cell cycle inhibitors can be activated by intracellular stimuli (e.g. DNA damage), or 
extracellular stimuli (e.g. deprivation of mitogenic factors)140. The regulation 
pathways related to intracellular DNA damage are shown in Figure 4 Box B. Upon 
sensing DNA damage, checkpoint kinases (encoded by Chek1 and Chek2) and the p53 
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tumor suppressor protein (encoded by Tp53) can be phosphorylated and activated, 
resulting in the G1 and G2 cell cycle inhibition141. Although these steps are regulated 
via post-transcriptional phosphorylation, the significant down-regulations of Chek1, 
Chek2, and Tp53 genes in both of the two processes (Table II) imply that DNA 
damage is less likely the cause of the cell cycle arrest. With regard to extracellular 
stimuli, the p21CIP1 can be induced by transforming growth factor beta (TGFβ, 
encoded by Tgfb), which acts as a negative paracrine/autocrine growth factor in 
growth regulation142–144, as shown in Figure 4 Box A. The TGFβ protein is activated 
from its latent complex upon sensing various environmental stresses such as reactive 
oxygen species145, pH146, and proteases147. The TGFβ signaling pathway is initiated by 
binding of TGFβ to TGFβ receptors (type I and II encoded by Tgfbr1 and Tgfbr2) and 
subsequently, induces p27KIP1 and p21CIP1 leading to the cell cycle inhibition (Figure 4 
Box A). The higher up-regulations of both the Tgfb (Tgfb3, FC=2.13, FDR.BH<0.5%) 
and Tgfbr (Tgfbr2, FC=1.61, FDR.BH<0.5%) genes in the ActiCHO process (Table II) 
indicate a higher TGFβ signaling activity. In addition, expression of CycD is strongly 
dependent on extracellular mitogens. The CycD/CDK4, 6 complexes, therefore, 
function early in G1 and act as mitogen sensors (Figure 4 Box A)148. The CycD genes 
(ccnd1, ccnd2, and ccnd3) are not regulated in the ActiCHO process (data to be 
published in Supplementary 1), indicating that deprivation of extracellular mitogens 
is not likely the cause of cell cycle arrest in the G1 phase. However, looking at the 
expression of various mitogen-activated protein kinases, we find both significant up- 
and down-regulations in the ActiCHO process. Therefore, it is not certain whether 
lacking of mitogen is the cause of the cell cycle arrest in the phases other than G1. In 
summary, the result from transcriptome analysis implies that the cell cycle arrest in 
the ActiCHO process was caused by an activation of cell cycle inhibitors and down-
regulation of Cdks and cyclins in reaction to extracellular environmental stresses 
and/or depletion of mitogen(s). 
Table II. Fold change (FC) cell cycle related genes from culture day 3 to 7 in the culture with cell size 
increase (ActiCHO) and with no cell size increase (FortiCHO). Positive values mean up-regulation and 
negative values mean down-regulation. Genes with a FDR.BH<5% and the absolute FC>1.4 are considered 
significant and are shown here. (Arrest) means the genes promote cell cycle arrest whereas (promote) means 
the genes promote cell cycle progression. 
 FC. ActiCHO FDR.BH FC. FortiCHO FDR.BH 
Cyclin-dependent kinase (Cdk) (promote)  
Cdk1 -3.89 <0.5% -1.17 9% 
Cdk2 -2.29 <0.5% -1.76 <0.5% 
Cdk4 -2.19 <0.5% -1.36 <0.5% 
Cdk5 1.47 <0.5% -1.03 81% 
Cdk6 -1.74 <0.5% -1.02 79% 
Cdk15 1.55 1% 2.21 <0.5% 
Cyclin (Cyc) (promote)  
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Ccna2 -14.97 <0.5% -1.77 <0.5% 
Ccnb2 -14.63 <0.5% -1.60 <0.5% 
Ccnb1 -11.20 <0.5% -1.64 <0.5% 
Ccne2 -3.09 <0.5% -1.85 <0.5% 
Ccnf -2.63 <0.5% -1.68 <0.5% 
Ccne1 -2.31 <0.5% -2.58 <0.5% 
Ccng1 1.41 <0.5% -1.22 3% 
Ccng2 2.34 <0.5% 1.70 <0.5% 
Cyclin-dependent kinase inhibitor (CDKN)     
(arrest) 
 
Cdkn2a 1.62 <0.5% 1.11 24% 
Cdkn1a 1.73 <0.5% 1.28 <0.5% 
Transforming growth factor beta (TGFβ) (arrest)  
Tgfb3 2.13 <0.5% 1.02 93% 
Tgfbr2 1.61 <0.5% 1.15 1% 
Checkpoint kinase (CHEK) (arrest)  
Chek1 -2.80 <0.5% -1.37 <0.5% 
Chek2 -2.47 <0.5% -1.23 6% 
Tumor protein p53 (P53) (arrest)  
Tp53 -1.77 <0.5% -1.79 <0.5% 
 
3.2.3 Cell growth regulation 
Besides the cell-cycle arrest, a continued biomass production is the other essential 
aspect for cell size increase. In this context, we found that in agreement with 
literature, the mTOR pathway is playing a central role in manipulating the cell 
biomass growth of the ActiCHO process. mTOR integrates the extracellular and 
intracellular signals through a number of upstream pathways, and regulates cell 
growth through its downstream effectors149. The regulation of these pathways in the 
ActiCHO process are summarized in Figure 4 Boxes C, D, E, and F. In addition, the 
significantly regulated genes involved in these pathways are shown in Table II. 
First of all, the downstream effectors of mTOR are studied. The activity of these 
effectors are regulated by mTOR in transcriptional and/or post-transcriptional 
approaches. Activation of mTOR results in phosphorylation of the eukaryotic 
initiation factor 4E-binding proteins (4EBPs). The phosphorylation prevents binding 
of these proteins to the eukaryotic initiation factor eIF4E110. This results in increased 
activity of eIF4E, which promotes protein translation150. In the ActiCHO process, the 
eukaryotic initiation factor 4E-binding protein (4EBP) genes are significantly down-
regulated (Eif4ebp1, FC=-2.53, FDR.BH<0.5% and Eif4ebp2, FC=-1.40, FDR.BH<0.5%). 
The down-regulation of 4EBP genes may have resulted in less binding to eIF4E and 
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thus, released the activity of protein synthesis (see Figure 4, Box E). As a result, the 
protein synthesis rate in the ActiCHO process remained high during the size increase 
phase. In contrast, the 4EBP genes are not regulated (Eif4ebp1, FC=-1.06, FDR.BH=67% 
and Eif4ebp2, FC=-1.09 FDR.BH=40%) in the FortiCHO process, which agrees with the 
stopped cell growth in this process. 
High mTOR activity also positively regulates the synthesis of lipids151 which is a 
necessary component for cell growth (see Figure 4, Box F). An increase in mTOR 
complex 1 (mTORC1) activity was reported to increase the sterol responsive element 
binding protein (SREBP) activity which led to higher lipid synthesis rate152. The 
higher up-regulation of the SREBP gene (Srebf1, FC=1.47, FDR.BH=3%) in the 
ActiCHO process correlates with the slightly higher fatty acid synthesis rate during 
the cell size increase phase compared to the proliferation phase and the formation of 
lipid droplets, as shown in our previous study116. In contrast, the SREBP gene is not 
regulated (FC=-1.02, FDR.BH=94%) in the FortiCHO process. In addition to by mTOR, 
lipid synthesis was also shown to be induced by Akt which is a positive upstream 
regulator of mTOR. Akt induces lipid synthesis by up-regulating the ATP citrate 
lyase (encoded by Acly gene) activity. ATP citrate lyase is a key enzyme that 
catalyzes the reaction from citrate to cytosolic oxaloacetate and acetyl-CoA134. The 
latter one is a precursor for lipogenesis. In the ActiCHO process, the transcriptional 
activity of the Acly gene remained unchanged (FC=-1.03, FDR.BH=72%, data to be 
published in Supplementary 1) whereas in the FortiCHO process, it decreased 
significantly (FC=-1.87, FDR.BH<0.5%). In agreement with the transcriptome data, 
the fatty acids synthesis rate in the ActiCHO process was maintained more or less 
constant during the cell size increase phase as compared to the exponential growth 
phase. In contrast, the pathways related to lipid synthesis experienced significant 
down-regulations in the FortiCHO process, which agrees with the fact that the cells 
went from the exponential growth phase on day 3 to the stationary phase on day 7 
since the requirement for lipids went down.  
Next, cascade pathways upstream of mTOR that channel extracellular signals to 
mTOR were studied (Figure 4 Box C, D and F). The differentially expressed genes in 
these pathways are shown in Table III. The presence of extracellular growth factors 
and nutrients are essential to the growth and biomass synthesis of the cells. A lack of 
either growth factors or nutrients can lead to growth attenuation, autophagy, and 
eventually cell death153. The concentration of extracellular growth factors and 
nutrients is sensed by the cells through a number of signaling pathways. The signal 
of growth factors, such as insulin-like growth factors (IGF), is channeled through the 
PI3K-Akt pathway133. The signal transduction starts with the binding of IGF to the 
IGF binding protein (IGFBP, encoded by Igfbps genes)154. Next, the binding of IGF 
with IGFBP phosphorylates phosphatidylinositol (4,5) biphosphate (PIP2) to produce 
PIP3 (Figure 4 Box C)155. The later one phosphorylates and activates the Akt pathway 
which subsequently promotes the mTOR activity, as mentioned previously. In the 
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ActiCHO process, Igfbps showed stronger up-regulations (Igfbps7, FC=1.90, 
FDR.BH<0.5%, and Igfbps4, FC=1.51, FDR.BH<0.5%) compared to in the FortiCHO 
process (Igfbps7, FC=1.15, FDR.BH=57%, and Igfbps4, FC=-1.34, FDR.BH<0.5%) (Table 
III). In agreement with this, it also can be seen in Table III that the PI3K (Pik3ip1 and 
Pik3c2a) genes are significantly up-regulated in the ActiCHO process.  
Besides the PI3K pathway, increasing evidence suggests that cytokines, such as 
tumor necrosis factor-α (TNFα) through the inhibitor of nuclear factor-κB kinase-β 
(IKKβ) mediated pathway, can also induce the Akt activity135. It can be seen in Table 
III that various genes for the TNFα induced proteins (Tnfaip) are up-regulated much 
stronger in the ActiCHO process compared to in the FortiCHO process. Both the 
PI3K and the TNFα-IKKβ pathways have a similar expression pattern in the 
ActiCHO process, and both have a positive contribution to the Akt activity. This 
together demonstrates that the extracellular growth factors and cytokines are likely 
the important factors for the activation of the Akt and subsequently the mTOR 
activity, meaning that they are also likely the cause of the cell size increase after the 
cell cycle inhibition.  
In addition to the growth factors and cytokines, sufficient extracellular amino acids 
concentrations are needed to maintain the mammalian cell growth. The signaling 
pathways related to sensing the amino acid levels are illustrated in Figure 4 Box D. 
Sufficient amino acid levels stimulate the vacuolar H+-ATPase (v-ATPase) on the 
lysosomal membrane156, leading to hydrolysis of ATP by v-ATPase. This signal 
stimulates the Regulator complex (encoded by the late endosomal/lysosomal adaptor, 
Lamtor genes) activity. The Regulator complex acts as a guanine exchange factor 
converting RagA/B·GDP to RagA/B·GTP156. The latter one can bind to and activate the 
mTORC1. As can be seen in Table III, several V-ATPase and Lamtor genes show 
higher up-regulation in the ActiCHO process compared to in the FortiCHO process, 
implying that the signals from the amino acids sensing pathways also play a role in 
promoting the mTOR activity for the continued biomass growth in the ActiCHO 
process.  
Glucose is a major nutrient for CHO cell lines. The characteristic consumption rate of 
glucose and the concomitant production rate of lactate are typically high in CHO cell 
lines. In addition, as shown in Chapter 28, the specific glucose consumption rate 
during the size increase phase of the ActiCHO process is significantly higher than it 
is during the stationary phase of the FortiCHO process. The high glucose 
consumption is likely the result of a high glycolysis activity and will correspondingly 
result in a high intracellular ATP/AMP ratio. The high ATP/AMP ratio can suppress 
the AMP-activated protein kinase (AMPK) activity157 and lead to an increased mTOR 
activity through phosphorylation (Figure 4 Box F). In this study, we are unable to 
confirm the state of the ATP/AMP ratio. However, one AMPK transcript (Prkaa1) 
showed an up-regulation in the ActiCHO process (Table III). Assuming the AMPK 
pathway is also regulated transcriptionally, this implies a decrease in the ATP/AMP 
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ratio. In this regard, the high specific glucose consumption rate seems to play no role 
in activating mTOR during the cell size increase of the ActiCHO process. 
Furthermore, several growth arrest specific (Gas) genes showed high (>5 FC) down-
regulations in the ActiCHO process (Table III). Expression of the Gas protein family 
is strictly related to the growth arrest state of mammalian cells158,159 (see Figure 4 Box 
E) and may be involved in various cellular activities including microfilaments 
reorganization, cell cycle, DNA synthesis, and apoptosis158,160,161. Smith and Steitz162 
showed that upon reduction of the mTOR activity, Gas5 transcript levels increased. 
Recently, the Gas5 transcript was shown to be an important tumor suppressor 
involved in various cancers163. In addition, the expression of Gas2 transcript has been 
shown to play a critical role in preventing cancer transformation by leading the cells 
to a premature senescence164. In the present work, greater down-regulations of the 
Gas genes in the ActiCHO process correlates with the continued cell growth in the 
ActiCHO process. It is however not fully clear how these Gas genes interact with 
intra- and extracellular signals to participate in growth control. 
Summarizing this section, it was shown that the mTOR upstream and downstream 
pathways were regulated in a strongly synchronized pattern in the ActiCHO process, 
leading to a higher mTOR activity in this process. In the FortiCHO process this was 
not observed. These results demonstrate that the activation of mTOR plays an 
essential role in the continued biomass growth after the stop of cell cycle progression. 
Furthermore, the activation of mTOR is closely related to the extracellular growth 
factors, cytokines, and amino acids levels, indicating that the cell size increase is 
related to these extracellular conditions. 
Table III. Fold change (FC) mTOR upstream and downstream genes from culture day 3 to 7 in the culture 
with cell size increase (ActiCHO) and with no cell size increase (FortiCHO). Positive values mean up-
regulation and negative values mean down-regulation. Genes with a FDR.BH<5% and the absolute FC>1.4 
are considered significant and shown here. (Promote) means the genes promote biomass synthesis whereas 
(inhibit) means the genes hamper biomass synthesis. 
 FC. ActiCHO FDR.BH FC. FortiCHO FDR.BH 
mTOR downstream effectors 
Eukaryotic translation initiation factor 4E-binding 
protein (4EBP) (inhibit) 
 
Eif4ebp1 -2.53 <0.5% -1.06 67% 
Eif4ebp2 -1.40 <0.5% -1.09 40% 
Sterol regulatory element-binding protein (SREBP) 
(promote) 
 
Srebf1 1.47 3% -1.02 94% 
mTOR upstream regulators 
Insulin-Like Growth Factor-binding protein (IGFBP) 
(promote) 
 
Igfbp7 1.90 <0.5% 1.15 57% 
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Igfbp4 1.51 <0.5% -1.34 <0.5% 
TNF alpha induced protein (TNFaIP) (promote) 
Tnfaip6 4.21 <0.5% 1.55 1% 
Tnfaip2 3.32 <0.5% 1.05 84% 
Tnfaip8 1.69 <0.5% -1.22 20% 
Tnfaip1 1.41 <0.5% -1.06 64% 
Tnfaip3 -1.43 <0.5% -1.30 2% 
Phosphoinositide 3-kinase (PI3K) (promote) 
Pik3ip1 2.01 <0.5% 1.47 3% 
Pik3c2a 1.76 <0.5% 1.01 94% 
Protein kinase B (PKB/AKT) (promote) 
Akt2 1.40 <0.5% 1.12 4% 
Tuberous sclerosis complex (TSC) (inhibit) 
Tsc2 1.45 <0.5% 1.11 18% 
Vacuolar-type H+-ATPase (V-ATPase) (promote) 
Atp6v1f 1.64 <0.5% 1.23 5% 
Atp6v1a 1.62 <0.5% 1.26 <0.5% 
Atp6v1b2 1.54 <0.5% 1.45 <0.5% 
Atp6v1e1 1.43 <0.5% 1.16 3% 
Late endosomal/lysosomal adaptor, MAPK and MTOR 
activator (Lamtor) (promote) 
  
Lamtor2 1.51 <0.5% 1.08 58% 
Lamtor4 1.22 4% 1.23 7% 
Lamtor5 1.2 3% -1.01 93% 
AMP-activated protein kinase (AMPK) (inhibit) 
Prkaa1 1.42 <0.5% 1.08 32% 
Growth arrest specific (GAS) (inhibit) 
Gas2 -5.77 <0.5% -1.95 <0.5% 
Gas2l3 -5.66 <0.5% -1.18 11% 
Gas7 -1.78 <0.5% -1.30 13% 
 
3.3 Extracellular stimuli for the cell size increase 
The cell size increase in this study is associated with the cell cycle arrest and the 
continued biomass formation. Two genes involved in osmotic regulation (Slc6a12 and 
Scn7a) showed up in the top 10 up-regulated fold changes (Table I). However, in a 
perfusion process using the same cell line and the ActiCHO-P medium as perfusion 
medium, a comparable change in cell size was observed (data not shown). In that 
experiment, the ActiCHO feed A/B was not used and the culture osmolality was 
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constant. It can therefore be concluded that the cell size increase is not specifically 
related to the ActiCHO feed A/B or osmolality.   
A significant cell cycle arrest was observed in the ActiCHO process. Cell cycle arrest 
could be caused by secretion of toxic metabolites (e.g. ammonia and lactate) or 
paracrine/autocrine proteins (e.g. TGFβ). As discussed before, ammonia and lactate 
are not likely the cause of the cell cycle arrest. The TGFβ pathway is significantly up-
regulated in the ActiCHO process, which may have caused cell cycle arrest. Another 
cause of the cell cycle arrest could be depletion of certain nutrients or mitogenic 
factors. If this was the case, these nutrients or mitogenic factors should not be present 
in the feeds or that the depletion causes irreversible cell cycle arrest which cannot be 
released by addition of the depleted nutrients anymore. This means that these factors 
are absent or not present in sufficient amounts in the feed. It could also be that 
depletion of a nutrient in the batch period causes the cells to enter a non-proliferative 
state from which it cannot recover by later addition of that nutrient. For example, our 
previous metabolic study on the ActiCHO process in Chapter 3116 identified the 
depletion of some non-essential amino acids including asparagine, glutamine, and 
tyrosine around the point where cells stopped dividing and started increasing size. 
Fomina-Yadlin et al.66 reported that depletion of individual amino acid can activate 
the amino acid response pathway (AAR), resulting in an overexpression of activating 
transcription factor 4 (ATF4). Consequently, cells experience down-regulation of cell 
cycle progression, DNA replication, nucleotide biosynthesis, and lipid metabolism. 
However, in the present study, the ATF4 gene (ATF4) was significantly down-
regulated from day 3 to 7 (FC=-4.2, FDR.BH<0.5%, data to be published in 
Supplementary 1), indicating that the AAR pathway was not triggered on day 7. 
Since depletion occurred at day 3 and was resolved by feed addition at day 7, it 
could still be that a temporary overexpression between day 3 and 7 of ATF4 triggered 
the AAR pathway at the moment of depletion of certain amino acid(s) and caused an 
irreversible cell cycle arrest. In the meantime, the high concentration of the other 
amino acids keeps the mTOR activity high resulting in continued biomass 
production and cell size increase. This hypothesis, however, needs to be further 
confirmed by a higher time resolution for the transcriptome data and by tuning the 
amino acids ratio in the ActiCHO process. 
4. Concluding remarks 
We performed a transcriptome analysis to identify the molecular mechanism 
associated with cell size increase for a CHO fed-batch process. Looking at the top 10 
fold-changes of up- and down-regulated genes in the ActiCHO process, genes related 
to redox regulation, protein transport, and osmotic regulations were highly up-
regulated. This result indicates that cells adapted transcriptionally to cope with redox 
and osmotic changes during the culture process. In addition, the top 10 down-
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regulated genes were related to cell cycle regulation and mitosis. This agrees with the 
observed cell size increase and cell cycle arrest in the ActiCHO process. In the next 
step, genes involved in cell cycle progression and biomass growth as well as in the 
signaling pathways of these processes were selected for further analysis. It was 
found that various cyclin (cyc) and cyclin-dependent kinase (cdk) genes were 
significantly down-regulated in the ActiCHO process, and a number of Cdk 
inhibitors (Cdkns) were significantly up-regulated, which agrees with the cell cycle 
arrest in both the G0/G1 and the G2/M phase. The gene expression results also indicate 
that the cell cycle arrest is not caused by DNA damage. Looking at the genes 
involved in regulation of biomass growth, the mTOR upstream and downstream 
pathways are regulated in a strongly synchronized pattern to stimulate the mTOR 
activity in the ActiCHO process. This agrees with a continued cell growth after cell 
cycle arrest. It is possible that the production of TGFβ as a negative 
paracrine/autocrine factor, or the depletion of certain nutrients and/or mitogenic 
factors in the basal medium resulted in the cell cycle arrest. Meanwhile, extracellular 
growth factors and high nutrients levels keep channeling the mTOR activity to 
maintain biomass production. This study showed that CHO cell size regulation is 
strongly related to the extracellular nutrient levels. Hence, by rational design of 
media and feeds, it may be possible to manipulate CHO cell size during industrial 
culture processes, which will further improve cell growth and specific productivity. 
 
         
 
 
 
 
         
 
 
 
Chapter 5 
 
Transcriptome analysis for the scale-down 
of a CHO cell fed-batch process 
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Abstract: 
Transcriptome and metabolism analysis were performed to evaluate the scale-down 
of a CHO cell fed-batch process from a 10 L bioreactor to an ambr 15®  (ambr) system. 
Two different agitation scale-down principles were applied, resulting in two 
different agitation rates in the ambr system: 1300 RPM based on the agitator tip 
speed, and 800 rpm based on the volumetric power input (P/V). Culture performance 
including cell growth, product titer, glycosylation, and specific consumption/ 
production rates of metabolites was the same for both agitation rates in the ambr and 
was comparable to that of the 10 L system. The initial variation in gene expression 
between the inocula for the ambr and 10 L system was no longer present after three 
days of culture, indicating comparable culture conditions in both systems. Based on 
principal component analysis, changes in gene expression over time were similar 
between both scales with less than 6% variation. 2455 genes were uniquely regulated 
in the ambr system compared to 1604 genes in the 10 L system. Functional analysis of 
these genes did not reveal their relations with scale or cellular function. This study 
further strengthens that the ambr system gives representative culture performance 
for the 10 L bench-scale bioreactor. 
 
Abdulaziz A. Alsayyari a, 1,  
Xiao Pan a, 1,  
Ciska Dalm b,  
Jochem W. van der Veen b,  
Nienke Vriezen b, 
Jos A. Hageman c,  
René H. Wijffels a, d,  
Dirk E. Martens a, * 
 
1 Both authors contributed equally to this publication 
  
a Bioprocess Engineering, Wageningen University & Research, PO 
Box 16, 6700 AA, Wageningen, the Netherlands 
b Upstream Process Development, Synthon Biopharmaceuticals 
BV, PO Box 7071, 6503 GN, Nijmegen, the Netherlands 
c Biometris, Wageningen University & Research, PO Box 16, 6700 
AA, Wageningen, the Netherlands 
d Faculty of Biosciences and Aquaculture, Nord University, N-
8049, Bodø, Norway  
 
    
88  
   
5.1 Introduction 
The development of a Chinese Hamster Ovary (CHO) cell production process within 
the biopharmaceutical industry aims at obtaining a consistent and robust cell culture 
process with a high product volumetric productivity, as well as a consistent and 
desired product quality. To achieve this, it is important to identify the parameters 
that influence the culture performance and the range within which these parameters 
should stay to ensure a reproducible process with a consistent product quality. This 
requires high throughput experimentation for which small-scale bioreactors are 
needed. The small scale bioreactors should be representative of the large-scale so that 
the process developed at small-scale, including the design space for the critical 
process parameters, can be translated to large-scale with the same process 
performance. Different scale-down criteria can be used to develop a representative 
small-scale process. These criteria include, for example, the oxygen volumetric mass 
transfer rate (kLa), the volumetric power input (P/V), and the agitator tip speed43,165. 
Production scale reactors can be properly scaled down to bench-scale reactors (1-10 L) 
which are traditionally used as the main platform for process development37,41. 
However, the number of experiments that can be done in a certain time frame at 
bench-scale is still too small for studying all the parameters that can be relevant to a 
culture process (pH, DO, temperature, nutrient concentrations, pre-culture age, 
seeding density, etc.). In order to increase the experimental throughput, several 
miniature bioreactor systems at mL scales have been developed during the past 
decade166,167. Like in large-scale reactors, DO, pH, agitation, and gas sparging can be 
monitored and controlled in these small-scale systems as well. The higher 
throughput allows for a shorter development time and the use of design of 
experiment (DoE) with a higher resolution, resulting in a more accurate definition of 
the design space.  
The ambr®  15 (from hereon called the ambr) system has advantages compared to 
other miniature systems due to the advanced automated operation which reduces 
handling errors and increases the experimental throughput. A characterization of 
both the ambr and large-scale stirred tank bioreactors (STRs) was conducted by 
Nienow et al.168. It was shown that the physical environment between the ambr and 
conventional STRs differs in some aspects including the flow regime, gas superficial 
velocity, and volumetric power input. Several studies have been performed to 
compare the culture performance of the ambr system to STRs ranging from 2 L up to 
1000 L for CHO cell fed-batch processes169–172. Overall, similar process performances 
were reported across all scales. In a recent study done by Rouiller et al.173, it was 
shown that the ranking of 12 CHO cell clones based on product titer reached in batch 
cultures was more similar between 3.5 L bioreactors and ambr (Pearson correlation 
coefficient=0.97) than between 3.5 L bioreactors and deep well plates and shake tubes. 
In the study of Janakiraman et al.174, for several studied process parameters, the 
ranges of these parameters which resulted in acceptable product quality attributes 
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were similar between ambr and 5 L bioreactors. These studies show that the result of 
screening experiments as well as determined process parameters ranges are 
transferable from ambr to bench-scale systems. In contrast, Siva et al.175 showed that 
for a fed-batch process using a CHO DHFR- cell line the ambr gave different results 
compared to 5-L and 250-L STRs. Lower cell density and final titer together with an 
earlier decrease of cell viability were observed in the ambr system. They 
hypothesized that a foaming problem along with a higher ammonium concentration, 
a higher osmolality, and a lower pH in the ambr cultures were the causes of these 
differences. Summarizing, representative culture performances have been reported in 
ambr as compared to the bench-scale systems in all studies except for one and the 
ambr system has gained acceptance for use in process development in 
biopharmaceutical industries. A better understanding of the effects of the different 
physical environments present in the small-scale ambr system as compared to bench-
scale systems on cell physiology could be helpful for further validating the ambr 
system, specifically for developing better small-scale reactors in general.  
A better understanding of cell physiology and gene regulation in relation to process 
conditions can be obtained using transcriptomics176. Transcriptome analysis can be 
used in different ways for process understanding. (i) The expression levels of genes 
can be used as a fingerprint to compare two process conditions, e.g. small- and large-
scale. Jayapal and Goudar30 used transcriptome analysis to confirm the scalability of a 
BHK cell perfusion culture process. (ii) The genes that are differentially expressed can 
be studied on a functional level. This approach can give mechanistic information on 
how differences in process conditions (e.g. differences between scales) influence cell 
physiology and process performance. For example, Sieck et al.32,177 found that 
transcripts related to DNA damage and repair mechanisms were up-regulated when 
elevated shear forces from agitation and sparging were applied to a CHO cell culture. 
The aim of this study is to evaluate whether the physiology and performance of the 
cells in the ambr systems is comparable to that in a 10 L system for a fed-batch 
process. The CHO cells are compared on the metabolic and gene expression level. 
Detailed analysis of the 10 L process, including cell metabolism and transcriptome 
has been presented in Chapter 3 and 4 and was the starting point for the comparison 
with the ambr system in this work. CHO gene microarrays were used to measure the 
transcriptome. In addition, in order to investigate the impact of different scale-down 
criteria for agitation on cell physiology and culture performance, two different 
impeller agitation rates (800 and 1300 RPM) were included in the ambr experiment. 
The 800 RPM in ambr is equivalent to the impeller volumetric power input (P/V) 
value that was employed at the 10 L scale, whereas the 1300 RPM is equivalent to the 
maximum impeller tip-speed at the 10 L scale. 
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5.2 Materials and methods 
5.2.1 Cell line and pre-culture 
A suspension CHOBC®  cell clone (BC-P, provided by Bioceros Holding BV) producing 
a recombinant immunoglobulin G1 (IgG1) was used in this study. Cells were thawed 
from a working cell bank and maintained in ActiCHO-P medium (GE Healthcare) 
supplemented with 4 mM glutamine (Gibco, Life Technologies) and 0.5% Anti-
clumping agent (Gibco® , Life Technologies). 200 µg/mL ZeocinTM and 5 µg/mL 
Blasticidin (both from Life Technologies) were added as two selection reagents 
during the pre-cultures. Sub-culture was conducted in repeated batch cultures in 
shake flasks grown under 37°C and 8% CO2 conditions. The inoculum for the 3×10 L 
bioreactors was prepared in a single culture bag on a rocking bioreactor system. For 
each 10 L bioreactor, a 500 mL inoculum at a viable cell concentration of 3×106 
cells/mL was directly inoculated in 4500 mL of pre-heated fresh medium, resulting in 
a starting density of 3×105 viable cells/mL at a starting volume of 5 L. The inoculum 
for the ambr bioreactors was expanded in shake flasks. To prepare the inoculum for 
the ambr cultures, the cells from the flasks were pooled together and spun down at 
300×g. Next, the used medium was discarded and cells were re-suspended in fresh 
medium at a viable cell concentration of 3×106 cells/mL. 1.4 mL inoculum was 
inoculated in 12.6 mL of pre-heated fresh medium in each ambr bioreactor, resulting 
in a starting density of 3×105 viable cells/mL at a starting volume of 14 mL. 
5.2.2 10 L culture experiment  
Triplicate fed-batch cultures were conducted in 10 L Sartorius bioreactors (sartorius 
stedim) controlled by BIOSTAT®  B-DCU II. Culture temperature was controlled at 
37°C, dissolved oxygen (DO) was controlled at 40% by pure O2 flow through a micro 
sparger, pH was controlled at 7.2, by using base, and CO2 through a macro sparger. 
An air flow through the macro sparger was used to strip out the accumulating 
dissolved CO2 (pCO2). Mixing was done by an impeller at 200 RPM. From day 3 on, 
feeds were added to each bioreactor daily. First, the glucose concentration was 
measured. If the concentration was lower than 18 mM, a 45% (w/w) glucose solution 
was added as one bolus to reach a glucose concentration of 28 mM in the reactor. 
Next, 4.5% (v/v) ActiCHO feed A, also containing about 500 mM glucose amongst 
other nutrients, and 0.45% (v/v) ActiCHO feed B (both from GE Healthcare, USA) per 
culture volume per day were fed to each reactor. Simethicone antifoam solution was 
added to each bioreactor prior to inoculation and during the culture when needed. 
For each 10 L bioreactor, a 15 mL sample was taken daily before and after feed 
addition. Total cell density, viable cell density, and cell diameter were measured 
using a CedexHiRes®  analyzer (Innovatis). 3 mL of the sample was spun down at 
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300×g for 5 min (Heraeus Multifuge X3R, Thermo Scientific). The cell pellet was 
collected and the total RNA was extracted using 3 mL TRIzol reagent (Invitrogen™) 
and stored at -80°C for later transcriptome analysis. The remaining sample was spun 
down at 3345 ×g for 15 min. 1 mL supernatant from the sample was measured for off-
line pH, pCO2, glucose, lactate, ammonium concentrations and osmolality by a nova 
BioProfile FLEX analyzer (nova biomedical). The remaining supernatant was stored 
at -20 °C for later analysis. On culture day 4, 7 and 10 biomass samples were taken. 
The preparation of the biomass samples was performed in the same way as in 
Chapter 3116. 
5.2.3 ambr culture experiment 
The ambr system used in this study consisted of 4 culture stations (CS), each CS 
contained 12 bioreactors. In total 48 bioreactors were used in this study. The reactor 
volume was kept between 13 and 15 mL throughout the culture. For all 4 CSs, the 
temperature was controlled at 37°C, dissolved oxygen (DO) was controlled at 40% by 
oxygen enrichment in gas supply through an open pipe sparger, and pH was 
controlled by 0.5 M NaOH and CO2 enrichment in gas supply. pH was measured off-
line on a different analyzer as the 10 L cultures, because of the smaller sample 
volume. Measurement differences in pH due to the different analyzer used were 
accounted for creating matching bands of control. The daily feeding strategy was 
similar as in the 10 L culture experiment with a difference that the feed can only be 
added at one time as a bolus. 4×diluted simethicone antifoam solution was added to 
each ambr bioreactor when needed. Two different agitation rates were tested in the 
ambr culture experiment being: CS-1 and CS-2 at 800 RPM which is equivalent to the 
volumetric power input (P/V) value of the 10 L culture experiment, and CS-3 and CS-
4 at 1300 RPM which is equivalent to the agitator’s tip-speed of 10 L culture 
experiment (Table I). The P/V value for the 10 L reactor is obtained from: 
𝑃
𝑉
=
𝑃0𝜌𝑁
3𝐷5
𝑉
     Equation 1 
where P is the power input from impeller (W), V is the culture volume (m3), P0 is the 
power number of the 10 L bioreactor impeller and was determined as 2.1 based on 
Van’t Riet, K. and Tramper, J.22, ρ is the liquid density (kg/m3), N is the impeller 
speed (s-1), D is the impeller diameter (m). The Reynolds number (Re) and the 
Kolmogorov length (λk, µm) scale in a turbulent flow are calculated based on Van’t 
Riet, K. and Tramper, J.22: 
𝑅𝑒 =
𝜌 𝑁𝐷2
𝜂
     Equation 2 
𝜆𝑘 = (
𝑃
𝜌𝑉𝜗3
)−
1
4     Equation 3 
where η is the dynamic viscosity (N∙s∙m-2), and ϑ is the kinematic viscosity (m2·s-1).  
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Table I. Physical comparison between ambr and 10 L reactors. The 300 RPM of the 10 L experiment is not 
used in this study. It is shown for comparison only. 
  
Agitation 
rate (RPM) 
Tip-
speed 
(m/s) 
P/V 
(W/m3) 
kLa 
(/h) 
Re Flow 
Kolmogorov 
(um) 
ambr 
800 0.48 65* 4-6* 2500 Laminar - 
1300 0.78 280* 5-8* 4000 Transient 27 
10 L 
200 0.82 40 
2-40 
29000 
Turbulent 
55 
300 1.23 135 43000 40 
*: values adopted from Nienow et al.168 
Maximum 800 µL daily sample volume was taken before feed addition from each 
individual ambr bioreactor. Individual ambr bioreactors were sampled every other 
day to measure off-line pH, pCO2, glucose concentration, and lactate concentration 
on a blood gas analyzer (ABL90 FLEX). Larger samples were obtained daily from 
paired cultures run under identical conditions which were analyzed for metabolites, 
cell density and culture viability, IgG concentration, spent media, biomass 
composition, and RNA preparation by using the same methods as for the 10 L 
cultures. 
5.2.4 Biomass, spent medium, and mAb analysis 
The analysis of biomass composition including cell dry weight, soluble cellular 
protein, fatty acids, and carbohydrate was performed using the same method as 
described in Chapter 3116. Compositions of the spent medium including extracellular 
amino acids and organic acids were quantified using NMR (Spinnovation Biologics 
BV). mAb (IgG1) titer was quantified by using Protein-A chromatography (Agilent, 
5069-3639). mAb N-glycan composition was analyzed by a Hydrophilic Interaction 
Chromatography (HILIC UPLC). The methods for mAb quantification and N-glycan 
analysis were described in Chapter 3116.  
5.2.5 Average specific metabolic rates 
The calculation of the specific production/consumption rate of a compound is the 
same as described in Chapter 3116. In brief, the following equation is used, assuming a 
constant qx 
𝑀𝑥(𝑡) − 𝑀𝑥(0) − 𝑉𝑓 × 𝐶𝑓 = 𝑞𝑥 × ∫ 𝑋𝑉𝐶
𝑡
0
𝑑𝑡    Equation 4 
where Mx (mg; mmol) is the total amount of compound x in a culture at time 0 and t, 
XVC (cells) is the number of viable cells in a culture, Vf (mm3) is the total volume of 
feed added, Cf (mM) is the concentration of compound x in the feed, and qx (mg·cell-
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1·day-1; mmol·cell-1·day-1) is the cell-specific production rate of compound x. When the 
rates are calculated based on cell volume, XVC (mm3) presents the volume of viable 
cells in a culture and qx (mg·mm-3·day-1 or mmol·mm-3·day-1) is the cell volume-
specific production rate of compound x. The average specific production rates (q) 
were obtained from the slope of a plot of accumulated consumed/produced 
compound mass against the accumulated integral of viable cell number (or the 
integral of viable cell volume) using linear regression.  
5.2.6 Transcriptome analysis 
For both scales, the transcriptome analysis was carried out on: cells from the 
inoculum just before inoculation, on day 3 which represents the exponential phase, 
on day 5 which represents the cell size increase phase, and on day 9 which represents 
the stationary phase. For the inoculum of the 10 L experiment, three samples were 
taken from the culture bag before inoculation. For the inoculum of the ambr 
experiment, three samples were taken from the pooled shake flasks just before 
centrifugation. During the culture, for the 10 L experiment, three samples were taken 
from the three individual bioreactors, whereas for the ambr experiment, also three 
samples were taken with each sample obtained by pooling the samples from two 
bioreactors of the 800 RPM condition. The detailed approach for transcriptome 
analysis is described in Chapter 4. Genes regulation that satisfied the criterion of 
FDR.BH<0.05 and absolute fold-change (FC)>1.4 were defined to be significant and 
were subjected to KEGG pathways over-representation analysis using fisher’s exact 
test and Venn diagram. The raw data on transcriptome analysis is data to be 
published in Supplementary A of the online published version. 
5.3  Results and discussion 
5.3.1 DO and pH control 
Proper control of dissolved oxygen (DO) and pH is critical for the culture 
performance. The online DO and pH profiles of a representative ambr reactor and a 
representative 10 L reactor are shown in Figure 1. For the ambr cultures, the DO and 
the pH were well controlled around the set-point. However, compared to the 10 L 
cultures, the ambr cultures showed higher spikes of DO and pH. In addition, slightly 
higher pH values from day 5 to 8 can be seen in the ambr cultures. The higher spikes 
of DO were caused by the opening of the vessels which was needed for feed addition, 
base addition, and sampling. The spikes in pH in both the ambr and the 10 L cultures 
were caused by the daily addition of ActiCHO feed B, which has a high pH value of 
11. The spikes were higher in the ambr cultures, due to the fact that for the ambr the 
feed was added as a bolus whereas for the 10 L it was added over a period of 2 hours.  
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Figure 1. Examples of the online measured pH and DO profiles. Graph A, B, and C show DO profiles of the 
ambr 800 RPM, the ambr 1300 RPM, and the 10 L bioreactor, respectively. Graph D, E, and F show pH 
profiles of ambr 800 RPM agitation, ambr 1300 RPM agitation, and 10 L, respectively. For DO the set-points 
are shown by red solid lines, and for pH the dead-bands are shown in red dashed lines. The differences in pH 
measurement due to the different analyzers used between the scales were corrected for as mentioned in 
materials and methods 5.2.2 and 5.2.3. 
5.3.2 Cell growth 
The cell growth characteristics including viable cell density (VCD), viability, and 
average cell diameter are shown in Figure 2 for the two agitation rates of the ambr 
experiment, and the 10 L experiment. As described in Chapter 3116, the fed-batch 
culture can be divided into a cell number increase phase (NI phase, day 0-4), a cell 
size increase phase (SI phase, day 4-8), and a stationary phase followed rapidly by a 
death phase (day 8-12). Similar cell growth and viability profiles were observed 
between the two agitation conditions in the ambr cultures. Compared between the 
two scales, the ambr cultures resulted in a slightly higher peak VCD (~8×106 cells/mL) 
than the 10 L cultures (~7×106 cells/mL). Due to a difference in inoculation method 
(see section 2.1), the ambr cultures are started with 100% fresh medium whereas the 
10 L cultures are started with medium that contains 10% spent medium from the 
inoculum. This led to lower starting nutrient concentrations in the 10 L cultures and 
most likely a lower maximum VCD in the 10 L cultures. This difference is however 
not associated with the bioreactor system and can easily be solved by also adding the 
pre-culture directly to the ambr reactor without replacing the medium. Apart from 
this, the profiles for viability, cell growth, and cell diameter are comparable between 
the two scales.  
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Figure 2. A. Viable cell density (VCD, 106 cells/mL) and viability (%), and B. average cell diameter (µm) of 
ambr 800 RPM (closed square, black lines), ambr 1300 RPM (closed diamond, black lines), and 10 L (close 
circle, green lines) cultures. The error bars represent the standard deviation for ambr (n=5 for each condition) 
and 10 L (n=3) cultures. 
5.3.3 mAb production and glycan distribution 
Product characteristics including product titer, cell-volume based specific 
productivity, and N-glycan distribution are presented in Figure 3 for the two 
agitation conditions of the ambr and 10 L cultures. In Chapter 3116, it was shown that 
the specific productivity increases linearly with the cell volume. The cell-volume 
specific productivity is constant during the whole process and therefore for 
comparison of the specific productivity the cell volume-based specific productivity is 
used instead of the cell-based value. First of all, the two agitation conditions in the 
ambr gave similar product characteristics. Compared between scales, the ambr 
cultures yielded a slightly higher mAb titer (750 mg/L) than the 10 L cultures (650 
mg/L) (Figure 3A). However, the cell volume-based specific mAb productivity 
(Figure 3B) was the same between the two scales, meaning that the difference in mAb 
titer was caused by the difference in viable cell density, since the volume per cell is 
comparable between scales (Figure 2). A difference in the N-glycan distribution is 
observed at culture day 12 between the ambr and 10 L cultures, represented by a 
higher fraction of G0 and G1, and a lower fraction of G0F for the ambr cultures 
compared to the 10 L cultures (Figure 3C). A survey from the historical data using 
the same cell line and culture media system (not published data from the Bioprocess 
Engineering group of Wageningen University) showed a 10-20% variation of the 
mAb N-glycan species, which could be caused by the difference in the pre-culture 
batches and in the sampling time. Considering this variation, the difference in mAb 
glycosylation between the ambr and 10 L experiment in this study (Figure 3C) is 
minor.  
 
 
A  B  
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Figure 3. A. mAb concentration (mg×L-1) of ambr 800 RPM (closed square, blue line), ambr 1300 RPM 
(closed diamond, blue line), and 10 L (close circle, green line) cultures. B. Cell volume-specific mAb 
productivity (g×L-1×day-1). C. Relative mAb N-glycan composition (%) of ambr 800 RPM, ambr 1300 RPM, 
and 10 L cultures of the culture day 12. N-glycans with different numbers of terminal residuals (G: galactose, 
F: fucose, S: sialic acid) are shown. *: P<0.05, T-test. The error bars represent the standard deviation (n=3) 
of biological triplicates. 
5.3.4 Metabolite profiles 
The primary metabolite concentrations and osmolality profiles are shown in Figure 4 
for the two agitation conditions tested in the ambr, and in the 10 L cultures. The other 
measured metabolite concentrations are data to be published in Supplementary B. 
The two agitation conditions in the ambr experiment gave similar results, only the 
pCO2 profile was lower at 800 RPM from day 5 onwards. This was probably the 
result of increased CO2 stripping due to the fact that the 800 RPM condition required 
a higher gas flow rate compared to the 1300 RPM condition to maintain the DO at the 
set-point. The higher gas flow rate was needed because of the lower oxygen transfer 
from the headspace due to the lower agitation rate.  
C  
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Figure 4. Profiles of the extracellular glucose concentration (mM) (A), lactate concentration (mM) (B), 
ammonium concentration (mM) (C), osmolality (mOsm/kg) (D), and dissolved CO2 (mmHg) (E) of ambr 800 
RPM (closed square), ambr 1300 RPM (closed diamond), and 10 L (closed circle) cultures. All measurements 
that were done using different methods were corrected between the two scales. The error bars show standard 
deviation for ambr (n=5 for each agitation condition) and 10 L (n=3) cultures. 
The glucose concentration profiles showed a similar pattern between the two scales. 
Note that the slightly lower glucose concentration and osmolality on the first days in 
the 10 L bioreactor were caused by the different treatments in inoculum media as 
explained before. The lactate concentration for both scales showed a similar increase 
until day 3. From day 4 to day 8, however, the lactate concentration was up to 20 mM 
higher in the ambr as compared to in the 10 L cultures. This was a consequence of 
both the higher cell density (Figure 2A) and the higher specific lactate productivity 
(Figure 5a) in the ambr as compared to in the 10 L culture. After day 9, all cultures 
showed a sharp increase in the lactate concentration again, which coincided with the 
decrease in viability (Figure 2). The profiles of the ammonium concentration and 
osmolality were similar between the two scales. The culture osmolality increased 
from day 3 on for all conditions due to the feed addition. pCO2 levels were 
comparable until day 5. From day 5 to day 9, a difference in the pCO2 level was 
observed between the two scales. The pCO2 in the ambr 1300 RPM cultures is more 
comparable to the 10 L cultures and they are both higher than in the ambr 800 RPM 
cultures.  
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5.3.5 Cell metabolism 
Small differences can be seen in the extracellular product (Figure 3A), lactate (Figure 
4B), and nutrient (Supplementary B of the online published version) concentrations 
between the two scales, which might be caused by the small difference in viable cell 
density. In order to compare the two scales at the cellular level we investigated the 
metabolism, by looking at specific metabolite consumption and production rates, and 
the biomass composition. The specific rates are the same for the two agitation rates in 
the ambr (data not shown). This demonstrates that the two agitation rates calculated 
based on two scale-down criteria did not cause a difference in cell metabolism. 
Therefore, in this section, only the ambr 800 RPM condition is shown and compared 
with the 10 L bioreactor. 
5.3.5.1 Specific consumption/production rates 
The cell specific rates of the primary metabolites and amino acids are compared 
between the ambr and 10 L cultures for the NI phase SI phase in Figure 5. In Chapter 
3116, it was shown that the cell specific rates are more or less constant despite the 
increase in volume. Slightly higher specific lactate production and consumption rates 
are observed in the ambr cultures compared to the 10 L cultures (Figure 5A). A 
possible cause was the different pH and DO profiles in these two systems (Figure 1). 
First of all, slightly higher pH values from day 5 to 8 and pH spikes towards higher 
values were observed in the ambr cultures (Figure 1D&E), which may favor the 
transport of lactate out of cells178. Furthermore, it was reported by Serrato et al.179 that 
compared to a constant DO, oscillating DO values resulted in an increased glycolytic 
metabolism and an increased lactate yield. Next to the specific rate of lactate 
production, minor differences in specific rates between the two scales can be 
observed for ammonium during the NI phase, and for a few amino acids in both the 
NI and the SI phase (Figure 4B). Overall, the specific metabolic rates of these primary 
metabolites are very comparable between the two scales.  
    
99 
 
5  
 
Figure 5. Average cell-specific production rates (µmol×106 cell-1×day-1) of glucose and lactate (A), 
ammonium (B), essential amino acids (C), and non-essential amino acids (D) of the 10 L (black) and the 
ambr (red) cultures during the number increase (NI, stripes), and the size increase (SI, filled) phase. Positive 
values indicate production, negative values indicate consumption. The error bars show the standard deviation 
(n=3) of biological replicates. * shows the rate was not constant over the measurement points in time (R2< 
0.9). “ ” shows a significant difference (P<0.05, T-test) between the values calculated from the two 
compared scales.  
 
5.3.5.2 Biomass composition 
The cell size increased during the fed-batch process (Figure 2B). In Chapter 3 it was 
shown that the biomass composition changes when the cells increase in size116. The 
biomass composition between two scales is compared on day 7 that represents the 
cell size increase phase. In addition to biomass dry weight (DW), the relative 
composition (w/w) of several main biomass components were measured including 
protein, fatty acids, and carbohydrates (Table II). The results show identical biomass 
composition between the 10 L and the ambr cultures on culture day 7. Together with 
the similar cell diameter profiles (Figure 2B), this indicates highly comparable 
biomass dynamics between 10 L and ambr cultures.  
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Table II. Biomass composition of the CHO cells from the 10 L and ambr cultures on day 7 of the fed-batch 
cultures.  
 
10 L 
 
ambr 
Dry weight (pg/cell) 1530 ±77 
 
1483 ±43 
Protein (w/w %) 70.0 ±1.2 
 
71.3 ±1.3 
Fatty acids (w/w %) 4.5 ±0.1 
 
4.4 ±0.2 
Carbohydrates (w/w %) 3.8 ±0.2 
 
3.9 ±0.1 
±: Standard deviation obtained from the results of three independent bioreactors 
5.3.6 Transcriptome analysis 
Gene expression was measured using CHO Gene microarrays of the cells in the 
inocula just before inoculation and on day 3, 5, and 7 in both systems in triplicate. For 
the transcriptome study, only the 800 RPM condition of the ambr experiment is used 
to compare to the 10 L experiment. First, principal component analysis (PCA) is used 
to study the global variation in gene expression between the two scales. Next, 
functional analysis is performed for the genes that are uniquely regulated in one of 
the systems in order to study their relationship with the differences between the two 
bioreactor systems and with cell behavior.   
5.3.6.1 Global variation analysis in gene expression  
The principal component analysis (PCA) result is presented in Figure 6A&B, which 
shows the overall variation in gene expression for all analyzed samples including the 
inocula. The inocula are included at first because the difference in the inocula may 
cause differences in cell behavior between both systems. The principal components 
(PC) PC1, PC2, and PC3 represent 33%, 10%, and 6% of the total variation, 
respectively. The other individual PCs have only a minor contribution (less than 5% 
per individual component) to the total variation and are not considered. The variance 
explained by PC1 correlates with the culture development over time. For the variance 
explained by PC2, no clear unique correlation to the culture performance can be 
found. PC3, which represents 6% of the total variance, mainly explains the variance 
between the inocula. After three days of culture, both systems group together on all 
three principle components and the variance in gene expression observed in the 
inocula has disappeared.  
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Figure 6. (A&B) Score plots generated from the transcriptome results of the 10 L (filled markers), ambr 
experiments with 800 RPM agitation rate (open markers), and pre-cultures at the moment of inoculation 
(filled diamond: pre-culture 10 L reactor, open diamonds: pre-culture ambr reactor). Samples for pre-cultures 
are grouped by red circles. Samples on the same culture day are grouped by green circles. On day 9, one 
replicate of the ambr culture was excluded due to a technical error in the microarray. (C) Venn diagram of 
the number of genes that are differentially regulated between the ambr and 10 L cultures for the pre-culture 
samples and the samples on day 3. 
The genes that are significantly differentially expressed (FDR.BH<0.05 and absolute 
FC>1.4, see section 2.6) between the two pre-cultures are compared to those that are 
significantly differentially expressed between both systems on day 3 (Figure 6C). 
Between the two inocula, 1089 genes (total number of genes in the pre-culture circle) 
were differentially expressed, while between the two systems on day 3, only 167 
genes (total number of genes in the day 3 circle) were differentially expressed. 
Moreover, of the genes that were differentially expressed between the inocula, only 
14 were also differentially expressed between both systems on day 3. Thus the 
differences in gene expression on day 3 involve different genes than those that 
caused differences between the inocula. In conclusion, the difference in gene 
expression between the inocula probably did not cause differences in gene 
expression between the two scales later on and thus did not influence the scale 
comparison. 
Next, the differences in gene expression between the ambr and 10 L system are 
studied by comparing the gene expression data from day 3, 5, and 9, excluding the 
C 
B A 
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inocula samples. The results of PCA are shown in Figure 7. PC1, PC2, and PC3 now 
represent 37%, 10%, and 6% of the total variation, respectively. The other individual 
PCs each have only a minor contribution (less than 5% per individual component) to 
the total gene expression variance and are not considered. Samples taken on the same 
culture day of the two scales are closely grouped on PC1 and PC2 (Figure 7A). PC1 
again correlates with the culture development over time. PC2 shows a transient 
pattern that correlates with the cell size increase, since the cell size increased on day 5 
but not on day 3 and 9. Based on PC1 and PC2 there is a slight separation of the ambr 
and 10 L cultures on day 3 and day 9. When looking at the development in time as 
represented by PC1 moving to the right and PC2 moving to a minimum on day 5, it 
seems that the ambr system is slightly ahead of the 10 L cultures in its development. 
In agreement with this, slightly larger cell diameters during the SI and the stationary 
phase are observed in the ambr cultures (Figure 2B). PC3 relates to the difference 
between the two scales. As can be seen the difference becomes more prominent for 
the later stage of the cultures (day 5 and 9). PC3 describes 6% of the total variance, 
which is much less than the variance that is due to the changes in gene expression 
over time (47%, PC1+PC2). To analyze whether this global difference in gene 
expression between the scales is relevant for the evaluation of the scale-down, the 
function of the genes that are differentially expressed between both systems were 
subsequently studied in more detail. 
 
 
    
Figure 7. Score plots for the transcriptome results of the 10 L (filled markers) and ambr experiments with 800 
RPM agitation rate (open markers) on day 3, 5, and 9. On day 9, one replicate of the ambr culture was 
excluded due to a technical error in the microarray. 
 
 
5.3.6.2 Gene functional analysis  
For the functional analysis, first, for each system the genes that are significantly 
differentially (as shown in section 2.6) expressed from day 3 to 5, day 5 to 9, and day 
A B 
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3 to 9 are selected. Genes are considered differentially expressed between two days if 
the FDR.BH is smaller than 0.05 and the absolute fold-change (FC) is larger than 1.4 
(section 2.6). Next, the differentially expressed genes over time are compared 
between the ambr and 10L system and the result is shown in Figure 8. Note that the 
day 3-9 comparison picks up genes for which the expression level goes up or down 
slowly in time such that they were still insignificant in the 3-5 and 5-9 time frames. 
However, the day 3-9 time frame misses genes that are first up-regulated and then 
down-regulated or vice versa. These genes are picked up by the day 3-5 and 5-9 time 
frames. The number of the genes that slowly change over time are shown between 
brackets in the day 3-9 time frame in Figure 8. Their number is roughly half of the 
total regulated genes from day 3-9. The Venn diagrams show for each time frame the 
number of genes that change in the same way for both systems, and the number of 
genes that change uniquely in a specific system and not in the other. From these 
comparisons, genes are selected that are only regulated in time in one system and 
never in the other system (unique for the system) as well as the genes that are always 
regulated in the same way in both systems (common for two systems). The numbers 
are given at the bottom of the figure. In this way differences in gene expression 
between the two systems due to time delays are filtered out. It can be seen from 
Figure 8 that: 
(i) The amount of commonly regulated genes is about twice the uniquely 
regulated genes for each system except for the up-regulated genes in ambr from day 
5-9 where it is more or less comparable. 
(ii) From day 3-5 the amount of uniquely regulated genes is the same between 
the two systems whereas from day 5-9 it is twice as much in the ambr as compared to 
the 10 L system. This is in agreement with the observation in the PCA analysis that 
the difference between both systems becomes progressively more with time. This 
may be related to the larger fluctuations in conditions, like the pH, DO, and nutrient 
concentrations in the ambr system. 
(iii) The total amount of uniquely regulated genes in two systems is 4059 (total 
number of genes in “unique for each system” in Figure 8), which is in the same range 
as the total amount of common genes in two systems (5304, “common for two 
systems” in Figure 8). The total number of uniquely regulated genes is higher in the 
ambr than in the 10L reactor, which again may be due to the higher fluctuations in 
conditions like pH, DO, and nutrient concentrations. 
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Figure 8. Venn diagram of the number of genes that are differentially regulated from day 3 to 5, 5 to 9, and 3 
to 9 for the ambr and 10 L cultures. Red numbers indicate up-regulation, blue numbers indicate down-
regulation. Numbers in brackets from day 3 to 9 show the number of genes significantly regulated from day 3 
to 9, but not from day 3 to 5 and day 5 to 9. The number of regulated genes that are unique to each system, 
and are common for two systems (dash boxes) are also shown. A gene is unique to a system means it is 
differentially expressed in at least one of the three time comparisons for that system and never differentially 
expressed in one of the three time comparisons for the other system. 
The biological function of the identified genes that were uniquely regulated in one of 
the systems (the genes in “unique for each system” in Figure 8) are next categorized 
based on the KEGG pathway database. The aim is to study whether these genes 
specifically belong to certain pathways that can be linked to the differences that exist 
between the scales. 
The genes unique to a system are distributed over almost all the functional pathways, 
including global metabolism of carbohydrate, protein, lipid, nucleotide, energy, 
signal transduction, etc. In the ambr cultures, overexpression of the hypoxia-
inducible factor 1 (HIF-1) signaling pathways (Supplementary C to be published in 
the online version) is observed. HIF-1 is known to respond to extracellular oxygen 
levels and to play a role in anaerobic respiration and lactate formation180. The higher 
regulation of the HIF-1 signaling pathways in ambr may be caused by the 
fluctuations in DO (Figure 1) and may be related to the higher lactate production 
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(Figure 5A). Moreover, as mentioned before, higher pH levels from day 4 to 8 and 
higher pH spikes towards higher values are observed in the ambr cultures (Figure 
1D&E), which would favor the transport of lactate out of cells. The transport is done 
by H+-monocarboxylate cotransporters (MCTs)181. Among several MCTs (MCT1-
MCT4) that are known for lactate transport, MCT2 (encoded by SLC16A7 gene) has a 
higher affinity for substrates compared to the other MCTs182 and it showed a higher 
up-regulation from day 3-9 in the 10 L cultures (3.6 FC, FDR.BH=0.00) compared to 
that of in the ambr cultures (2.2 FC, FDR.BH=0.00) (to be published in the 
Supplementary A of the online version). This might be associated with the 
differences in lactate production/consumption between the two systems (Figure 5A). 
Regulations of MCT1, MCT3, and MCT4 are however similar between the two 
systems. Furthermore, for the N-glycan biosynthesis pathway (to be published in the 
Supplementary C of the online version), the one up-regulated gene unique to the 10 
L system is Fut8 (1.5 FC from day 3-9, FDR.BH=0.00) which gene encodes the 
fucosyltransferase that is responsible for the α-1,6-fucosylation. This agrees with the 
observation of the higher percentage of fucosylated mAb in the 10 L cultures (Figure 
3C).  
In summary, only for a few genes a possible relationship between their expression 
and differences that exist between both scales can be found, which could be related 
to the fact that the differences between both systems in terms of process performance 
are small. Given this fact, the fraction of uniquely regulated genes of 20% is rather 
high (4059 uniquely regulated genes out of a total of 20858, Figure 8). Possibly the 
difference in gene expression of these genes between both scales represents an 
adaptive response to differences that exist between scales, leading to a comparable 
process performance. Overall, this study shows that transcriptomics is a sensitive 
tool to measure differences in the physiological response of cells to different 
bioreactor environments. However, these differences in gene expression could not be 
related to the process performance, which was comparable between scales or 
differences in the bioreactor systems. To be able to rate the importance of the 
observed differences, comparison is needed on gene expression data of other scale 
comparisons from both successful and failed scale-up/scale down experiments. These 
data are currently lacking in literature.    
5.4  Conclusion 
For the specific cell line and the fed-batch process tested in this study, the results 
obtained in the ambr at two different agitation rates are comparable to that obtained 
in a 10 L bioreactor in terms of cell growth, metabolism, productivity, and product 
quality. Transcriptome analysis showed differences in gene expression between both 
systems. The number of genes that were significantly regulated over culture time in 
only one of the systems and never in the other was higher in the ambr (2455) than in 
the 10 L system (1604), which may be related to the higher fluctuation of conditions 
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like DO, pH and nutrient concentrations in the ambr. In general, these genes were 
spread over all KEGG pathways and could not be linked to differences in bioreactor 
system or differences in cell physiology. For a few genes possible functional 
relationships with differences in DO and pH patterns, lactate metabolism, and 
glycosylation pattern could be identified. Furthermore, transcriptome analysis 
showed that a difference in gene expression between the inocula was not present 
anymore after three days of culture, and thus did not influence the system 
comparison. In addition to existing literature, this study further strengthens the 
opinion that the ambr system gives representative culture performances for the 10 L 
bench-scale bioreactor. Differences in gene expression between scales could be 
observed by using transcriptome analysis. However, the differences could not be 
linked to specific process conditions. More studies are needed to determine the 
sensitivity of the transcriptome analysis on scale comparison. 
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Abstract: 
Bioprocess scale-up is an important step during the upstream development of 
mammalian cell culture processes. Considerable progress has been made to 
understand the principles of process scale-up as well as to develop representative 
scale-down bioreactor systems. In this chapter, the current opinion on cell culture 
process scale-up is reviewed. Furthermore, with the increasing pressure on 
shortening the development timelines for biopharmaceutical manufacturing, 
miniature bioreactor systems which offer the high-throughput solution have received 
a lot of attention in recent years. These miniature bioreactor systems are being 
further incorporated into process development as scale-down models for the 
traditional bench-scale (10 L) bioreactors for the exploration of the process design 
space. The development of miniature bioreactor systems brings opportunities as well 
as challenges to the current process development. These are discussed in this chapter. 
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6.1 Introduction 
Monoclonal antibodies (mAbs) are an important class of biopharmaceutical products2. 
Currently, mAbs are mainly manufactured in mammalian cell cultures in bioreactors. 
Chinese Hamster Ovary (CHO) cells are the widely used hosts for the production of 
mAbs. In industry, a CHO cell culture process is typically developed at laboratory 
scale (<20 L) and scaled up to large scale (e.g. kL-scale) for commercial production183. 
The scale-up is done stepwise: from bench scale (1 L to 20 L) to pilot scale (500 L to 
1000 L) and finally to production scale (>2000 L). The aim of scale-up is to increase 
the batch size while maintaining the same process performance. An important aspect 
of the process performance is product quality. During process scale-up, critical 
quality attributes (CQAs, e.g. oxidation, deamination, glycosylation, and aggregate 
levels) which influences the efficacy and safety of the product should be kept within 
acceptable ranges. In addition, key performance indicators for the process (KPIs, e.g. 
product concentration, cell growth, and viability) that reflect the performance of the 
cells need to be kept similar as well between scales184. The chemical (e.g. nutrient and 
waste concentrations, pH, dissolved oxygen, dissolved carbon dioxide) and physical 
(shear) conditions experienced by the cells are important factors to consider during 
scale-up. These conditions depend on a combination of cell kinetics, liquid-gas mass 
transfer and mixing, which together determine the nutrient and product 
concentrations as well as whether significant gradients will be present in the 
bioreactor. In bioreactors, mass transfer, mixing, and shear can be linked to a number 
of parameters, for example, volumetric energy input (P/V), impeller tip speed (vtip), 
impeller pump rate (Q), and Reynolds number (Re)185. However, it is not possible to 
keep all these parameters the same across scales. Consequently, keeping mass 
transfer between scales the same will result in different shear conditions. Hence, it is 
important to understand the interactions between these parameters and whether 
they affect the cell and process performance in the applied ranges for the different 
scales. Based on this, choices can be made on which parameters are important to be 
kept constant across scales. Although a better understanding has been obtained on 
how to keep the scaling parameters within acceptable ranges during the past 
decades37–39, scale-up is still not a straightforward and uniform task. It remains a 
critical and challenging step in mammalian cell process development especially due 
to the fact that the scales used in development are getting smaller. 
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Table I. Examples of currently available miniature bioreactor systems 
Bioreactor 
systems 
Working 
volume (mL) 
Multi
plex 
Feed addition Aeration 
Singl
e-use 
Reference 
Applikon 
Mini Bio 
50-800 2-8 
Continuous feeding 
possible 
Sparging/Overlay 
Porous sparger /L-type 
sparger 
N 
http://www.applikon-
bio.com/ 
186 
ambr®  15 10-15 24-48 Bolus feeding 
Sparging/Overlay 
Open pipe sparger 
Y 
www.sartorius.com 
174 
ambr®  250 100-250 12-24 
Continuous feeding 
possible 
Sparging/Overlay Y 
www.sartorius.com 
33 
DASbox®  60-250 4/Unit 
Continuous feeding 
possible 
Sparging/Overlay N 
www.eppendorf.com 
187 
BioXplorer 100-400 
4-
8/Unit 
Continuous feeding 
possible 
Sparging 
Open pipe sparger 
N 
http://www.helgroup.
com/ 
166 
MSBR 10 N/A Bolus feeding Sparging N 
Not  available 
commercially  
188 
 
Bench-scale bioreactors (1-10 L) have been used as the main platform for process 
development and they were traditionally considered as the smallest scale that is still 
representative for the bioreactors at production scale. However, in order to obtain an 
accurate definition of the process design space, high throughput experimentation 
(n>100) is needed175,189. Using bench-scale bioreactors for high throughput 
experimentation is not practical due to the substantial cost associated with materials, 
space, time, and labor. Therefore, during the past few years, miniature bioreactor 
systems (mL-scale) have received a lot of attention in process development189. The 
larger number of experiments that can be done using a miniature bioreactor system 
as compared to the 1-10 L bench-scale bioreactors can expand the process knowledge 
space and help to define more accurately the process design/control space, which 
facilitates the quality by design (QbD) approach. Several miniature systems at the 
mL-scale have been developed with similar control and operational capabilities as 
production-scale bioreactors (Table I). These capabilities include the monitoring and 
control of culture DO and pH, mechanical mixing, gas sparging, and the addition of 
feed, antifoam, and base solutions. The mL-scale systems were originally designed 
for quick screening of clones, media, and culture parameters such as pH and 
temperature. In recent years, many studies165,172,190,191 have shown that these mL-scale 
systems are quite representative for the bioreactors ranging from L-scale to kL-scale. 
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Data presented in Chapter 5 and in other studies34,169,170,172–174,192,193 showed that the 
current mL-scale systems are promising tools to be integrated into process 
characterization and design space exploration during upstream process development. 
Current research is focusing on the further implementation of mL-scale systems into 
process development and replacing the traditional bench-scale bioreactors with mL-
scale systems (Figure 1).  
Nevertheless, challenges with regard to gas transfer, mixing, shear, and liquid 
handling still exist in the current mL-scale systems due to small culture volume and 
how these systems are operated. In this chapter, the current challenges in process 
scale-down to the mL-scales are discussed in relation to the ambr®  15 system as a 
model system. 
 
 
Figure 1. Scale-up/down during process development 
6.2 The scale-down approach 
In order to develop a representative small-scale bioreactor system, reversed scale-up 
as a scale-down approach (Figure 2) was proposed by Oosterhuis194. As the first step 
of the scale-down approach, it should be identified which are the parameters that can 
be kept the same between scales and which cannot. Next, for the parameters that 
cannot be easily kept the same between scales, their effects on the cells and the 
process performance have to be analyzed195,196 in order to make sure that they are 
kept in ranges where they do not affect the process outcome. Based on this 
information, choices can be made on how to perform scale-down. For mammalian 
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cell culture the three aspects that cannot all be kept the same between scales and for 
which the importance for process performance has to be studied are: 
 Gas-liquid mass transfer, which determines the supply of O2 and removal of 
CO2. 
 Mixing, which is used to homogenize the culture and is related to gradients in 
the reactor. 
 Shear effects, which are the result of sparging and agitation and thus are 
associated with the previous two aspects. 
 
Figure 2. The general scale-down approach 
The performance of the scaled-down process with regards to quality attributes, 
productivity, etc. needs to be validated against the production-scale reactor. If a 
deviation is observed, further optimization of the scaled-down process will be 
needed (Figure 2). 
6.2.1 Mass transfer 
Dissolved oxygen (DO) and dissolved carbon dioxide (pCO2) concentrations are 
critical parameters for mammalian cell culture performance. Insufficient O2 transfer 
results in O2 limitation, which leads to slower cell growth, changes in cell metabolism, 
cell death, and changes in product quality179,197. In practice, the O2 volumetric mass 
transfer coefficient (kLa) is often used as a criterion during scale-up/down37,165,196,198. 
Matching the kLa ensures that similar maximum O2 transfer rates (OTRs) can be 
obtained between scales.  
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CO2 is a by-product of mammalian cell metabolism and is produced at roughly the 
same rate as with which O2 is consumed199. High pCO2 values (>150 mmHg partial 
pressure, or >4.5 mM concentration) were reported to negatively influence cell 
growth, productivity, and protein quality20,42,200,201. Mostafa and Gu202 reported a 40% 
loss of specific productivity in CHO cell culture when the pCO2 increased from 68 
mmHg in a bench-scale (1.5 L) STR to 179 mmHg in a pilot-scale (1000 L) STR. In 
order to maintain a similar pCO2 profile between scales, it is important to have a 
similar volumetric CO2 removal rate in bioreactors of different volumes.  
Aeration using micro-bubbles (e.g. db<200µm) with pure O2 is favorable for O2 
transfer and is often applied at bench and manufacturing scales. The use of pure O2 
increases the driving force for O2 transfer, while the smaller bubble size and the 
slower rising velocity of these micro-bubbles result in a high specific surface area of 
bubbles and thus a high O2 volumetric mass transfer coefficient (kLa)22,203–206. As a 
consequence, higher OTRs can be achieved and a significantly lower volumetric gas 
flow rate is needed. Furthermore, some of the small bubbles collapse and thus never 
reach the surface207, which in combination with the lower volumetric gas flow rate 
reduce problems with foaming and risks with bubble-burst associated cell damage. 
However, the use of micro-sparging and pure O2 results in high pCO2 levels43,203,204,208. 
When micro-bubbles with pure O2 are used, the volumetric gas flow rate that is 
required for O2 transfer is considerably lower compared to when large bubbles are 
used. At a lower volumetric gas flow rate in order to reach the same volumetric CO2 
removal rate, the CO2 concentration in the gas has to be higher. This means that the 
concentration of CO2 in the liquid phase must also be higher to have a concentration 
gradient required for diffusion from the medium to the bubble. Therefore, the pCO2 
level will build up with the use of micro-sparging. In order to reduce the pCO2 level 
in these bioreactors, an additional sparger generating large bubbles with air or N2 is 
used for stripping CO2 165,209. In this way, the DO and pCO2 can be independently 
controlled.  
An obvious difference between scales is that the contribution of the headspace 
surface to gas transfer becomes relatively more important upon scale-down, because 
the volume decreases more rapidly than the headspace surface and thus the specific 
surface area increases. At 10 L scale, the contribution of the headspace surface to gas 
transfer is still negligible. However, in the ambr®  15  bioreactors according to Nienow 
et al.168, the apparent kLa from the headspace surface aeration can contribute to more 
than 50% of the total apparent kLa. The difference in the contribution of the 
headspace surface to gas transfer results in different gassing strategies and pCO2 
between scales. For example, because of the high gas transfer from the headspace 
surface in the ambr®  15   bioreactors, micro-sparging is not needed and only large 
sparging bubbles are used in the ambr®  15 bioreactors (Chapter 5). As a consequence, 
the volumetric gas flow rate in the ambr®  15 bioreactor is significantly higher (e.g. 2 
to 9 times higher in Chapter 5) than in the 10 L scale bioreactors. Subsequently, lower 
    
116  
   
pCO2 levels were observed in the ambr®  15 bioreactors compared to in the 10 L 
bioreactors (Chapter 5). A way to improve this is to use micro-sparging for DO 
control in the ambr®  15, similar to those used in bench scales, and to use headspace 
aeration for pCO2 control, for example, by gassing air through the headspace 
enriched with N2 or CO2 depending on the oxygen transfer and culture pCO2, 
respectively. 
The higher contribution by surface aeration also means that a small change in culture 
volume in the mL-scale bioreactors due to, for example, sampling or feed addition 
will result in more significant changes in the kLa due to the change in the headspace 
specific surface area. Nienow et al.168 showed that a 2 mL volume decrease from 15 to 
13 mL in the ambr®  15 bioreactor results in a 20~60% increase in the apparent kLa. 
This might lead to a change in gas flow rate and difficulties in controlling the DO and 
pCO2, which could influence the process performance at the mL-scale. Finally, in the 
ambr®  15 system, the lid is opened for sampling and feed/base addition. This causes a 
sudden change in gas composition in headspace, which will also introduce 
temporary changes in DO and pCO2 (Chapter 5). 
In order to better simulate the pCO2 condition in the large-scale bioreactors, as 
mentioned before, it may be necessary to increase the pCO2 in mL-scale bioreactors 
by enriching the inlet gas with CO2. Although several studies have attempted this 
simulation using scale-down bioreactors, to precisely reproduce the pCO2 levels 
between scales remains a difficult task since by manipulating the pCO2 level the 
gassing strategy, pH control, and osmolality will be influenced20,42,200,201. Ideally, in the 
mL-scale bioreactors, micro-sparging should be used to simulate the shear conditions 
as in the large-scale bioreactors, and macro-sparging or headspace aeration should be 
used to control the pCO2 levels. This will be a technical challenge for the systems 
with extremely small volumes (e.g. ambr®  15 system), however, it may easily be 
implemented, for example, in the ambr®  250 system. These modifications will only be 
necessary if the shear caused by micro-bubbles (see 2.3) and the pCO2 level are 
critical for the process performance. 
6.2.2 Mixing 
Sufficient mixing in a bioreactor is needed to maintain homogeneous conditions for 
the cells. Mixing time (Tm= time to reach 95% homogeneity after a local change) is 
used to evaluate the mixing characteristics of a bioprocess185,210. Tm tends to be longer 
in large-scale bioreactors than in small-scale bioreactors22,207, meaning that in larger 
bioreactors a cell travels through regions with different environments (gradients of 
pH, DO, nutrient concentration, etc.) for a longer time195. In manufacturing-scale 
bioreactors, the mixing time is generally in the range of minutes185. In mL-scale 
bioreactors, mixing times are much shorter (e.g. according to Nienow et al.168, the 
typical Tm for the ambr®  15 bioreactors is below 10 s). This may result in a different 
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cell performance compared to large-scale reactors if the longer mixing time in these 
large-scale reactors causes gradients that affect cell physiology. Gradients may be 
caused by the local addition of feeds and base or the metabolic activity of the cells 
(e.g. local consumption/depletion of O2). In the case of local addition of feeds and 
base, sudden changes in local pH, DO, osmolality, and nutrients concentration will 
occur195. These changes are steep but last only for short periods of time. The Tm 
determines how long the gradients will be present and how steep these gradients are. 
The influence of such gradients on cells will also be dependent upon the sensitivity 
of the cells, which needs to be determined experimentally. Gradients caused by the 
metabolic activity of the cells will in general be less steep but persist for longer 
periods of times. If the mixing time Tm is larger than the cell characteristic time for the 
uptake of nutrients or production of waste products, gradients for these components 
are likely to be present, and cell metabolism may be affected, again, depending on 
sensitivity of the cell195,211. Oxygen is one of the most critical components since it has a 
low solubility and is consumed by cells at a high rate and is thus most likely the first 
component to be locally depleted212. The characteristic time for oxygen uptake 
depends on the cell concentration and the specific oxygen uptake rate, which depend 
on the cell line and the conditions used. Typical values for a CHO cell fed-batch 
process are a viable cell concentration of 2×107 cells/mL and a specific O2 uptake rate 
of 10-16 mol/cell/s, which results in a characteristic time for O2 uptake of ~100 s 185. For 
perfusion cultures, which reach cell densities about 5 times as high, the characteristic 
time becomes ~20 s.  
Practically, a maximum allowed mixing time is applied in industry for designing 
operating conditions of large-scale bioreactors. This value can be determined 
experimentally based on, for example, the characteristic time for O2 uptake. If the 
mixing time is kept below this threshold, it is assumed that the gradients do not 
affect the performance of the process. For large-scale STRs, sufficient mixing is 
ensured by adding baffles and extra impellers, and by intensifying agitation. 
However, elevated shear forces are associated with these options (see section 2.3). As 
a result, limits in either mixing time or shear may be reached as the scale increases43.  
Several studies have attempted to simulate the mixing conditions in large-scale 
bioreactors using scaled-down bioreactors. In the study of Nienow et al.171, an 
external plug-flow reactor (PFR) connected to a 3-L STR through a peristaltic pump 
has been used to simulate the impact of spatial variations in pH and nutrients as 
found at commercial scale. Substrate and alkali with different pH (9.7 and 12.3) were 
fed to the STR or the PFR under different circulation rates (60 s and 120 s). However, 
the use of the peristaltic pump in that study always resulted in reductions in culture 
time and product titer, which was dominant enough to mask other effects. In contrast, 
a one-compartment study was performed by Serrato et al.179 in a 220-mL bioreactor to 
simulate DO oscillations in large-scale hybridoma cultures producing a mAb. The 
study showed that compared to a constant DO (10%), the oscillating DO (0%-14%) in 
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a time-scale ranging from 800 to 12800 s decreased maximum cell concentrations, cell 
growth rates, and viability, and increased cell glycolytic metabolism and lactate 
production. Furthermore, the oscillating DO resulted in a higher amount of 
triantennary and sialylated glycans, which may affect the quality of the mAb. 
Recently, Brunner, M. et al.213 studied the impact of pH inhomogeneity on CHO cell 
fed-batch process performance using a two-compartment (a 3 L STR and a 0.7 L STR) 
scale-down modelling. Their study simulated a well-mixed zone of pH 7.0 in the 3 L 
STR and a temporary pH zone of pH 9.0 in the 0.7 L STR, connected by recirculation 
peristaltic pumps. The study showed that the temporary pH zone has a strong 
impact on maximum viable cell density and ﬁnal product titer. Unlike the previous 
study done by Nienow et al.171, in the study of Brunner, M. et al.213, the use of 
peristaltic pumps did not show an effect on performance of the applied cell line. In 
conclusion, only a few experiments have been performed to understand the effects of 
gradient and poor mixing conditions in mammalian cell culture bioreactors. There is 
still a lot to be done to study the effect of gradients on relevant conditions and time-
scales for the factors like pH, DO, and individual nutrients. 
6.2.3 Shear 
As mentioned before, in large-scale bioreactors, the chosen operating parameters for 
mixing (e.g. stirrer types and agitation speeds) and mass transfer (e.g. sparging 
bubble sizes and rates) will have an impact on the shear level. If shear affects the 
process performance, it is important that the shear level is comparable between large- 
and small-scale systems so that the potential problems related to this can be 
identified early at the small-scale systems.  
The most obvious and often considered source of shear stress is agitation. Research 
has been done to investigate maximum allowed power input per volume (W/kg, also 
called volumetric energy dissipation rate, from here on symbolized as [ε]) for 
mammalian cells37,38,165,177,196,214. The results of these studies indicate that shear 
generated from agitation is generally well below the critical level of mammalian cells. 
In typical large-scale bioreactors, the average [ε] is around 0.01 W/kg and the 
maximum [ε] from agitation would be in the order of 1 W/kg 207. Nienow et al.171 
reported that the cell growth and productivity remained unchanged at significantly 
higher [ε] values, i.e. 290 W/kg, created by an extensional flow device, or an average 
[ε] of 1 W/kg (i.e. a maximum [ε] of 50 W/kg), created by agitation with dual Rushton 
turbines. In the studies of Godoy-Silva et al.215,216 and Ma et al.217, mammalian cells 
were subjected to very high shear stresses in external “torturing chambers”. Changes 
with respect to cell growth, viability, and antibody glycosylation were found only at 
[ε] values (e.g. ~290 W/kg) that were orders of magnitude higher than the estimated 
maximum [ε] generated from agitation in large-scale STRs. In contrast, when an 
agitation rate condition of 700 RPM (~0.5 W/kg) was applied in a 4 L bioreactor 
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experiment done by Sieck et al.32, reduced culture viable cell density and viability 
were observed compared to a standard agitation rate condition (267 RPM, ~0.03 
W/kg). This stress level at which damage occurs is thus substantially lower than 
those reported by others. Although not mentioned in that study, bubble entrainment 
could have been the cause of the cell damage. It can also be that the specific cell line 
used is very sensitive to stress. 
In industry, an appropriate agitation scale-up/down criterion is chosen between 
scales to ensure similar mixing intensities, and for some shear sensitive cell lines, also 
similar shear levels169,218. The aforementioned [ε], which is also referred to as the P/V 
value, is often used as the criterion. Li et al.37 did a scale-down from a 2000 L to a 2 L 
STR based on a constant impeller tip speed, resulting in 550 RPM in the 2 L STR, and 
based on a constant impeller P/V value, resulting in 350 RPM in the 2 L STR. The 2 L 
cultures based on the P/V value gave a representative performance, whereas the 2 L 
cultures based on the constant impeller tip speed showed a lower cell density and 
viability. Also here it could be that the high RPM led to vortex formation that caused 
bubble entrainment40, which in turn caused cell damage. In Chapter 5 of this thesis, 
two agitation scale-down approaches were tested in the ambr®  15 compared to a 10 L 
bioreactor system: 800 RPM based on matching impeller tip speed and 1300 RPM 
based on matching impeller specific power input P/V. No difference in process 
performance was found between both approaches. This can be expected due to the 
fact that the P/V values of both approaches (0.065 W/kg and 0.28 W/kg, respectively) 
were far below the aforementioned threshold that would influence the process 
performance. Although agitation is an obvious source of shear, current studies 
suggested that it is not a major limitation for large-scale mammalian cell culture 
anymore and thus is not important for scale-down, as long as there is no bubble 
entrainment from a vortex. 
In addition to agitation, shear can also be caused by the interaction between cells and 
bubbles. In a STR, bubble-associated cell damage may occur in three main regions: (i) 
at the sparger due to bubble generation, (ii) in the bulk of the liquid due to rising of 
the bubbles, and (iii) at the surface due to bubble bursting.  
Within these three regions where cell damage may occur, generally, it is believed that 
the (ii) rising of the bubbles has little effect on cell damage207. However, the (iii) 
bubble bursting is considered as the most important cause of cell death219–222. Studies 
have shown that upon bubble rupture, substantial energy (~1×105 W/kg) is 
discharged to the surrounding liquid which damages the cells11,21,223. More 
importantly, the [ε] associated with the bubble burst is inversely correlated to bubble 
size21,221,224, i.e. the burst of smaller bubbles is more detrimental to cells. Currently, 
shear protective reagents such as the Pluronic F-68 have largely solved the problem 
related to the bubble damage225–227. Several possible protective mechanisms of 
Pluronic F-68 have been proposed. One is that it forms a protective layer on the cell 
membrane which increases the shear resistance of the cells227. Another explanation is 
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that it saturates the air-liquid interface and therefore displacing cells226. In addition, 
Pluronic F-68 may also decrease surface tension and thus decrease the energy 
generated from bubble bursting228. Increase in Pluronic F-68 up to 2 g/L generally 
showed increasing protection effect for CHO and insect cells against shear 
damage225,227,229. 
Furthermore, some studies focused on cell damage in the (i) bubble generation 
region. Barbosa et al.230 showed that at high gas entrance velocities (52 m/s) death of 
algal cells may occur at the sparger site. Similar to the result of Barbosa et al.230, Zhu 
et al.231 studied the influence of sparging on a mammalian (NS0) cell line in 8 L 
spinners. It was shown in that study that a gas entrance velocity above 30 m/s 
resulted in cell death at the sparger site and the cell death was mainly a function of 
the gas entrance velocity with minimum contributions of total gas flow rate and 
bubble burst (db=6-20 mm). Liu et al.232 developed a hydrodynamic model which 
showed a good correlation with experimental data indicating that the increased gas 
flow rate enhances cell damage at the gas inlet region near the sparger. These studies 
indicate that cell damage may occur in the bubble formation region. Practically, gas 
entrance velocities can be easily kept below 30 m/s if the spargers are properly 
designed, meaning cell death at the sparger is not a major problem in scale up/down.  
Alternatively, the cell death from cell-bubble interaction can be determined using the 
hypothetical killing volume model. The model relates the first order death rate 
constant kd (s-1) to reactor parameters: 
𝑘𝑑 =
6𝐹𝑉𝐾
𝜋𝑑𝑏
3𝑉
    (1) 
where F is the gas flow rate (m3×s-1) Vk is the hypothetical killing volume (-), db is the 
bubble diameter (m) and V is the culture volume (m3). The hypothetical killing 
volume Vk is a scale-independent parameter, meaning differences between scales can 
be accounted for using this theory. However, the only problem is that Vk is 
dependent on bubble diameter (db) 22 and the relation is not exactly known. 
According to Tramper et al.233,234, Vk is proportional to 𝑑𝑏
3. While in other studies, it 
was shown that the killing volume is proportional to 𝑑𝑏
2 21,222. This model was never 
verified for micro-sparging. In traditional low cell density (<1×107 cells/mL) 
bioreactors often no micro-sparging is used and the use of Pluronic F-68 makes cell 
death at the surface negligible. In this circumstance, the differences in gassing will 
not be a problem in scale-down/up. However, the current mammalian cell culture is 
progressing towards high-density (>5×107 cells/mL) processes (e.g. intensified fed-
batch or perfusion cultures). In such cases, micro-sparging and higher sparging rates 
will be needed, which may bring back the issues associated with the bubble damage. 
In conclusion, the effect of bubble size on cell death needs to be studied in more 
detail. 
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6.2.4 Additional challenges of the current mL-scale systems 
Besides the challenges associated with the traditional scale-up/down problems, 
additional challenges exist with further scale-down to the mL-scale. These challenges 
are primarily associated with the small culture volume. 
First, small volumes of liquid addition are needed for feeding and for pH control of 
the mL-scale bioreactor. In Chapter 5, the daily addition of feed medium for a 15 mL 
ambr®  15 bioreactor can be as low as 60 µL, which is not possible to be added 
accurately in a continuous way over 24 hours and thus can only be added as a bolus. 
The addition of feed as a bolus can lead to fluctuations in pH and DO profiles at the 
moment of addition (Chapter 5). Furthermore, bolus addition results in periodic 
variations in nutrient concentrations, whereas upon continuous addition, nutrient 
concentrations stay more or less constant. Thus, in case the continuous feeding is 
applied at large scale, the different feeding strategy applied at the mL-scale may 
cause changes in process performance such as cell metabolism and product quality. 
The further development of mL-scale systems requires liquid handling devices that 
can add liquid in small amounts continuously235. 
Second, the sample volume is limited in the mL-scale bioreactor. A large sample 
volume withdrawal in a mL-scale bioreactor will disturb the kLa and DO. If the 
sample volume is larger than the feed volume, it will also result in a continuous 
decrease in culture volume and eventually emptying of the bioreactor. In order to 
solve this, in Chapter 5, destructive sampling for several ambr®  15 bioreactors and 
pooling of the sample content from two ambr®  15 bioreactors were used to achieve 
enough sample volume. The main problem with respect to this approach is that the 
number of experiments and the data output per experiment (i.e. the experimental 
power) are significantly reduced. Moreover, the size of the required sample is 
directly related to the volume required for the analytics. The solutions for decreasing 
the volumes required for analytics are further discussed in the next section. 
6.2.5 Scale-down verification 
Whether the small scale process is truly representative for the larger scale should be 
justified by experimental verification (Figure 2). For the process verification, ideally, 
the same analytics should be carried out between scales. However, as mentioned 
before, the sample volume that can be taken from a mL-scale bioreactor is much 
smaller than for a bench-scale or a production-scale bioreactor, which may limit the 
time resolution and the number of process parameters on which the scales are 
compared. To improve this, analytical methods with lower volume requirements 
have to be developed for mL-scale processes. A number of analytical methods that 
require much smaller volumes are being implemented into the mL-scale bioreactors 
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to solve this problem. The OctetTM system (Pall ForteBio Corp, USA) is able to 
perform protein quantitation and affinity analysis for µL sample volumes directly 
from culture supernatant, by employing advanced microfluidics and label-free 
assays. Miniature chromatography columns and antibody purification platforms 
have also been developed that can purify mAbs at a few milligrams level192,236–238. 
Several methods have enabled glycosylation analysis directly from culture 
supernatant and with a volume requirement in µL ranges239–242.  
For the analytics of the mL-scale system, a second challenge arises due to the 
requirement of high experimental throughput. Large numbers of samples from the 
mL-scale system need to be analyzed and interpreted, which is a labor-intensive and 
time-consuming task at the moment. To tackle this, high throughput sample 
preparation, transfer, and analysis are necessary. Currently, instruments for online 
sampling, sample preparation, and transfer to analytical devices are being integrated 
into cell culture systems243. Several automation programming platforms have been 
developed that allow for cross-platform liquid handling using microfluidic 
devices244,245. Such systems can drastically decrease the time requirement and labor 
intensity on the sampling actions of mL-scale systems. Advanced online cell culture 
monitoring technologies are available, including online dielectric spectroscopy246 and 
light scattering191, which can be used to measure viable cell density and viable cell 
volume, and online Raman spectroscopy247 and infrared spectroscopy248, which can 
be used to monitor several culture metabolites and glycoprotein titer. Integration of 
these technologies into mL-scale bioreactors can reduce the liquid handling activities, 
solve the problem related to the small sample volume, and more importantly, 
increase the data throughput and resolution. 
Besides the routinely measured KPIs and CQAs, in this thesis, transcriptome analysis 
is used as a fingerprinting technique to evaluate the scale-down process. For the cell 
culture process run in Chapter 5, the overall process performance and transcriptome 
profile resulted from the ambr®  15 system was representative for the 10 L bioreactor 
system. Similarly, Jayapal et al.30 used transcriptome as a fingerprint to assess the 
scalability of BHK cells in perfusion cultures and showed that the gene expression 
was similar between laboratory-scale and manufacturing-scale bioreactors. It was 
concluded in that study that gene expression data can substantially strengthen the 
confidence in scale-down model qualification compared to the traditional approach 
which primarily relies on cell density and product quality information. 
Transcriptome function analysis can also be beneficial for process development and 
characterization by providing a mechanistic insight into the influence of culture 
parameters and variations on the process performance, for example, culture 
temperature19,27,249,250, DO251, osmolality252, specific medium components125,249,253, etc. In 
Chapter 5, transcriptome functional analysis was used to identify genes that are 
differentially expressed between scales, which gives insight into differences in 
environmental conditions that exist between two systems of different scales and how 
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they affect cell physiology. For a few genes, possible functional relationships with 
differences in DO and pH patterns, lactate metabolism, and glycosylation pattern 
were identified. The expression pattern of these genes can be used to interrogate 
future scale-up/down processes. 
At this moment, high cost and time-demanding tasks such as complete transcriptome 
data processing and interpretation are still the problems for such an analysis to be 
carried out on a large number of samples. Studies are being undertaken to reduce the 
costs and to identify the genes that are associated with process performance and 
product quality attributes27,249,254,255. More rapid gene sequencing, assembly, 
annotation, and data processing have been achieved, and high throughput 
transcriptome analysis with commercial microarray systems (e.g. Affymetrix as used 
in Chapter 4 and 5) have become available. With further development, omics 
analysis or at least a subset of it can be implemented as routine analysis for high 
throughput culture process characterization. 
6.3 Conclusions and outlook 
During the past decades, considerable experience has been obtained on scale-up of 
animal cell culture processes and on development of representative scale-down 
bioreactor systems for these processes. Currently, miniature (mL-scale) bioreactors 
have been routinely incorporated into process development primarily for process 
parameter and clone screening studies. With the increasing pressure on shortening 
the development timeline and on reducing the manufacturing cost, it would be ideal 
if the miniature bioreactor system can largely or even completely replace the bench-
scale bioreactors in exploring the design space for the production-scale bioreactors. 
In order to do so, more results from industrial and academic users are needed to 
interrogate the miniature system for different process conditions and for various cell 
types. 
As discussed in this chapter, the overall chemical environment, for example, DO and 
pH in the mL-scale bioreactors can be kept comparable to bench-scale bioreactors. As 
a result, comparable process performance is normally obtained. However, although 
aeration in mL-scale bioreactors is sufficient to maintain similar DO as in bench-scale 
bioreactors, the gassing situation between the two scales is very different, which 
affects pCO2 and shear conditions. To improve the mL-scale bioreactors, micro-
sparging and CO2-enriched headspace aeration may be used to deliver similar pCO2 
and shear conditions as in large-scale bioreactors. In addition, better understanding 
of the effect of bubble size on cell death is needed. In this way, the cell death event in 
scale-up/down can be accounted for using a modeling approach. In terms of mixing, 
a similar agitation approach as large-scale bioreactors is incorporated into mL-scale 
bioreactors. However, the mixing time is significantly shorter in the miniature 
bioreactors. This will become a problem if gradients in the large scale occur that 
affect the cell behavior. Certainly for the intensified processes at high cell 
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concentrations this may be the case. With the development of culture processes, a 
better understanding of the effect of gradients is needed in the near future. 
Finally, the small culture volume continues to challenge the miniature systems in 
terms of the representative sampling volume and associated analytics and liquid 
handling. A high throughput cell culture system also requires high throughput 
sample preparation, transfer, analysis, and interpretation approaches. A higher 
degree of automation, for example, automated microfluidics devices and online 
sampling and analytical devices can be helpful to further increase the experiment 
and data throughput and dimension.  
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Mammalian cell culture has become the main platform for the production of 
therapeutic monoclonal antibodies (mAbs). Significant progress has been made 
during the past decades with regard to understanding culture processes, 
development of more robust culture processes, and shortening the development 
timelines. This has resulted in more affordable monoclonal antibodies in the market. 
The market demand for mAb-based products is still increasing at a fast pace. In order 
to meet the market demand, efforts are being made to further increase product yield 
as well as to incorporate high-throughput technologies to accelerate the process 
development. In this context, this thesis aims to gain a better understanding of the 
fed-batch culture process and the process scale-up/down.  
In Chapter 2, a clone and medium screening experiment is done in order to establish 
a culture platform for the subsequent process development and scale-up/down 
studies. In this chapter, two CHO cell clones derived from the same parental CHO 
cell line and producing the same monoclonal antibody (BC-G, a low producing clone; 
BC-P, a high producing clone) were tested in four basal media in all possible 
combinations with three feeds (=12 conditions) in fed-batch cultures. The highest 
mAb product titer (1.2 g/L) was obtained with ActiCHO basal medium and feeds for 
the BC-P clone. Moreover, this study showed that culture media and feeds have a 
strong impact on cell metabolism, mAb specific productivity, as well as cell size.  
From Chapter 2, we selected a fed-batch process (the BC-P clone cultured in the 
ActiCHO media system) that resulted in a high biomass concentration (i.e. requires a 
high mass transfer) and mAb product titer for further process development and 
scale-up/down studies. The process was next characterized in detail at 10 L scale in 
Chapter 3 and 4. The 10L bench-scale bioreactor system can be used as the validated 
small-scale model for the production-scale bioreactors. As described in Chapter 3, 
during the selected fed-batch process, in addition to the traditionally observed 
exponential growth and stationary phase, an additional phase is observed where the 
cell division comes to a halt but the cell growth continues with an increase in cell size. 
We carried out metabolic flux analysis in order to better understand the relationship 
between mAb production and cell size. It was found that during the cell size increase 
(SI) phase, the increase in mAb specific productivity correlated linearly with the 
increase in cell volume and cell dry weight. Furthermore, the amount of mAb 
production per mol of oxygen and amino acids consumed increased as cells grew 
larger (~1.7 times higher for oxygen and ~3.4 times higher for amino acids). Chapter 
3 demonstrates that cell size is an important factor in a cell culture process. 
Furthermore, it implies that controlling cell size in a culture process may improve 
mAb production.  
In Chapter 4, we moved a step forward to explore the molecular mechanisms 
involved in cell size regulation using transcriptome analysis. In this chapter, we 
studied the changes in gene expression occurring when cells started increasing in 
size in the process using the ActiCHO medium system. The changes in gene 
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expression in another fed-batch process using FortiCHO medium system, during 
which no cell size increase occurred, was used as a “filter” to enrich for the genes that 
are related to cell size regulation. It was found out that various cyclin (cyc) and 
cyclin-dependent kinase (cdk) genes were significantly down-regulated in the 
ActiCHO process and a number of Cdk inhibitors (Cdkns) were significantly up-
regulated. These observations agree with the cell cycle arrest in both the G0/G1 and 
the G2/M phase. The mTOR upstream and downstream pathways are regulated in a 
strongly synchronized pattern to stimulate the mTOR activity in the ActiCHO 
process. This agrees with a continued cell growth after cell cycle arrest. More 
importantly, the activities of the cell cycle and mTOR regulator genes could be linked 
to the extracellular nutrient conditions through a number of cascade pathways. This 
suggests that by rational design of media and feeds, CHO cell size can be 
manipulated during fed-batch or perfusion processes and this can further improve 
cell growth and cell-specific productivity. The genes which showed a close link to 
cell size regulation may also be used in CHO cell engineering during clone 
development steps to further increase the productivity. 
The well-characterized 10 L fed-batch process next served as a control for further 
down-scale to a 15 ml ambr®  system in Chapter 5. A miniature bioreactor system 
that is representative for the production scale can greatly shorten the development 
time and enable a more accurate definition of the process design space by increasing 
the data resolution and dimension. In Chapter 5, we aim to better understand the 
challenges in using these miniature bioreactor systems as scale-down models for the 
bench-scale bioreactors. The metabolism and transcriptome results obtained from the 
10 L scale bioreactors in Chapter 3 and 4 are used as the process fingerprints to check 
the scale-down performance. The main conclusion from the comparison study was 
that the ambr®  15 system gave in general a representative culture performance 
compared to the 10 L process in terms of cell growth, cell size, metabolism, 
productivity, and product quality. Two agitation scale-down approaches based on 
different criteria (constant agitation P/V value and constant tip speed between scales) 
did not result in meaningful differences in cell physiology and overall culture 
performance. Transcriptome comparison showed a 6% difference in gene expression 
by principal component analysis (PCA) between the two scales. By looking at the 
differential gene expression, 2455 genes were unique to the ambr®  15 systems while 
1604 genes were unique to the 10 L system. The functional analysis of these unique 
genes gave a few indications on a link between differences in gene expression and 
differences in certain process parameters. Nevertheless, the influence of these 
differences on the overall comparability between the two scales was negligible. The 
result from Chapter 5 agrees with the literature that the ambr®  15 system is in general 
a representative scale-down system for the bench-scale bioreactors. To this end, we 
are one step closer to solely using a miniature bioreactor system in exploring the 
process design space. In order to really achieve this, more results from industrial and 
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academic users are needed to test the miniature system for different process 
conditions and for various cell lines.  
Finally, in Chapter 6, the current knowledge and the recent advances in process 
scale-up/down were discussed, and improvements on the current miniature 
bioreactor systems are proposed. In addition, the challenges and opportunities on 
further implementing miniature bioreactor systems into process development were 
discussed. This thesis gives insight in the different biological aspects that are 
important for the scale-down of CHO fed-batch cultures, ranging from the selection 
and characterization of a fed-batch process to the validation of the scale-down. This 
will help in further shortening the development times and in developing processes 
that are more robust. 
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